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Molecular and behavioral assays were used to examine the effects of HIV-1 on 
synaptodendritic integrity, motivated behavior and the therapeutic potential of natural 
isoflavones in ameliorating both synaptodendritic injury in vitro and changes in 
motivation in vivo. The overarching hypothesis of the present dissertation is twofold: 1. 
HIV-1 causes a decrease in motivation for sucrose and cocaine and the change in 
motivational state is driven by compromised synaptic integrity as evaluated by F-actin 
and DAT function and, 2. Treatment with phytoestrogens will prevent synaptodendritic 
damage, normalize the internal motivational state of the HIV-1 Tg rat for sucrose and 
cocaine, and alter dendritic spine morphology.   
Primary neuronal cell cultures were utilized to evaluate the effects of HIV-1 Tat 
and cocaine on synaptodendritic integrity and the therapeutic potential of phytoestrogens. 
We demonstrate that the cysteine rich domain of Tat is required to initiate 
synaptodendritic injury, and damage can be prevented by pre-treatment with 
phytoestrogens daidzein, liquiritigenin, and equol in an estrogen receptor dependent 
manner. Addition of daidzein and liquiritigenin to the cell culture medium following Tat 
exposure resulted in a significant restoration of the fine network which was an estrogen 
receptor mediated mechanism. Simultaneous treatment with Tat and cocaine, at 
independently non-damaging concentrations, resulted in significant synaptodendritic
vii 
 injury. Tat + cocaine induced damage is prevented by S/R-equol treatment in an estrogen 
receptor beta dependent mechanism. 
The HIV-1 transgenic rat was utilized to evaluate the effects of HIV-1 on 
motivated behavior for sucrose and cocaine, and the ability of equol treatment to 
potentially modulate changes in goal-directed behavior. HIV-1 Tg rats respond less 
overall for sucrose (0-30%; w/v) and may be more sensitive to cocaine. Equol treatment 
resulted in a differential response to sucrose and cocaine in both HIV-1 Tg and F344 rats. 
Control animals respond in a functionally linear manner for higher sucrose 
concentrations, but equol treatment produced a quadratic response. Equol increased 
cocaine intake in F344 rats but resulted in a decrease in responding in HIV-1 Tg rats. 
Finally, equol treatment shifted choice behavior in F344 animals. Together, these studies 
indicate equol may be a beneficial treatment for HIV-1+ individuals, but may not be 
suitable for seronegative individuals. 
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HIV-1: Dopamine, apathy, and motivation 
 Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that currently 
infects 34 million people world-wide, with roughly 1.5 million living in the United States 
(World Health Organization, 2011). HIV-1 enters the CNS shortly after infection 
(Resnick, Berger, Shapshak, & Tourtellotte, 1988; Nath, 2002), where it can be found in 
microglia and a small percentage of astrocytes (An, Groves, Gray, & Scaravilli, 1999; 
Ellis, Langford, & Masliah, 2007; Gonzalez-Scarano & Martin-Garcia, 2005). Once HIV-
1 has infected the CNS, it remains unaffected by combined anti-retroviral therapy 
(cART) for the lifetime of the infected individual. The inability of cART to cross the 
BBB and the longevity of astrocytes make the brain important viral reservoir despite 
effective viral suppression in the periphery.  
 HIV-1 infection frequently results in a spectrum of neurocognitive deficits (HIV-1 
associated neurocognitive disorders; HAND) that can range from mild (minor cognitive-
motor disorder; MCMD) to severe (HIV-1 associated dementia; HAD) (Antinori et al., 
2007). Following the implementation of cART there was a significant reduction in the 
incidence of HAD; however, the overall prevalence of HAND has not declined with more 
than 40% of HIV-1+ individuals exhibiting symptoms (Lindl, Marks, Kolson, & Jordan-
Sciutto, 2010; Letendre, 2011). Despite the continued prevalence of HAND, there
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 are no therapeutic options for these individuals nor are the underlying mechanisms fully 
understood. 
Depression frequently occurs in HIV-1+ individuals (Vance et al., 2014), however 
the severity of depressive symptoms are generally not found to be predictive of 
neurocognitive impairment (Goggin et al., 1997; Cysique et al., 2007). Depression and 
apathy are frequently comorbid disorders, however they can occur independently of one 
another (Marin, 1991; Marin, Firinciogullari, & Biedrzycki, 1993). Apathy is defined as a 
reduction in self-initiated, goal-directed behavior, or a lack of motivation. HIV-1 positive 
individuals consistently report higher incidence of apathy than seronegative controls 
(Kamat, Woods, Marcotte, Ellis, & Grant, 2012; Castellon, Hinkin, Wood, & Yarema, 
1998a; Paul et al., 2005a). Elevated apathy scores are predictive of decreased medication 
adherence (Panos et al., 2014), increased cognitive complaints, diminished 
neurocognitive performance (Shapiro, Mahoney, Zingman, Pogge, & Verghese, 2013; 
Kamat et al., 2012), and suboptimal everyday functioning (Kamat et al., 2012; Kamat et 
al., 2013).  Elevated levels of apathy are related alterations in learning efficiency and 
cognitive flexibility (Paul et al., 2005a), in addition to deficits in working memory 
performance (Castellon et al., 1998a) and executive function in HIV-1+ individuals 
(Castellon, Hinkin, & Myers, 2000). 
Motivation is not considered a facet of cognition, however it is an important 
supporting factor for normal cognitive function (Keeler & Robbins, 2011). Due to the 
importance that motivation may play in supporting optimum cognitive functioning, and 
the correlation between motivation disturbance (Castellon et al., 2006; Castellon, Hinkin, 
Wood, & Yarema, 1998b), with cognitive function (Panos et al., 2014) in HIV-1+ 
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individuals, evaluating the internal motivational state may be an important and predictive 
state to assess during HIV-1 infection to identify individuals at risk for cognitive 
impairment. 
Dysfunction of, and damage, to the frontal-subcortical system is believed to play a 
role in manifestation of apathy (Masterman & Cummings, 1997; Tekin & Cummings, 
2002). The mesocorticolimbic system encompasses several dopamine rich regions, which 
are known to be more susceptible to HIV-1 infection (Berger & Nath, 1997; Nath et al., 
2000). HIV-1+ individuals display a sensitivity to dopamine receptor agonists (Berger & 
Nath, 1997), less dopamine in cerebral spinal fluid (Berger, Kumar, Kumar, Fernandez, 
& Levin, 1994), reduced dopamine transporter (DAT) binding in the striatum (Chang et 
al., 2008), lower TH levels in the susbstantia nigra (Silvers et al., 2006), and 
Parkinsonian-like symptoms (Tse et al., 2004). Apathy in HIV-1 positive individuals is 
associated with decreased performance on tasks known to involve the frontal-subcortical 
circuitry (Cole et al., 2007), and lower overall volume of the nucleus accumbens (Paul et 
al., 2005b). The hallmark features of HAND, e.g. poor memory and poor performance on 
executive function tasks, have been associated with decreased levels of dopamine and its 
metabolite, homovanillic acid, in individuals infected with HIV-1 (Di Rocco et al., 2000). 
In sum, the susceptibility of the dopaminergic system may play a role in the expression of 
apathy and executive function in HAND. 
Neural systems that mediate the motivational features of goal-directed behavior 
are damaged by HIV-1 (Everitt & Robbins, 2013; Purohit, Rapaka, & Shurtleff, 2011). 
The striatum (caudate and putamen) of the basal ganglia receive major dopamine input 
from the ventral tegmental area and the substantia nigra, the mesocorticolimbic and 
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nigrostriatal dopamine systems, respectively. HIV-1 positive individuals exhibit a high 
viral load in the caudate (Kumar, Borodowsky, Fernandez, Gonzalez, & Kumar, 2007; 
Kumar et al., 2009a) and extensive atrophy in the caudate and putamen are reported in 
people exhibiting cognitive impairment and apathy (Paul et al., 2005a; Paul, Cohen, 
Navia, & Tashima, 2002; Hestad et al., 1993; Dal Pan et al., 1992; Ances et al., 2006). 
The mesolimbic portion of the dopamine system is associated with motivation, and the 
nigrostriatal system with the organization of motor systems to complete, and consummate 
responding, together resulting in goal-directed behavior. Mesolimbic dopamine, which is 
associated with reward, mediates several aspects of motivation, specifically related to 
activity, such as behavioral activation (Koob, Riley, Smith, & Robbins, 1978), approach 
behavior (Robinson & Berridge, 2003; Nicola, 2010) and exertion of effort (Salamone, 
Cousins, & Bucher, 1994) particularly regarding food-maintained operant responding 
(Salamone & Correa, 2012). The mesolimbic dopamine system is also responsible for 
partially mediating drug-maintained responding, and highly reinforcing stimuli such as 
cocaine have been investigated extensively (Roberts, Morgan, & Liu, 2007; Espana & 
Jones, 2013; Nader, Balster, & Henningfield, 2014). Thus, goal-directed behavior relies 
on mesolimbic and nigrostriatal dopamine for normal function, and HIV-1 produces 
extensive neuropathology throughout the striatum, the major dopamine output regions of 
these systems. 
HIV-1: Viral proteins and their effects on the CNS 
 HIV-1 infection has been primarily studied as an immunological process since its 
emergence in the 1980s. The virus is made up of 9 distinct genes which code for proteins 
required for successful entry into the cell, and replication within the cell. There are three 
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structural genes core (gag), polymerase (pol), and envelope (env); and six regulatory 
genes the transactivator of transcription (tat), regulator of viral RNA splicing and 
transport (rev), viral protein U (vpu), viral protein R (vpr), negative factor (nef), and viral 
infectivity protein (vif) (Nath, 2002; Pavlakis & Felber, 1990). Each of these genes plays 
an important role in infectivity, replication, and maintenance of the virus. 
Although HIV-1 enters the brain early in infection and induces neuronal death and 
damage (Everall et al., 1999; Masliah et al., 1997), it does not directly infect neurons. 
Each HIV-1 gene codes for a specific protein(s) that generally correspond in name, and 
of these proteins Tat, glycoprotein 120 and 41(gp120, gp41; encoded by env), Rev, Vpr, 
and Nef are known to be neurotoxic (Nath, 2002; Aksenova, Aksenov, Adams, Mactutus, 
& Booze, 2009; Agrawal et al., 2010; Bansal et al., 2000). The neurotoxic activities of 
these proteins play a major role in the neuronal damage and death that result in HAND. 
HIV-1 Tat is one of the most well studied neurotoxic proteins produced by HIV-1. 
Tat is a non-structural protein that exists from 86-101 amino acids that is encoded by two 
axons (Nath, 2002). The viral function of Tat is to stabilize the transcription process and 
more efficiently replicate the virus (Dayton, Sodroski, Rosen, Goh, & Haseltine, 1986; 
Debaisieux, Rayne, Yezid, & Beaumelle, 2012; Gatignol & Jeang, 2000; Pugliese, 
Vidotto, Beltramo, Petrini, & Torre, 2005). Unlike the majority of HIV-1 proteins, Tat is 
released into the extracellular space by infected glial cells (Tardieu, Hery, Peudenier, 
Boespflug, & Montagnier, 1992; Chang, Samaniego, Nair, Buonaguro, & Ensoli, 1997; 
Ensoli et al., 1993) where it interacts with neurons to produce oxidative stress (Aksenov 
et al., 2001; Kruman, Nath, & Mattson, 1998), and calcium channel imbalance (Kruman 
et al., 1998). HIV-1 Tat also modulates NMDA receptors (Li et al., 2008), D1 receptors 
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(Aksenov, Aksenova, Mactutus, & Booze, 2012; Silvers, Aksenova, Aksenov, Mactutus, 
& Booze, 2007), and the dopamine transporter (DAT) (Midde, Gomez, & Zhu, 2012; 
Midde et al., 2013). Together the extracellular actions of HIV-1 Tat result in neuronal 
cell death (Adams, Aksenova, Aksenov, Mactutus, & Booze, 2012; Aksenov et al., 2012; 
Bonavia et al., 2001; Kruman et al., 1998; Mattson, Haughey, & Nath, 2005) and 
dendritic injury (Bertrand, Aksenova, Mactutus, & Booze, 2013; Kim, Martemyanov, & 
Thayer, 2008a; Shin, Kim, & Thayer, 2012a) in dopamine rich areas. 
DAT, which regulates dopaminergic tone via reuptake, is also compromised by 
HIV-1. Patients exhibiting HAND show reductions in DAT throughout the putamen and 
nucleus accumbens (Chang et al., 2008; Wang et al., 2004). Furthermore, animal models 
indicate that HIV-1 viral proteins, such as Tat and gp120, are neurotoxic and impair DAT 
function (Aksenov, Aksenova, Silvers, Mactutus, & Booze, 2008; Ferris, Frederick-Duus, 
Fadel, Mactutus, & Booze, 2009a; Zhu, Mactutus, Wallace, & Booze, 2009; Zhu, 
Ananthan, Mactutus, & Booze, 2011). Tat mediates these effects by allosterically 
modulating the DAT through protein-protein interactions (Zhu et al., 2011). Although 
HIV-1 protein/DA interactions are not the sole mediator of death and damage in the CNS, 
it is clear that HIV-1 viral proteins produce damage to the mesolimbic and nigrostriatal 
DA systems, and that such interactions play an important role in the development of 
HAND. 
HIV-1 and Cocaine Use 
Cocaine is a highly addictive stimulant drug extracted from the leaves of the coca 
plant, Erythroxylon coca.  Erythroxylon coca use originated in South America, where 
Andean tribes have chewed the leaves for increased alertness, anti-appetitive properties, 
7 
and a general sense of wellbeing  for thousands of years (Schwartz, Rezkalla, & Kloner, 
2010; Maraj, Figueredo, & Lynn, 2010).  Coca leaves are also rich in vitamins and 
minerals, and do not produce the stimulant effects of cocaine (Stolberg, 2011).  Although 
there were several attempts at exporting the coca leaf, it rotted quickly and lost any 
medicinal value during exportation.  In 1858, German chemist Albert Niemann managed 
to separate cocaine from the coca leaf (Stolberg, 2011).   The initial extract from 
Erythroxylon coca is alkaloid, and is dissolved in hydrochloric acid to form the water-
soluble salt cocaine hydrochloride and could easily be shipped over long distances (Das, 
1993).   
In the late 19th and early 20th century cocaine was thought to be a remedy for 
many medical maladies, such as fatigue, toothaches, headaches, hay fever, seasickness, 
and even vomiting during pregnancy. Cocaine was first used as a local topical anesthetic 
in 1884 (Maraj et al., 2010), and William Halsted furthered this practice when finding 
that injecting cocaine under the skin was more effective and lessened bleeding (Stolberg, 
2011). Unfortunately, it was believed that the powder form of cocaine was as non-
addictive as the leaf form of the drug.  During this time, pure cocaine was sold in the 
open market and popular beverages, such as the wine Vin Mariani and Coca-Cola, were 
laced with cocaine for ‘health benefits’ (Das, 1993).   
However, signs of abuse soon began to show in the general public.  Death, 
deterioration of the nasal cavity, and signs of dependence began to surface in users 
nationwide. In 1914 the U.S. government banned use of cocaine except when used by a 
physician as a local anesthetic as public knowledge of the toxic side effects of cocaine 
and the abuse potential of cocaine spread (Das, 1993).  Today, under the U.S. Controlled 
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Substance Act of 1970 cocaine is a schedule II drug, meaning that cocaine has a high 
potential for abuse and its use may lead to severe physical and psychological dependence; 
however, cocaine still has accepted medical use as a local anesthetic.   
Despite federal regulation, cocaine abuse continues to be a national health crisis: 
in 2009 and 2010 4.7 million Americans age 12 and older indicated that they had abused 
cocaine in the last month (SAMHSA, 2012).  Cocaine use is responsible for 24% of drug-
related hospital visits every year, presenting a significant financial burden on users and 
the welfare system of users who cannot afford health care coverage (NIDA, 2010).  
Additionally, risky behaviors and intravenous injection of cocaine put users at a higher 
risk for contracting HIV/AIDS, and hepatitis C, highlighting the need to treat current 
addicts.   
Despite the prevalence of severe risks associated with HIV-1+ cocaine use, there 
are currently no effective pharmacotherapies, and although behavioral therapy is effective 
for drug abuse, pharmacotherapeutic options may enhance outcomes (NIDA, 2010).  
Therapeutic intervention in addiction may be an important step in not only increasing the 
quality of life of these individuals, it may prevent further HIV-1 transmission. Large 
pharmaceutical companies do not have the financial incentive to develop therapeutics for 
cocaine addiction or HIV-1+ cocaine addicts, because most addicts are of low 
socioeconomic status and not likely to have the ability to afford a new drug (NIDA, 
2010).  However, natural plant derived therapies have been used for thousands of years 
by a variety of cultures for various ailments. Several naturally occurring compounds have 
anti-viral and anti-inflammatory properties (Harborne & Williams, 2000; Vrijsen, 
Everaert, & Boeye, 1988). Within the last 20 years, various natural therapies have been 
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tested in clinical trials for drug addiction with mixed efficacy, mostly due to the mixtures 
used in these trials (Lu et al., 2009).  Presently, investigations into natural compounds 
have resulted in the identification of multiple active constituents.  The identification of 
active components coupled with the increase in the knowledge of neurobiological 
mechanisms of drug addiction and HIV-1 neurocognitive disorders allows researchers to 
better identify useful plant derived compounds for treatment of drug abuse and HAND. 
More than 30% of HIV-1+ individuals in the US admit to using illicit drugs 
regularly (Korthuis et al., 2008), with up to half displaying neurocognitive impairment 
(Devlin et al., 2012), and cocaine is one of the most commonly abused drugs among 
HIV-1+ individuals (Korthuis et al., 2008). Although the increase in prevalence and 
severity of neurocognitive deficits in HIV-1+ drug users is well known (Nath, 2010; 
Purohit et al., 2011), preclinical studies have yielded complex answers in regards to an 
underlying mechanism. Administration of dopaminergic drugs, like L-DOPA or 
selegiline, restore dopaminergic tone in rhesus monkeys, however, it also results in 
enhanced viral replication and brain lesions (Czub et al., 2001). Indeed, in vitro studies 
reveal that cocaine enhances viral replication in monocytes (Peterson et al., 1991), 
macrophages (Roth et al., 2002), and astrocytes (Reynolds et al., 2006). Cocaine can also 
enhance monocyte migration across the blood brain barrier and disrupt intercellular 
junctions (Fiala et al., 1998; Fiala et al., 2005), potentially allowing greater infectivity of 
CNS cells and exposing CNS cells to potentially neurotoxic molecules that would have 
previously been excluded by an intact blood-brain barrier. Together, these pre-clinical 
studies reveal that the enhancement of neuronal damage in vivo by cocaine is most likely 
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a combination of interactions with neurotoxic proteins and increased presence of infected 
cells, resulting in dire consequences in HIV-1+ patients. 
Pre-clinical and clinical studies have attempted to elucidate the mechanism 
underlying cocaine + HIV-1 neurocognitive deficits, in hopes to reveal a therapeutic 
target. Cocaine potentiates the neurotoxicity of HIV-1 proteins in vitro (Nath, Maragos, 
Avison, Schmitt, & Berger, 2001; Turchan et al., 2001; Aksenov et al., 2006). HIV-1+ 
individuals with cognitive deficits have fewer DATs regardless of cocaine use, although 
there is a trend for cocaine users to have lower DAT levels in the nucleus accumbens and 
basal ganglia (Chang et al., 2008; Wang et al., 2004). As previously discussed in section 
1.1, the dopaminergic system is particularly sensitive to HIV-1, and increased damage to 
this system is correlated with the severity of neurocognitive deficits (Purohit et al., 2011; 
Berger & Nath, 1997; Chang et al., 2008; Kumar, Ownby, Waldrop-Valverde, Fernandez, 
& Kumar, 2011; Nath et al., 2000). However, results from a CHARTER study indicated 
that past drug use was not predictive of neurocognitive impairment (Byrd et al., 2011), 
suggesting that enhanced neuronal injury induced by illicit drugs is reversible if 
abstinence is achieved. 
Estrogen and Phytoestrogens: Implications for HIV-1 and Cocaine Use 
Flavonoids are secondary metabolites of plant compounds containing a common 
phenyl benzopyrone feature (Harborne & Williams, 2000).  Frequently found in 
medicinal plants, flavonoids originally caught the attention of researchers due to their 
natural affinity for GABAA receptors, specifically the benzodiazepine binding site, and 
the potential anxiolytic properties mediated at this site (Marder & Paladini, 2002). The 
flavonoid family includes six major subclasses: flavonols, flavones, isoflavones, 
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catechins or flavanols, flavanones, and anthocyanidins.  These compounds share a 
common backbone system with varying degrees of oxidation of the pyran ring (Marder & 
Paladini, 2002), and movement of the B-ring to carbon 2 of the 3-carbon chain to form 
the isoflavonoids (Romano et al., 2013).  Flavonoids are polyphenolic compounds that 
are frequently found attached to glycosides (sugars), making the compounds water 
soluble (Ross & Kasum, 2002).  
The soy derived compounds genistein, daidzein, the daidzein metabolite equol, 
and a compound derived from Chinese licorice root, liquiritigenin, are found in the 
isoflavone class of the flavonoids, and are more specifically identified as phytoestrogens.  
Unlike the majority of flavones and isoflavones, which were first noticed for their 
affinities for the benzodiazepine receptor site, phytoestrogens have an affinity for 
estrogen receptors. There are three subtypes of the estrogen receptor: alpha (ERα), beta 
(ERβ), and G protein-coupled receptor-30 (GPR-30).  ERα and ERβ are classic examples 
of steroid receptors; they are found intracellularly where the estrogen-ER complex binds 
to the estrogen response elements (ERE), the general transcription factors that transcribe 
estrogen responsive genes (Marino, Galluzzo, & Ascenzi, 2006).  GPR-30 is a membrane 
associated receptor thought to be responsible for the more immediate effects of estrogen 
(Soltysik & Czekaj, 2013). Similar to other flavonoid compounds, genestein and daidzein 
have been found to be successful in treating various types of cancer, cardiovascular 
diseases, and osteoporosis (Havsteen, 2002; Jackson, Greiwe, & Schwen, 2011). 
Estrogen suppresses HIV-1 replication at the transcriptional level through 
modulation of the Tat-LTR interaction in glial cells, and this mechanism is not mediated 
through ERα (Wilson et al., 2006). Conversely, over expression of ERα in glial cells 
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precludes estrogen mediated transcription suppression (Heron, Turchan-Cholewo, Bruce-
Keller, & Wilson, 2009), and ERα may actually increase HIV-1 transcription in the 
presence of estrogen (Katagiri, Hayashi, Victoriano, Okamoto, & Onozaki, 2006). 
Meanwhile, activation of ERβ does not increase HIV-1 transcription (Katagiri et al., 
2006), however it is unclear whether ERβ plays a role in the estrogen mediated 
suppression of HIV-1 transcription in glial cells. 
Phytoestrogens have a higher affinity for the beta subtype of the estrogen 
receptor. Relative to 17β-Estradiol genestein has a relative binding affinity for ERβ of 
6.8%, with 324 fold selectivity for ERβ over ERα, while daidzein has a lower relative 
binding affinity of 0.051% for ERβ with 17-fold selectivity for ERβ over ERα.  Daidzein 
is metabolized in the gut to form the more potent metabolite equol; Equol has a 1.52% 
relative binding affinity compared to 17β-estradiol for ERβ, and a 24-fold selectivity for 
ERβ over ERα (Jiang et al., 2013a).  Liquiritigenin does not preferentially bind to ERα or 
ERβ, but only initiates transcription through ERβ (Paruthiyil et al., 2009; Mersereau et 
al., 2008). The ERβ specificity of these compounds indicates that they may provide 
neuroprotection and more importantly suppress HIV-1 transcription.   
ERβ is found in the brain with differing regional densities. The distribution of the 
ER nuclear receptors α and β in the midbrain has yielded different, and often opposing, 
results.  Although it is generally accepted that ERα and ERβ are found throughout the 
brain, the localization within regions of the midbrain remain unclear.  Zhou and 
colleagues (Zhou, Cunningham, & Thomas, 2002a) found little to no signal for either α or 
β mRNA in the VTA of ovariectomized (OVX) female rats, and unquantifiable amounts 
of ERβ transcript in the midbrain.  On the other hand, an earlier study found the exclusive 
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expression of ERβ mRNA in the VTA of ovariectomized (OVX) female rats (Shughrue, 
Lane, & Merchenthaler, 1997a).  Another study found ERβ protein was co-localized with 
TH and located in a small population of neurons in the rostral portion of the VTA (Creutz 
& Kritzer, 2002a), suggesting the ERβ may modulate the dopaminergic system. 
There are few studies examining the effects of the different estrogen receptor 
subtypes on any stage of addiction, and the studies that do exist provide a conflicting 
picture. In one of the few studies examining the precise role of estrogen receptors in 
cocaine reinstatement, rats treated with an ERβ agonist prior to drug-induced 
reinstatement responded significantly more on a lever previously paired with cocaine 
(Larson & Carroll, 2007a), suggesting the ERβ plays an important role in drug-primed 
reinstatement.  However, another study found that ERβ agonists inhibited ACTH and 
corticosterone release in response to stress (Weiser, Foradori, & Handa, 2008); 
suggesting that stress induced reinstatement of cocaine seeking behavior, in which 
corticosterone plays a major role (Goeders, 2002), may be prevented or attenuated by a 
selective ERβ agonist, like the phytoestrogens. These studies highlight the importance of 
understanding the role receptor subtypes play in addiction. 
 Estrogen may interact with the dopaminergic system through a variety of ways – 
however, the roles of the relatively newly described estrogen receptor, GPR-30, in 
addiction and modulation of the dopaminergic system are ill-defined.  Estradiol increases 
dopamine release in the striatum following amphetamine treatment (Xiao & Becker, 
1998), suggesting the involvement of estrogen receptors in stimulant effects.  
Surprisingly, this effect was still present following conjugation of estradiol with BSA 
(Xiao & Becker, 1998), which would prevent the steroidal hormone from crossing the 
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cell membrane and interacting with either nuclear ERα or ERβ, indicating an interaction 
at the membrane level.  As previously described GPR-30 is a newly classified membrane 
estrogen receptor and has been found in the substantia nigra of the striatum (Brailoiu et 
al., 2007).  Thus, suggesting that estrogen and the phytoestrogens may act to enhance 
dopamine release during exposure to stimulants via the GPR-30, and not ERα or ERβ. 
Flavonoids and isoflavonoids are compounds found in an abundance of natural 
products. These compounds have novel therapeutic value, including antiviral and anti-
inflammatory properties (Ding, 1987; Harborne & Williams, 2000; Vrijsen et al., 1988). 
A recent study determined that the flavonoid luteolin had anti-HIV-1 properties; 
specifically through preventing activity at the Tat-LTR interaction site, preventing 
transcription (Mehla, Bivalkar-Mehla, & Chauhan, 2011). ERβ selectivity may prevent 
unwanted side effects associated with non-selective treatments, and may also minimize 
the negative effects of ERα activation on Tat-HIV-1 LTR interactions. 
HIV-1 Transgenic Rat 
 The HIV-1 Transgenic Rat (HIV-1 Tg) was developed almost 15 years ago (Reid 
et al., 2001). This small animal model of HIV-1 includes 7 of the 9 HIV-1 genes, with 
gag and pol deleted. The functional deletion of gag and pol, genes responsible for 
structural integrity of the virus (Nath, 2002; Pavlakis & Felber, 1990), eliminates the 
ability of the virus to become infectious or produce an efficient virus. Although this viral 
construct has been inserted into the mouse, highest viral expression was found in the 
muscle and skin of the mouse (Dickie et al., 1991). Mouse cyclin T, an important co-
factor for LTR-Tat interaction, does not interact functionally with Tat thus preventing 
transcription initiation (Wei, Garber, Fang, Fischer, & Jones, 1998). Unlike this mouse 
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model, the viral promoter is fully functional in the HIV-1 Tg rat as evidenced by the 
presence of spliced and unspliced viral transcripts in the brain, lymph nodes, thymus, 
liver, kidney, and spleen (Reid et al., 2001; Peng et al., 2010). The active viral promoter 
and production of HIV-1 viral proteins makes this an excellent model of HIV-1+ 
individuals with viral suppression. 
 Initial reports of the HIV-1 Tg rat detail the development of mild to highly opaque 
cataracts, and the development of AIDS-like pathology (skin lesions, wasting, 
neurological abnormalities, and respiratory difficulty) within 5-9 months of age (Reid et 
al., 2001). Later reports using the now commercially available HIV-1 Tg rat describe a 
model that is relatively healthy for up to 11 months of age, however there was a shift of 
mRNA expression from the periphery to the CNS in young vs older animals (Peng et al., 
2010). The shift in viral expression suggests more severe neurocognitive deficits with 
age, which is similar to what is seen in humans with HAND (Wiley et al., 1998; 
Marquine et al., 2014). 
 The HIV-1 Tg rat displays spatial learning and memory deficits (Lashomb, 
Vigorito, & Chang, 2009; Vigorito, Lashomb, & Chang, 2007), deficits in executive 
function (Moran, Booze, & Mactutus, 2014), alterations in sensorimotor gating (Moran, 
Booze, & Mactutus, 2013), and alterations in behavioral responses following 
methamphetamine challenge (Moran, Aksenov, Booze, Webb, & Mactutus, 2012; Liu et 
al., 2009). Neuropathological indicators in the HIV-1 Tg rat are also similar to humans 
with HAND. The HIV-1 Tg rat has alterations in dendritic spines on the medium spiny 
neurons in the nucleus accumbens (NAc), lower dopamine binding in the ventral and 
dorsal striatum, decreased striatal volume, decreased levels of tyrosine hydroxylase (Lee 
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et al., 2014), and altered sensitivity to cocaine (McIntosh, Sexton, Pattison, Childers, & 
Hemby, 2015). Methamphetamine challenged HIV-1 Tg rats not only had decreased 
levels of TH, but also an increase in monoamine oxidase-A (MAO-A) levels (Moran et 
al., 2012), suggesting a potential compensation mechanism in the HIV-1 Tg rat in 
response to increased dopamine release due to methamphetamine exposure.  
Experimental Goals and Hypotheses 
 The experimental hypotheses of this dissertation involve both behavioral and 
neurochemical questions:  
1. (Chapters 2-4) Since synaptic loss occurs before cell death and HIV-1 proteins and 
cocaine result in elevated levels of cell death, do HIV-1 proteins interact with cocaine to 
increase neuronal damage? Can this damage be attenuated or reversed with the use of 
phytoestrogen compounds? What is the underlying mechanism of phytoestrogen 
treatment in vitro?  
Hypothesis: HIV-1 Tat and cocaine will produce enhanced levels of synaptodendritic 
damage and treatment with phytoestrogens will prevent and restore synaptic loss. 
Phytoestrogenic effects will be mediated through an estrogen receptor mediated 
mechanism. 
2. (Chapter 5) HIV-1 produces extensive damage throughout the dopaminergic system of 
both HIV-1+ humans and HIV-1 Tg rats, a key regulator of motivated behavior.  HIV-1+ 
humans display increased levels of apathy, do HIV-1 Tg rats also display altered 
motivational processes for natural and/or drug reinforcement? Is dopamine regulation 
altered following cocaine self-administration?  
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Hypothesis: The HIV-1 Tg rat will have an altered response to sucrose and cocaine. 
Dopamine transporter function will be significantly altered by self-administration, and 
the HIV-1 Tg rat will have a dysfunctional dopamine transporter relative to F344 
controls. 
3. (Chapter 6) Can ingestion of dietary phytoestrogens attenuate or normalize altered 
motivation in the HIV-1 Tg rat? Does equol alter morphological characteristics of the 
medium spiny neurons in the nucleus accumbens? 
Hypothesis: Treatment with the phytoestrogen S-equol will normalize the internal 
motivational state of the HIV-1 Tg rat for sucrose and cocaine. S-equol will have long-
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 Human immunodeficiency virus (HIV)-1 infects up to 34 million people 
worldwide (World Health Organization, 2011).  HIV-1 enters the central nervous system 
early in infection (Nath, 2002; Resnick et al., 1988), where it has been shown to be 
present in microglia and in a small percentage of astrocytes (An et al., 1999; Ellis et al., 
2007; Gonzalez-Scarano & Martin-Garcia, 2005). HIV-1 infection of the central nervous 
system result in a spectrum of neurocognitive deficits referred to as HIV-1 associated 
neurocognitive disorders (HAND) (Antinori et al., 2007). The incidence of the most 
severe form of HAND (i.e., HIV-1 associated dementia), has decreased since the 
implementation of combination anti-retroviral therapy (cART); nevertheless, 
neurocognitive impairments still affect 40%-70% of HIV-1 infected individuals (Heaton 
et al., 2011; Letendre, 2011; Lindl et al., 2010). 
 The HIV genome consists of three major coding regions: core (gag); polymerase 
(pol); and envelope (env). Regulatory proteins, such as Tat, play a key role in the 
pathogenesis of HIV infection and are also encoded in the HIV genome (Pavlakis & 
Felber, 1990). The HIV-1 transactivator of transcription (Tat) stabilizes the transcription 
process in order to more efficiently replicate the virus (Dayton et al., 1986; Debaisieux et 
al., 2012; Gatignol & Jeang, 2000; Pugliese et al., 2005). Tat protein is encoded by two 
exons with several well-conserved protein domains found on the first exon: the acidic 
domain (1-21), the cysteine rich domain (22-37), the core/hydrophobic region (38-48), 
and the basic domain (49-72). Mutations of deletions in residues 22-40 of the first exon 
21 
are deleterious to transactivation function, whereas modifications are relatively well 
tolerated within the acidic domain (1-21) and within the glutamine rich region (58-72) 
found in the basic domain, thereby highlighting the importance of the different domains 
of the HIV-1 Tat protein (Jeang, Xiao, & Rich, 1999; Kalantari et al., 2008; 
Kuppuswamy, Subramanian, Srinivasan, & Chinnadurai, 1989; Ruben et al., 1989). More 
investigations examining the biological effects of Tat protein functional domains have 
focused on the transactivational ability of the protein (Debaisieux et al., 2012; Hauber, 
Malim, & Cullen, 1989; Kalantari et al., 2008; Kubota, Endo, Maki, & Hatanaka, 1989; 
Kuppuswamy et al., 1989; Li et al., 2012). 
 HIV-1 does not directly infect neurons (Gonzalez-Scarano & Martin-Garcia, 
2005; Nath, 2002). However, HIV-1 Tat is released into the extracellular space of the 
brain (King, Eugenin, Buckner, & Berman, 2006; Nath, 2002; Pugliese et al., 2005). 
Elevated levels of Tat mRNA have been found in the brain tissue of individuals with 
HAD and HIV-1 encephalitis (Cowley, Gray, Wesselingh, Gorry, & Churchill, 2011; 
Hudson et al., 2000; Wesselingh et al., 1993; Wiley, Baldwin, & Achim, 1996). HIV-1 
Tat has also been detected via immunostaining of brain tissue in individuals with HIV-1 
encephalitis (Del et al., 2000; Hudson et al., 2000; Kruman et al., 1999; Liu et al., 2000), 
and can also be detected in the brains of rhesus macqaques infected with a HIV/SIV 
chimera (Hudson et al., 2000; Kruman et al., 1999). HIV-1 Tat has been shown to initiate 
neuronal cell death in vitro (Adams, Aksenova, Aksenov, Mactutus, & Booze, 2010; 
Adams et al., 2012; Aksenov, Aksenova, Mactutus, & Booze, 2009; Aksenova et al., 
2006; Bonavia et al., 2001) and in vivo (Aksenov et al., 2003; Aksenov et al., 2001; 
Bansal et al., 2000; Fitting, Booze, & Mactutus, 2008; Fitting, Booze, Hasselrot, & 
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Mactutus, 2008; Fitting, Booze, Hasselrot, & Mactutus, 2010; Kim et al., 2003; Wang, 
Barks, & Silverstein, 1999). Neuronal cell death has been reported in post-mortem HIV-1 
brain tissue (Adle-Biassette et al., 1995; Adle-Biassette et al., 1999); however, cell death 
correlates poorly with neurocognitive status (Adle-Biassette et al., 1999; Kaul, Garden, & 
Lipton, 2001).  
 In contrast to cell death, dendritic pruning, synaptic loss, and dendritic 
simplification correlate well with HAND (Adle-Biassette et al., 1999; Everall et al., 1999; 
Kaul et al., 2001). Synaptic injury may reflect early, sometimes asymptomatic, stages of 
HAND, before extensive neuronal loss occurs (Masliah et al., 1997). The HIV-1 Tat 
protein has been reported to cause a loss in synaptic density, dendritic pruning, and 
dendritic simplification both in vivo (Fitting et al., 2010a)  as well as in vitro (Kim et al., 
2008a). Although the role of the functional domains of Tat has been explored in regard to 
neuronal cell death (Aksenov et al., 2009; Mishra, Vetrivel, Siddappa, Ranga, & Seth, 
2008), the role of the Tat protein functional domains in producing early synaptodendritic 
damage is poorly understood. 
 Filamentous actin (F-actin) is a major cytoskeletal protein that makes up both pre- 
and post-synaptic structures (Bleckert, Photowala, & Alford, 2012; Cingolani & Goda, 
2008), and F-actin is a key target for stabilizing or destabilizing cellular signals which 
ultimately produce stable synapses (Zhang & Benson, 2001). In this process, globular 
acting (G-actin) is polymerized into F-actin, a more stable form of actin (Hotulainen et 
al., 2009; Johnson & Ouimet, 2006; Sekino, Kojima, & Shirao, 2007). Although dendritic 
spines are some of the most well-studied F-actin rich structures, F-actin is a component 
of a variety of neural structures. For example, F-actin is a major cytoskeletal protein in 
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filopodia (long, headless structures or “pre spines”) (Hotulainen et al., 2009; Jacinto & 
Wolpert, 2001; Kaech, Parmar, Roelandse, Bornmann, & Matus, 2001; Sekino et al., 
2007), and patches or “hot spots” along the dendrite appear as F-actin rich puncta 
(Halpain, Hipolito, & Saffer, 1998). F-actin rich patches appear both at the initiation of 
spinogenesis (Johnson & Ouimet, 2006), as well as in non-spiny synapses, which are 
typically GABA-ergic (Craig, Blackstone, Huganir, & Banker, 1994; van Spronsen & 
Hoogenraad, 2010). Phalloidin, a form of phallotoxin isolated from the death cap 
mushroom (Amanita phalloides) selectively binds to F-actin, but not monomeric G-actin, 
and has been used to examine the dynamic activity of F-actin in modulating synaptic 
changes (Halpain et al., 1998; Hotulainen et al., 2009; Kaech, Fischer, Doll, & Matus, 
1997; Korobova & Svitkina, 2010). In the present study, the term F-actin puncta referes 
to filopodia, patches, and protruding spines but not growth cones (F-actin rich structurese 
at the most distal ends of the neurite). Quantification of F-actin puncta detects pre- and 
post-synaptic changes as awell as changes in the number of inhibitory and excitatory 
synapses. Thus, increases or decreases in the quantity of F-actin puncta suggest 
disruptions in excitatory and inhibitory signaling, which may translate to dysfunctional 
synaptic communication. 
 Previous work in our laboratory has shown that neuronal death in vitro occurs 
after 48 hours of exposure to Tat 1-86 (Aksenov et al., 2009), and moreover, a mutation 
at Cys22 in Tat 1-86 eliminates neuronal death induced by HIV-1 Tat 1-86 exposure 
(Aksenov et al., 2009). The present study examines early Tat protein effects on dendritic 
integrity at a time prior to cell death, and additionally uses synthetic HIV-1 Tat peptides 
to examine the importance of the highly conserved cysteine rich domain in producing 
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synaptodendritic injury, an important indication of function in HAND. Full length Tat 1-
101, Clades B and C, was used to examine specific genetic differences of the Tat protein 
in producing early synaptic damage which may reflect differences in neurocognitive 
impairments between Clades B and C. Synthetic peptide lengths 1-72, 1-72δ31-61, 1-86, 
1-86[Cys22] and 47-57 were used to partition the capacity of the various Tat protein 
functional domains for inducing synaptodendritic damage. Our results suggest that 
synaptic injury due to Tat exposure occurs prior to cell death and is dependent upon key 
protein residues. 
Methods 
 Primary hippocampal cell cultures. Primary hippocampal cell cultures were 
prepared from 18-day old Sprague-Dawley rat fetuses as previously described (Aksenov 
et al., 2009; Aksenov et al., 2006; Bertrand, Aksenova, Aksenov, Mactutus, & Booze, 
2011). Procedures were carried out in accordance with the University of South Carolina 
Institutional Animal Care and Use Committee (animal assurance number: A3049-01). Rat 
hippocampi were dissected and incubated for 10 minutes in a solution of 2mg/ml trypsin 
in Hank’s balanced salt solution (HBSS) buffered with 10 mM HEPES (GIBCO Life 
Technologies, Grand Island, NY). The tissue was then exposed for 2 minutes to soybean 
trypsin inhibitor (1mg/ml in HBSS) and rinsed 3 times in HBSS. Cells were dissociated 
by trituration and distributed to poly-L-lysine coated culture dishes (Costar, Cambridge, 
MA; MatTek Corporation, Ashland, MA). For cytomorphological studies, hippocampal 
cells were cultured in 35mm glass-bottom cell culture dishes (MatTek Corporation, 
Ashland, MA). For cell viability measurements, hippocampal cell cultures were grown in 
96-well plastic plates (Costar, Cambridge, MA). At the time of plating, plates contained 
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DMEM/F12 (GIBCO) supplemented with 100 mL/L fetal bovine serum (Sgima 
Chemicals, St. Louis, MO). After a 24-h period, DMEM/F12 was replaced with an equal 
amount of serum-free Neurobasal medium supplemented with 2% v/v B-27, 2mM 
GlutaMAX supplement and 0.5% w/v D-(1)-glucose (all ingredients from GIBCO). 
Cultures (maintained in the serum-free growth medium) were used for experiments at the 
age of 14-21 days in vitro (DIV) and were >85-90% neuronal as determined by 
anti0MAP-2/anti-GFAP/Hoescht fluorescent staining. 
 Experimental treatment of cultures. The treatment of hippocampal cell cultures 
with HIV-1 Tat was carried out by the addition of 10µL of freshly prepared stock 
solution of a recombinant Tat variant (Table 1.1) into the cell culture growth medium. An 
equal volume of vehicle was added to control cell cultures. Tat variants were produced 
using similar recombinant and purification techniques and were determined to be greater 
than 90% pure and free of endotoxin contamination. Primary hippocampal cells were 
incubated with 50nM of each Tat variant for either 24 h (F-actin) or 48 h (Live/Dead 
viability). Investigators were blind to the treatment condition of the cultures. 
Table 2.1 List of HIV-1 Tat variants, lengths, and vendors. 
Peptide Length Clade Vendor 
 1-86  B Diatheva, Italy 
1-86[Cys22] -- Diatheva, Italy 
1-101 B Immunodiagnostic, MA USA 
1-101 C Prospec, Israel 
1-72δ31-61 -- U. of Kentucky, USA 
1-72 B U. of Kentucky, USA 
47-57 -- Anaspec, CA USA 
 
 Fluorescent labeling and immunocytochemistry – 24 h Tat exposure. The 
fluorescent and immunofluorescent labeling of hippocampal cells were carried out in 
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primary cultures prepared in 35 mm glass-bottom cell culture dishes (MatTek 
Corporation, Ashland, MA). Cultures were fixed with 4% paraformaldehyde and cells 
were permeabilized in 0.1% Triton X-100 and then incubated for 20 minutes at room 
temperature with an F-actin specific probe, Alexa Fluor 488 phalloidin (0.165µM) 
(Invitrogen Life Technologies, Grand Island, NY). Fixed hippocampal cell cultures were 
incubated with 10% normal horse serum (NHS) in PBS to block nonspecific binding and 
then used for labeling the cells with rabbit polyclonal MAP2 (1:1000, Santa Cruz 
Biotechnologiy, Inc, Santa Cruz,CA). The secondary antibody for immunofluorescent 
staining was Alex Red 594-conjugated goat anti-rabbit IgG (1:5--, Invitrogen Life 
Technologies, Grand Island, NY). Blue fluorescent Hoescht dye was used to identify cell 
nuclei. 
 Images of F-actin/MAP2 fluorescently co-labeled hippocampal cell cultures were 
acquired using a high resolution CCD camera attached to the Nikon Eclipse TE2000-E 
inverted fluorescent computer-controlled microscope (20x objective, 1600 x 2000 pixel 
image size, 0.17 µm/px image resolution at 1x zoom). At least 3 [Green (F-actin; 
phalloidin staining)/Red (MAP2 immunolabeling)/Blue (Hoescht staining)] individual 
pyramidal neurons with clearly defined dendritic arbors and normal nuclear morphology 
per culture well were randomly selected and analyzed using the NIS-Elements software 
package (Nikon). For each neuron selected, F-actin rich synaptic structures were 
manually counted in several (2-3) digitally magnified dendrites (25-75µm-long, second 
order bifurcations). Only those dendritic segments with normal morphology (continuous 
MAP-2 staining; no beading or varicosities) were included in the analysis. F-actin puncta 
were identified by using the 518 wavelength emission channel. The low background 
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fluorescence of non-synaptic structures was subtracted (20-60 fluorescence units), 
allowing clear visualization of puncta. The length of the neurite segment was recorded 
and the number of puncta was divided by this length and multiplied by 10 yielding puncta 
per 10 µm. F-actin rich structures, or puncta, included for analysis were fine filopodia, 
spine protrusions, and dendritic F-actin patches. Growth cones (F-actin rich structures 
located at the most distal dendritic terminus) were excluded from analysis. 
 Cell viability – 48 h Tat exposure. The hippocampal cell viability was assessed in 
primary neuronal cell cultures prepared in 96-well cell culture plates (Costar, Cambridge, 
MA) using the microplate reader-formatted variant of the fluorescent calcein 
AM/ethidium bromide cell labeling assay (Live/Dead kit, Invitrogen, Carlsbad, CA) as 
described previously (Adams et al., 2010; Adams et al., 2012; Aksenova et al., 2009; 
Aksenov et al., 2006; Aksenova et al., 2006). Fluorescence was measured using a Bio-
Tek Synergy HT microplate reader (Bio-Tek Instruments, Inc., Winooski, VT). Data are 
presented in a ratio of calcein fluorescence (live) divided by ethidium fluorescence 
(dead). 
 Statistical analysis. Statistical comparisons were performed with SPSS version 19 
(IBM, New York, NY) using a two-way ANOVA. Tukey’s multiple comparison tests 
were used to determine specific treatment effects. Significant differences were 
determined with an alpha level set at p≤0.05. Data are presented as mean values ± 





 Tat 1-86B and Tat 1-101B produce similar synaptodendritic damage.  
Tat 1-86B and Tat 1-101B are both Clade B protein variants differing only in their 
residue length. The current experiment was performed to evaluate differences, if any, in 
puncta loss, cell viability and neurite integrity between the two variant lengths. The 
synaptodendritic integrity of primary hippocampal cells was evaluated by calculating the 
density of F-actin puncta 24 h after exposure to Tat 1-101B (50nM) or Tat 1-86 (50nM). 
There was an overall significant main effect of treatment on puncta loss F(2,24)=13.14, 
(p≤0.001). Tukey’s multiple comparison tests confirmed that Tat 1-101B (p≤0.001) and 
Tat 1-86 (p≤0.001) induced significant loss of F-actin puncta when compared to controls, 
but failed to differ significantly from one another (Fig 2.1A). 
 Cell viability of primary hippocampal cell cultures was evaluated 48 h after 
exposure to 50nM Tat 1-86B or 50nM Tat 1-101B using a Live/Dead assay. There was an 
overall significant main effect of treatment on viability F(2.24)=70.24, (p≤0.001). Post-
hoc analyses using Tukey’s multiple comparisons test determined that Tat 1-101B 
(p≤0.001) and Tat 1-86 (p≤0.001) produced significant cell death, 34% and 29% 
respectively, when compared to controls, but failed to differ significantly from one 
another (Fig 2.1B). 
 After 24 h, neurons displayed a normal pyramidal morphology (Fig 2.1C). 
However, relative to control neurons, which had robust F-actin staining and complex 
dendritic branching patterns, both Tat 1-86B and Tat 1-101B treated neurons 




Figure 2.1 Tat 1-86 and Tat 1-101B produce similar synaptodendritic damage. A. Tat 1-
86 or Tat 1-101B treatment (50nM) for 24 h produced significant loss of F-actin puncta. 
Second order dendritic branches were selected from 20x images of F-
actin/MAP2/Hoescht-stained Tat-treated control pyramidal hippocampal neurons for 
puncta quantification. Results are presented as mean F-actin labeled puncta per 10 µm of 
neuronal dendrite ± SEM. *-- indicates a significant (p≤0.05) difference relative to 
control. B. Tat 1-86 and Tat 1-101B treatment (50nM) for 48 hours produced significant 
cell death. Fluorescent units were determined in hippocampal cell cultures using 
Live/Dead assays. Results are presented as mean fluorescence values ± SEM. *--indicates 
a significant (p≤0.05) difference relative to control. C. Contronl Tat 1-86 (50nM) and Tat 
1-101B (50nM) treated neurons labeled with F-actin (green)/MAP-2 (red)/Hoescht (blue. 
The hippocampal pyramidal neuron in the control condition demonstrated robust F-actin 
labeling (green) and complex branching patterns. Both of the Tat treated neurons had 
greatly diminished F-actin staining (green), and decreased dendritic branching (red) 
relative to controls. Scale bar = 50µm. 
 Tat 1-86[Cys22] and Tat 1-101C do not produce damage.  
Tat 1-101C is a naturally occurring variant of the Tat protein with a mutation at Cys31, 
whereas Tat 1-86[Cys22] is a synthetic peptide with a mutation at Cys22. Our previous 
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work demonstrated that a mutation in the cysteine rich domain attenuates decreases in 
cell viability at 48h after Tat 1-86 exposure (Aksenov et al., 2009). The present 
experiment was undertaken to determine if changes in puncta loss, viability or neuronal 
morphology were residue specific, or could be generalized to the cysteine rich domain. 
The synaptodendritic integrity of primary hippocampal cells was evaluated by calculating 
the density of F-actin puncta 24h after exposure to either Tat 1-101C (50nM) or Tat 1-
86[Cys22] (50nM). There was no significant overall main effect of treatment on F-actin 
puncta (Fig 2.2A). Cell viability of primary hippocampal cell cultures was evaluated 48 h 
after exposure to 50nM Tat 1-101C or 50nM Tat 1-86[Cys22] produced neuronal cell 
death (Fig 2.2B). The morphologic appearance of the hippocampal pyramidal cells (Fig 
2.2C) did not differ from controls with all groups displaying intact dendrites, complex 
branching patterns and abundant F-actin staining. 
The cysteine rich region of Tat is critical for synaptodendritic damage.  
The prior experiments determined that the cysteine region was vital to the loss of F-actin 
puncta and cell death. This experiment examined the effects of the cysteine region 
relative to the core and basic domains of the Tat protein. Tat 1-72 was used to determine 
if the second exon was essential for either the puncta loss, cell death, or dendritic 
integrity. The Tat protein deletion mutation, Tat 1-72δ31-61, further assessed the relative 
importance of the cysteine rich domain and the arginine rich domain. However, as a small 
portion of the cysteine rich domain was present in the deletion mutant, the short peptide 
Tat 47-57 was also examined to assess the importance of internalization of the protein to 
puncta loss and cell death. 
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Figure 2.2 Tat 1-101C and Tat 1-86 (Cys22) do not produce synaptodendritic injury.  
A. Tat 1-86 (Cys22) or Tat 1-101 Clade C treatment (50nM) for 24 h did not produce 
significant loss of F-actin puncta relative to controls. Second order dendritic branches 
were selected from 20x images of F-actin/MAP2/Hoescht-stained Tat-treated and non-
treated control pyramidal hippocampal neurons for puncta quantification. Results are 
presented as mean F-actin labeled puncta per 10 µm of neuronal dendrite ±SEM. B. Tat 
1-101 Clade C or Tat 1-86 (Cys22) treatment (50nM) for 48 h did not produce cell death. 
Fluorescent units were determined in hippocampal cell cultures using Live/Dead assays. 
Results are presented as mean values ± SEM. C. Control, Tat 1-86 (Cys22) (50nM) and 
Tat 1-101 Clade C (50 nM) treated neurons labeled with F-actin(green)/MAP-2 
(red)/Hoescht (blue). The hippocampal pyranmidal neuron in the control condition 
demonstrates robust F-actin labeling (green), and complex branching patterns, suggesting 
that treatment with these peptides does not produce significant changes in dendritic 
integrity. Scale bar = 50µm.  
 
 The synaptodendritic integrity of primary hippocampal cells was evaluated by 
calculating the density of F-actin puncta 24h after exposure to Tat 1-72 (50nM), Tat 1-
72δ31-61(50nM), or Tat 47-57 (50nM). There was a significant overall effect of 
treatment on puncta density F(3,32)=4.91 (p≤0.006). Tukey’s multiple comparisons 
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confirmed that Tat 1-72 produced significant puncta loss (p≤0.05), but Tat 1-72δ31-61 
and Tat 47-57 failed to produce significant puncta loss compared to controls (Fig 2.3A). 
 The control, Tat 1-72δ31-61, and Tat 47-57 treated pyramidal neurons all 
displayed complex branching patterns, extensive fine networks and strong F-actin 
labeling (Fig. 2.3C). In contrast, neurons treated with Tat 1-72 produced less branching, 
resulting in simplification of the fine network and reduced F-actin staining. 
Figure 2.3 The cysteine rich domain of Tat protein is critical for producing 
synaptodendritic injury. A. Tat 1-72 treatment (50nM) for 24 h produced significant loss 
of puncta relative to controls; however, Tat 1-72δ31-61 (50nM) or Tat 47-57 treatment 
(50nM) for 24 h did not produce significant loss of F-actin puncta. Second order dendritic 
branches were selected from 20x images of F-acin/MAP2/Hoescht-stained Tat-treated 
and non-treated control pyramidal hippocampal neurons for puncta quantification. 
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Results are presented as mean F-actin labeled puncta per 10 µm of neuronal dendrite 
±SEM. *--indicates a significant (p≤0.05) difference relative to control. B. Tat 1-72 
treatment (50nM) for 48 h produced significant cell death; however, Tat 1-72δ31-
61(50nM) or Tat 47-57 treatment (50nM) for 48h did not produce cell death. Fluorescent 
units were determined in hippocampal cell cultures using Live/Dead assays. Results are 
presented as mean values ±SEM. *--indicates a significant (p≤0.05) difference relative to 
control. C. Control, Tat (47-57) (50nM), Tat 1-72 (50nM), and Tat 1-72δ31-61 (50nM) 
treated neurons labeled with F-actin (green)/MAP-2 (red)/Hoescht (blue). The 
hippocampal pyramidal neuron in the control condition, Tat (47-57) and Tat 1-72δ31-61 
show robust F-actin labeling (green), and complex branching (red). Treatment with Tat 1-
72 resulted in diminished F-actin staining (loss of green) and decreased dendritic 
branching. Scale bar = 50 µm. 
Discussion 
 In the current study, synthetic HIV-1 Tat peptides of varying lengths with specific 
mutations or deletions were used to examine the effects of the Tat functional domains on 
synaptodendritic injury. We found that Tat variants with an intact cysteine rich region 
(residues 22-37) in the first exon, regardless of protein length, produced significant early 
damage to the synaptic network and later cell death. Conversely, Tat protein variants with 
a mutation, deletion, or a lack of a cysteine rich domain, failed to induce synaptic damage 
or later cell death. These results suggest that the cysteine rich domain plays a role in the 
early neuropathological event of synaptodendritic injury. Synaptic injury is currently the 
best neuropathologic correlate of cognitive decline in HAND (Ellis et al., 2007). Synaptic 
dysfunction and neurocognitive impairments are generally evident long before neurons 
die in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease (van 
Spronsen & Hoogenraad, 2010; Coleman, Federoff, & Kurlan, 2004). Although the direct 
relationship between specific synaptic dysfunction(s) and HAND remains unclear, the 
identification of viral attributes capable of producing synaptic damage/dysfunction (one 
being the presence of specific Tat protein domains) is key to understanding HAND. 
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 F-actin is a key marker for synapse stability (Zhang & Benson, 2001). Our F-actin 
stained puncta structurally include excitatory synapses (Hotulainen et al., 2009; Jacinto & 
Wolpert, 2001), inhibitory synapses (Craig et al., 1994), and both pre-/post-synaptic 
structures (Bleckert et al., 2012; Cingolani & Goda, 2008), allowing for the overall 
assessment of synaptic integrity. We observed a reduction of F-actin puncta and general 
dendritic field simplification in response to Tat peptides with the cysteine rich region 
intact (Tat 1-72, Tat 1-86, Tat 1-101B). Extending the peptide length (from 72 to 86 and 
101 aa) did not significantly affect the pronounced loss of puncta, suggesting that the 
second exon does not play a key role in Tat-induced synaptodendritic injury. Tat 1-72 is 
not a naturally occurring human isolate; however, Tat 1-101 (Rosen et al., 1986) and Tat 
1-86 (Barre-Sinoussi et al., 1983) have both been reported in human plasma following 
HIV-1 infection. Although the neural uptake of Tat 1-86 has been shown to be more 
efficient than that of Tat 1-72 (Ma & Nath, 1997), the present results suggest that protein 
uptake may not be necessary for puncta loss and dendritic network degradation. 
 Additionally, Tat 1-72, Tat 1-86, and Tat 1-101B have previously been shown to 
cause cell death at later time points in cell culture models (Aksenova et al., 2009; King et 
al., 2006; Mishra et al., 2008). In the present studies we confirmed these original reports 
for the individual proteins (cell death at 48 h), and further demonstrate that these protein 
variants do not significantly differ in their ability to decrease viability. Moreover, we now 
report that these recombinant proteins (1-86[Cys22], 1-101C, 1-72δ31-61), from the same 
manufacturers and produced under similar conditions, did not produce damage, thereby 
eliminating the concern of endotoxin contamination confounding the synaptodendritic 
damage and cell death profile for these particular Tat protein variants. 
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 The Tat protein is subject to genetic variations and modifications (Li et al., 2012). 
HIV-1 Tat is encoded by two exons, and has several distinct functional domains which 
are essential for viral replication and are responsible for cell death (Karn, 1999; 
Kuppuswamy et al., 1989). The first three domains: the acidic domain (1-21), the 
cysteine rich domain (22-37), and the core/hydrophobic region (38-58) represent the 
minimal number of residues required for the transactivation capabilities of Tat 
(Debaisieux et al., 2012; Kuppuswamy et al., 1989). The basic domain (49-72) can be 
broken down into two subdomains: the arginine-rich domain (49-57) and the glutamine 
rich domain (58-72) (Li et al., 2012). Modifications and mutations are relatively well-
tolerated within the acidic domain (1-21), but mutations in residues 22-40 are deleterious 
to transactivation function (Jeang et al., 1999; Kalantari et al., 2008; Kuppuswamy et al., 
1989; Ruben et al., 1989) and have been shown to attenuate Tat induced neuronal cell 
death (Aksenov et al., 2009; Campbell, Watkins, Loret, & Spector, 2011). 
 The present study used peptides with mutations at Cys22 (1-86[Cys22]), and Cys 
31 (Tat 1-101C), and demonstrated that these mutations do not cause significant puncta 
loss. Additionally, we used Tat 47-57 which includes the last two residues of the core 
domain (38-48) and the arginine rich domain (49-57) – the region responsible for binding 
to cell membranes and for uptake into adjacent cells (Debaisieux et al., 2012; Jeang et al., 
1999; Kuppuswamy et al., 1989; Ruben et al., 1989) – but lacks the cysteine rich 
domain(22-37), Tat 47-57 did not produce losso f F-actin puncta, suggesting that 
neuronal uptake aloe is not responsible for Tat effects. Indeed, Tat 1-72δ31-61 (the first 
exon with the end of the cysteine rich domain, the arginine rich domain, and part of the 
glutamine rich region deleted), did not produce significant loss of F-actin puncta, 
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accentuating the importance for the cysteine rich domain for induction of puncta loss, and 
moreover, that neuronal uptake of the Tat peptide is not necessary for puncta loss. 
 HIV-1 neurocognitive related deficits have been reported as more common in 
Clade B prevalent areas (North America and Europe) relative to Clade C areas (Sub-
Saharan Africa and Asia) (Satishchandra et al., 2000; however, see Gupta et al., 2007). 
HIV-1 Tat C, which has a mutation t Cys31, has been shown to be less neurotoxic than 
Clade B Tat (Aksenov et al., 2009; Mishra et al., 2008; Ranga et al., 2004). The present 
study confirms that Tat 1-101C also does not produce a significant loss of F-actin puncta. 
Although Tat may not mediate neurocognitive deficits in the Clade C population, there 
are other HIV-1 proteins, such as  gp120, known to cause neuronal death (Bansal et al., 
2000; Kaul et al., 2001) and synapse loss (Kim, Shin, & Thayer, 2011). Thus, elucidating 
further differences in HIV-1 proteins between the two clades remains an important 
question and may shed light on the relationship between synaptic dysfunction and 
HAND. 
Conclusions 
 In the present study, F-actin puncta provided a broad assessment of early 
synaptodendritic damage produced by variants of HIV-1 Tat protein. An intact cysteine 
rich domain of the Tat protein exon 1 is critical for producing synaptodendritic injury; 
however, Tat protein uptake into the neurons is not necessary for damaging synapses. 
Greater understanding of the cellular mechanisms of synaptodendritic damage and 
dysfunction may aid in the treatment of HIV-1 assciated neurocognitive disorders. 
Although the direct relationship between specific excitatory/inhibitory synaptic 
dysfunction(s) and HAND remains unclear, the identification of viral attributes capable 
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of producing synaptic damage/dysfunction (e.g. the presence/absence of specific Tat 
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 HIV-1 enters the central nervous system early in the infection process and may 
ultimately result in an array of deficits, collectively known as HIV-1 associated 
neurocognitive disorders (HAND) (Antinori et al., 2007). Although the incidence of the 
most severe dementia has decreased as the development of combination anti-retroviral 
therapy (cART), neurocognitive deficits continue to persist in more than 40% of HIV-1 
infected individuals (Lindl et al., 2010; Letendre, 2011). The continued prevalence of 
HAND despite the success of cART (Ances & Ellis, 2007; Lindl et al., 2010; Letendre, 
2011) indicates a need to understand the underlying mechanism(s) of HAND and identify 
effective treatments. 
 Neuronal cell death has been observed in post-mortem brain tissue of patients 
with HAND; however, cell death does not correlate well with neurocognitive status 
(Adle-Biassette et al., 1999; Kaul et al., 2001; Ellis et al., 2007). Dendritic pruning, 
decreases in spine density, and degradation of synaptic proteins all correlate more readily 
with HIV-1 induced neurocognitive decline than does cell death (Masliah et al., 1997; 
Adle-Biassette et al., 1999; Kaul et al., 2001). Moreover, loss of dendrites and decreased 
synaptic density in the frontal cortex from HIV+ patients has been reported with latent 
viral infection (Desplats et al., 2013). 
 During latent HIV-1 infection, the provirus is incorporated into cellular DNA, 
without the expression of viral RNA  (Wu, 2004). Current anti-retroviral drugs 
effectively suppress peripheral viral load, but do not prevent the continued latent 
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production of HIV-1 neurotoxic proteins (i.e. Tat) once the proviral DNA is incorporated 
into the brain (Li, Li, Steiner, & Nath, 2009). HIV-1 provirus containing cells can thereby 
produce and release Tat into the extracellular space (Pugliese et al., 2005; Bachani, 
Sacktor, McArthur, Nath, & Rumbaugh, 2013) and Tat can interact with the cell surface 
of other, non-infected cells, such as neurons. HIV-1 Tat protein has been found to 
decrease dendritic spine and synaptic density in vitro and in vivo (Everall et al., 1999; 
Kim et al., 2008a; Fitting et al., 2010a). Therefore, a more detailed understanding of how 
HIV-1 Tat interacts with the dendritic network may aid in preventing neuropathological 
dendritic pruning and synaptic loss during latent HIV-1 infection. 
 Filamentous actin (F-actin) is one of the major cytoskeletal proteins that make up 
pre- and post-synaptic structures. Polymerization of globular actin (G-actin) into F-actin, 
a more stable form of actin, occurs prior to spinogenesis (Johnson & Ouimet, 2006). 
Although dendritic spines are rich in F-actin, where F-actin is found in the spine head and 
shaft (Sekino et al., 2007; Dent, Merriam, & Hu, 2011), dendritic spines are not the only 
F-actin rich structures found on the neurite (Hotulainen et al., 2009; Halpain et al., 1998; 
Lau, Zucker, & Bentley, 1999; Johnson & Ouimet, 2006). F-actin is associated with both 
pre- and post-synaptic structures (Johnson & Ouimet, 2006), including non-spiny 
synapses; therefore, changes in the F-actin rich structures i.e. dendritic F-atin puncta, 
suggest overall alterations in synaptic connectivity not limited to spines. Phalloidin, a 
form of phallotoxin isolated from the death cap mushroom (Amanita phalloides), 
selectively binds to F-actin, but not monomeric G-actin, and has been used to examine 
the dynamic activity of F-actin in modulating synaptic plasticity (Kaech et al., 1997; 
Halpain et al., 1998; Hotulainen et al., 2009; Korobova & Svitkina, 2010). 
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 Interestingly, estrogens modulate spine concentrations of F-actin (Kramar et al., 
2009; Sanchez et al., 2009), suggesting estrogenic therapeutic approaches to correcting F-
actin loss and restoration of neuroplasticity. Phytoestrogens are plant-derived diphenolic 
compounds found to partially mimic mammalian estrogen in structure and function 
(Glazier & Bowman, 2001; Lephart, Setchell, & Lund, 2005). Daidzein (DAI) is a 
phytoestrogen isoflavone found in soybeans (Mortensen et al., 2009). DAI has been 
shown to be neuroprotective against glutamate excitotoxicity and Aβ25-35 –induced 
apoptosis (Zhao, Chen, & Diaz, 2002). We have reported that DAI is protective against 
acute HIV-1 Tat-induced apoptosis (Adams et al., 2012). 
 The novel flavonoid, liquiritigenin (LQ), is one of the active compounds of 
MF101, an herbal remedy used to treat menopausal symptoms (Mersereau et al., 2008). 
LQ has been isolated from Chinese licorice root, glycyrrhiza uralensis, and identified asa 
selective estrogen receptor beta (ERβ) agonist (Paruthiyil et al., 2009). Previous studies 
have shown that LQ has anti-inflammatory effects, prevents neurocognitive deficits and 
neurotoxicity induced by the Aβ protein in animal models (Liu, Zou, & Lu, 2009; Liu, 
Zou, Fu, & Lu, 2010; Liu, Tang, Zou, Fu, & Lu, 2011). LQ has been used in Traditional 
Chinese Medicine to treat senile dementia (Lin et al., 2012). Together, the ERβ 
specificity of LQ as well as the ability of LQ to prevent neurocognitive decline in animal 
models, sugget that LQ could be neuroprotective against HIV-1 Tat-mediated cell death 
and synaptodendritic damage. 
 Neurocognitive deficits associated with latent HIV-1 infection continue to persist 
despite successful suppression of peripheral viral load by anti-retroviral therapy (Heaton 
et al., 2010; Desplats et al., 2013). Synaptodendritic injury is closely tied to cognitive 
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decline in HAND (Ellis et al., 2007). However, there are currently no treatments to 
prevent or attenuate synaptodendritic injury that occurs during HIV-1 infection. In this 
study, the neurorestorative potential of DAI and LQ was evaluated by monitoring their 
ability to prevent, and enhance recovery from, synaptodendritic injury produced in vitro 
by the HIV-1 protein, Tat 1-86B. The effects of DAI and LQ on restoration of the 
dendritic network were determined following withdrawal of Tat, and the role of estrogen 
receptors in the phytoestrogen-induced recovery process was determined through the use 
of tamoxifen. Collectively, these results determined the neuroprotective and 
neurorestorative potential of DAI and LQ treatment in HIV-1 Tat-induced 
synaptodendritic injury. 
Methods 
Primary neuronal cell culture 
Primary cell cultures were prepared from embryonic 18  Sprague-Dawley rat fetuses as 
previously described (Aksenova et al., 2009; Bertrand et al., 2011). Timed-pregnant 
females were obtained from Harlan Laboratories, Inc., Indianapolis, IN, USA. In brief, 
hippocampal regions were dissected and incubated for 10 min in a solution of 2mg/mL 
trypsin in Hank’s balanced salt solution (HBSS) buffered with 10mM HEPES (GIBCO 
Life Technologies, Grand Island, NY, USA). The tissue was then exposed to soybean 
trypsin inhibitor (1mg/mL in HBSS) and rinsed three times in HBSS. Cells were 
dissociated by trituration and distributed to poly-L-lysine coated glass bottom   35mm 
dishes (MatTek Corporation, Ashland, MA, USA) for cell viability measurements. Initial 
plating density in 96-well plates was approximately 160-180 cells/mm2; in the 35 mm 
dishes the initial density was 120-140 cells/mm2. A lower plating density was usedi n 35 
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mm dishes for clear identification of second order branching patterns. At the time of 
plating, culture dishes contained Dulbecco’s modified Eagle’s medium/Ham’s nutrient 
mixture F-12 (GIBCO, Life Technologies) supplemented with 10% fetal bovine serum 
(Sigma Chemicals, St Louis, MO, USA). After a 24-h period, Dulbecco’s modified 
Eagle’s medium /Ham’s nutrient mixture F-12 was replaced with an equal amount of 
Neurobasal (serum-free) medium, without phenol red, supplemented with 2% v/v B27, 
2mM GlutaMAX supplement, and 0.5% w/v D-1 glucose (all ingredients from GIBCO). 
Cultures were maintained at 37°C in a 5% CO2/95% room air-humidified incubator at all 
times. Serum-free culture medium was supplemented at weekly intervals. Cultures were 
used for experiments at the age of 21 days in vitro (DIV) and were >85-90% neuronal as 
determined by anti-MAP2/antGFAP/Hoescht fluorescent staining (Bertrand et al., 2011). 
 All animal protocols were reviewed and approved by the Animal Care and Use 
Committee at the University of South Carolina (animal assurance number: A3049-01). 
 Experimental treatment of cell cultures. 
The treatment of hippocampal cell cultures with HIV-1 Tat was carried out by the 
addition of 10µl freshly prepared stock solutions of recombinant Tat 1-86B (LAI/Bru 
strain of HIV-1 clade B. GenBank accension no. K02013) (Diatheva, Fano, Italy) to the 
serum-free cell culture growth medium (50nM final concentration). An equal volume of 
vehicle was added to control cultures. Prior work has shown that Tat 1-86B effects on the 
synaptodendritic arbor to be highly selective and dependent upon the presence of an 
intact cysteine domain, which is present in the HIV-1 Tat 1-86B (Bertrand et al., 2013). 
 Hippocampal cell cultures were treated with DAI (≥98.5% purity; Indofine 
Chemical Hillsborough, NJ, USA), LQ (≥98.5% purity; Indofine Chemical), and 
tamoxifen (TMX) (Tamoxifen citrate; Tocris Bioscience, Ellisville, MD, USA), DAI and 
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TMX were initially dissolved in dimethylsulfoxide and then diluted in phosphate-
buffered saline (PBS). LQ was initially dissolved in methanol and then diluted in PBS. 
For the studies of acute injury and cell death, the cells were treated with DAI and LQ for 
24 h prior to Tat treatment and assessed at either 24 h (F-actin puncta) or 48 h (Cell 
death). For recovery studies, DAI or LQ, (with or without TMX) were added to cultures 6 
days after Tat treatment with assessments of F-actin puncta conducted 3 days later (i.e. 9 
days after initial Tat treatment). TMX was used as initially described (Murphy & Segal, 
1996) in studies of primary hippocampal cell cultures/spine morphology to modulate 
spine density. TMX was found to block the 17-β-estradiol-induced increase in spine 
density in the cultured hippocampal cells (Segal & Murphy, 2001), and not to increase 
neuronal process outgrowth or morphological complexity (O'Neill, Chen, & Brinton, 
2004). For our hippocampal cell culture/morphological endpoints, the long-standing 
evidence in the literature supported the use of TMX. 
 Cell viability.  
Hippocampal cell viability was assessed in primary hippocampal cell cultures prepared in 
96-well culture plates (Costar) using the microplate reader-formatted variant of the 
fluorescent calcein AM/ethidium bromide cell labeling assay (Live/Dead kit; Invitrogen 
Life Technologies) as described previously  (Aksenov et al., 2009; Aksenova et al., 2009; 
Adams et al., 2010; Adams et al., 2012). Initial cell viability measurements were carried 
out after 1, 24, 72, 96, and 144h incubation periods with Tat 1-86B (50nM). Subsequent 
cell viability measurements were carried out after 48-h incubation period with Tat 1-86B 
(50nM) which was preceded by a 24-h pre-treatment with DAI or LQ. Fluorescence was 
measured using a Bio-Tek Synergy HT microplate reader (Bio-Tek Instruments Inc., 
Winooski, VT, USA). Data from treated cells were normalized to data from untreated 
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control cells in adjacent wells from the same plate and are presented as a percent of 
control. For cell viability tests, groups of 7-8 culture wells were analyzed. Two replicates 
for each experiment were performed using cell culture preparations from different 
animals. 
 Fluorescent labeling and immunocytochemistry.  
The immunofluorescent labeling of primary hippocampal cell cultures was carried out in 
glass bottom cell culture dishes (MatTek Corporation). F-actin was visualized using a 
modified protocol for filamentous actin (F-actin) staining (Invitrogen Life Technologies). 
Briefly, treated and control cells were fixed with 4% paraformaldehyde and 
permeabilized with 0.1% Triton X-100 and then treated for 20 min at 21°C with an F-
actin specific probe, AlexaFluor 488 Phalloidin (1:40) (Invitrogen Life Technologies). 
Following F-actin labeling, cells were incubated with 10% normal horse serum (NHS) in 
PBS to block non-specific binding and co-labeled with rabbit polyclonal anti-MAP2 
(1:1000) (Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA) or anti-Tat rabbit 
polyclonal antibody (1:1000) (Diatheva) overnight. The secondary antibody for MAP-2 
and Tat labeling was Alexa Red 594-conjugated goat anti-rabbit IgG (1:500, Invitrogen 
Life Technologies). Identification of cell nuclei was accomplished using direct Hoescht 
dye techniques (ImmunoChemistry Technologies LLC, Bloomington, MN, USA). 
 F-actin puncta.  
Images of co-labeled F-actin/MAP-2 neurons were acquired using a high-resolution CCD 
camera attached to the Nikon Eclipse TE2000-E inverted fluorescent computer controlled 
microscope (20X objective, 1600 x 1200 pixel image size, 0.17 µm/px image resolution 
at 1X zoom; Nikon Instruments, Melville, NY USA). Between 3 and 5 Green (F-
actin)/Red (MAP-2) immunolabeled/Blue (Hoescht) fluorescent images of individual 
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neurons with clearly defined dendritic arbors and normal nuclear morphology per culture 
well were randomly selected and analyzed using the NIS-Elements software package 
(Nikon Instruments). For each neuron selected, F-actin rich structures were identified in 
several (3-4) second order dendritic fragments (length range 25-75 µm) with continuous 
MAP-2 immunofluorescence. Fine folapodia, spine protrusions, and F-actin patches were 
considered F-actin rich structures; in contrast, growth cones (F-actin rich structures 
located at the most distal dendritic terminus) were excluded (Bertrand et al., 2013). 
 Trained independent observers manually counted F-actin puncta from identically 
treated cultures at different times, with a very high correlation (r2=0.97), indicating that 
the green F-actin puncta were readily identified. 
 For computer-assisted methods, F-actin labeled puncta were identified by 
subtracting 20-50 au from the green channel to set the threshold for baseline staining of 
the dendritic shaft. Density was calculated by dividing total F-actin labeled puncta (N) by 
the length (L) of the MAP-2 labeled dendrites. For this study, puncta (size ≤1.5µm) of F-
actin fluorescence with a peak intensity of at least 50% above the average intensity of 
staining in the dendritic shaft were included in each selected dendritic fragment. 
Statistical analysis.  
Statistical coparisons were made using ANOVA techniques with specific a priori 
contrasts and regressions, and were used to determine specific treatment effects. 
Pearson’s product-moment correlation coefficient was calculated to verify inter-rater 
reliability and correlations between computer assisted profiling and manual counting. 
Comparisons and correlations were calculated using BMDP version 2009 (Statistical 
solutions, Saugus, MA, USA). Significant differences were set at p≤0.05. 
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GraphPad/Prism (V5.02; GraphPad Software, San Diego, CA, USA), was used for time 
course analyses. 
Results 
 Tat 1-86B synaptodendritic injury and cell death time course.  
After treatment with 50 nM Tat 1-86B cell viability was monitored at 1, 24, 48, 72, 96, 
and 144 h (Fig. 3.1A). Tat 1-86B failed to induce significant cell death through 24h. Tat 
1-86B induced significant cell death at 48 h (p< 0.001). Cell death reached a plateau at 72 
h with no additional changes at 96 or 144 h. 
 Cell cultures were co-stained for F-actin and MAP-2 at 1, 24, 72, and 144 h after 
addition of Tat (50nM). Tat exposure resulted in degradation of pyramidal cell dendrites, 
indicated by loss of F-actin staining (Fig. 3.1B). In addition to simplification of the 
cellular network, the presence of fibril bundling and fragmentation suggested microtubule 
dysfunction. Tat 1-86B mediated F-actin network degradation occurred earlier than Tat-
mediated cell death, with degradation observed at 24 h. 
 Figure 3.1C illustrates the association of Tat 1-86B (red) with the neuronal 
network (green) at 1 and 24 h in primary hippocampal cell cultures. Subsequent acute 
experiments were performed at 24 h because of the visible change in F-actin rich 
structures, lack of overt cell death, and persistence of Tat 1-86B within the neuronal 
network. 
Computer assisted identification of F-actin puncta.  
Computer-assisted intensity profiling was used to determine the number of F-actin rich 
structures within selected dendritic segments. Figure 3.2A shows representative 
selections of Tat 1086B treated and vehicle treated controls. The computer-assisted  
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Figure 3.1 Time-course of Tat-induced cell death and synaptodendritic alterations. A. 
The viability of primary cultures was assessed at 1, 24,48, 72, 96, and 144 h after 
treatment with Tat. There was no significant cell death through 24 h; however, by 48 h 
there was a significant decrease in cell viability (p≤0.001). By 72 h, cell death reached a 
plateau and remained stable through 144 h. Mean ± 95% confidence interval (CI). B. F-
actin/MAP-2 staining of cell cultures at 1, 24,72, and 144h after Tat 1-86B exposure. Tat 
1-86B treatment produced a simplification of the fine network, as well as bundling and 
fragmentation of neurites at 24 h, which preceded Tat-mediated cell death. Tat-induced 
alterations in the neuronal network persisted through 144 h. C. Representative images 
(20X) of second branch order neuritic fragments co-stained with Alexa 488 phalloidin 
and rabbit polyclonal anti-Tat primary/Alexa Red 594. Tat was associated with the F-
actin labeled network at 1h and 24h post-treatment. 
 
profiles of MAP-2 immunofluorescence (25-75µm length; intensity range 37-110 
arbitrary units, au) in cultures were continuous, indicating the absence of fragmentation 
of MAP-2 labeled dendrites, regardless of treatment group. The peak F-actin fluorescence 
(puncta) varied from 60-200 au within the dendritic segments.  
 As shown in Fig. 3.2b, F-actin rich puncta per 10µm of F-actin/MAP-2 labeled 
dendrite, was significantly (non-overlapping distributions) decreased in neurons exposed 
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to 50 nM Tat for 24h using both computer-assisted and manual counting methods. There 
was a very high correlation between the two methods (r2=0.97). 
 Phytoestrogens are not neurotoxic at 1.0µM doses.  
An overall significant effect of phytoestrogens in protecting against Tat-induced cell 
death was suggested (F(1,71)=54.4, p≤0.001), with a most prominent linear effect of dose 
(F(1,71)=166.4, p≤0.001) and a less prominent quadratic effect of dose (F(1,71) =7.3, 
p≤0.001). 
 To determine the ability of DAI to provide protection against neuronal death, cells 
were pre-treated with DAI for 24 h and then incubated with Tat 1-86B for 48h. There was 
an overall significant main effect of DAI treatment on viability F(4,36)= 40.2, p≤0.001, 
as pre-treatment with DAI protected against Tat-induced toxicity (Fig. 3.3A). Planned 
comparisons indicated that cell viability following treatment with 1.0µM DAI alone was 
not significantly different from untreated control cultures (F<1.0), suggesting that DAI 
alone did not produce neurotoxicity at the highest dose. A quadratic dose-dependent 
effect of DAI was found (F(1,36)=32.6, p≤0.001), with complete neuroprotection 
achieved, as pre-treatment with DAI prevented Tat 1-86B induced cell death in both the 
0.2 and 1.0µM DAI treatment groups (Fs(1,36) >78.0, ps <0.001). 
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Figure 3.2 Computer-assisted identification of F-actin puncta after Tat treatment. A. 
Segments of second order dendritic branches (shown as boxes) were selected from 20X 
images of F-actin/MAP2/Hoescht-stained Tat-treated and non-treated control neurons. 
The computer-assisted intensity profile of F-actin fluorescence (green) showed numerous 
peaks corresponding to F-actin rich structures and valleys corresponding to low baseline 
staining of dendritic shafts. The computer-based intensity profile of MAP2-specific 
immunofluorescence (red) showed uniform labeling of all dendritic segments selected for 
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green line) to provide the mean number of F-actin labeled puncta per 10µm of neuronal 
dendrite ±SEM. B. F-actin puncta were significantly reduced in neurons exposed to Tat 
for 24 h using both computer-assisted intensity profiling and manual counting methods. 
F-actin puncta are readily distinguished and there was a very high correlation between the 
two methods (r2=0.97). 
To determine the ability of LQ to provide protection against cell death, cells were 
pretreated with LQ and then incubated with Tat 1-86B for 48h. There was an overall 
significant main effect of LQ treatment on viability F(4,35) = 25.7, p≤0.001, as pre-
treatment with LQ protected against Tat-induced toxicity (Fig. 3.3B). There was no 
significant difference between LQ-treated cultures and controls, indicating that LQ was 
not neurotoxic (F < 1.0). A linear dose-dependent effect of LQ was found F(1,35)= 77.6, 
p < 0.001, with significant, although not complete, neuroprotection. Specifically, planned 
comparisons indicated that pre-treatment with LQ provided significant prevention of Tat-
mediated cell death in both the 0.1 and 1.0µM LQ dose groups (Fs(1,35) > 7.2, ps<0.01), 
but that both LQ dose groups displayed significantly decreased cell viability relative to 
controls (Fs(1,35) > 7.6, ps< 0.009). Based on the lack of neurotoxicity of 1.0 DAI and 
1.0 LQ (i.e. phytoestrogen treatments not different from untreated controls), the 1.0µM 
doses were used in subsequent studies of dendritic recovery. 
 Phytoestrogen pre-treatment provides protection against acute HIV-1 Tat 
mediated synaptodenritic injury.  
An overall significant effect of phytoestrogens protecting against acute Tat-induced 
synaptodendritic injury was suggested by the significant phytoestrogen treatment effect 
(F(1,58)=8.9, p <0.004) and the significant interaction between Tat and phytoestrogen 
treatments (F(1,58) = 4.9, p≤0.03), without any significant difference between the two 
phytoestrogens (DAI vs LQ) in their neuroprotection (Fs < 1.0). 
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Figure 3.3 Pre-treatment with phytoestrogens provides dose-dependent protection against 
neuronal cell death. A. Cell viability after daidzein (DAI) 24 h pre-treatment and a 48 h 
incubation with 50nM Tat 1-86B. Treatment with 1 µM DAI alone had no significant 
effect on cell viability relative to control cultures (F<1.0). DAI pre-treatment provided 
complete neuroprotection in both the 0.2 µM and 1 µM treatment groups (ps<0.001). 
Results are presented as mean % of control ± SEM. *Indicates significant protection of 
Tat-induced neurotoxicity. B. Cell viability after 24 h liquiritigenin (LQ) pre-treatment 
and a 48h incubation with 50nM Tat 1-86B. There was no significant difference between 
LQ-treated cultures and controls, indicating 1 µM LQ was not neurotoxic. A linear dose-
dependent effect of LQ was found (p≤0.001) with significant, although not complete, 
neuroprotection. Results are presented as mean % of control ± SEM. * Indicates 
significant protection of Tat induced neurotoxicity. 
 
 Daidzein. Fine network integrity was assessed by counting F-actin puncta after 
pre-treatment with DAI (Fig. 3.4A) and then 24h of incubation with Tat 1-86B (Fig. 
3.4B). Planned contrasts indicated that DAI was not significantly different from controls 
(F < 1.0), suggesting that DAI was not significantly different from controls (F < 1.0), 
suggesting that DAI was neither toxic nor stimulatory. However, Tat 1-86B produced a 
significant loss of F-actin puncta (F(1,31) = 10.2, <0.003), and DAI provided significant 
protection against the synaptodendritic damage/puncta loss caused by Tat (F(1,35)= 4.7, 
p < 0.039). 
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 Representative images (Fig. 3.4c-e) show that relative to control cultures (Fig. 
3.4c), Tat treatment induced a simplification of the network (Fig. 3.4d). Moreover, there 
was no significant difference between DAI+Tat treated cultures and controls (Fig. 3.4e), 
indicating that DAI pre-treatment protected against F-actin puncta loss induced by Tat 1-
86B. 
Figure 3.4 Pre-treatment with DAI protects against Tat-induced loss of F-actin puncta. 
A. Chemical structure of daidzein (7,4’-Dihydroxyisoflavone). B. F-actin puncta 
following pre-treatment (24h) with 50nM Tat 1-86B. DAI was neither toxic nor 
stimulatory to production of F-actin puncta; however Tat treatment produced a significant 
loss of F-actin puncta (p≤0.003), and DAI provided significant protection against the 
puncta loss caused by Tat. Results are presented as mean number of F-actin labeled 
puncta per 10µm of neuronal dendrite ± SEM. *Indicates 1 µM DAI pre-treatment 
provided significant protection from damage induced by Tat 1-86B (50nM; 24 hours) 
when compared with cultures treated with Tat 1-86B alone. C-E. Neurons from C. 
vehicle-treated control cultures, D. Tat 1-86B-treated (50nM; 24h) cultures, and E. pre-
treated DAI (1µM; 24 h) + incubated with Tat 1-86B (50nM; 24 h) cultures displaying 
typical F-actin (green), MAP-2 (red) and Hoescht (blue) staining for each treatment 
group. The control image shows robust F-actin presence, complex branching patterns, 
and an extensive fine network. Tat 1-86B treatment induced a simplification of the 
network. In contrast, in the DAI pre-treated culture, Tat 1-86B failed to cause network 
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simplification, suggesting DAI pre-treatment protected against Tat-induced 
synaptodendritic alterations. 
Liquiritigenin.  
To determine the ability of LQ to provide synaptodendritic protection, cultures were pre-
treated with LQ to provide synaptodendritic protection, cultures were pre-treated with LQ 
(Fig. 3.5A) and then incubated with Tat 1-86B (Fig. 3.5B). Planned comparisons 
indicated that pre-treatment with LQ did not alter puncta density from controls (F<1.0), 
suggesting that LQ was neither toxic nor stimulatory. However, Tat 1-86B again 
produced a significant loss of F-actin puncta (F(1,27)=13.8, p≤0.001), and LQ provided 
significant protection against the synaptodendritic damage/puncta loss caused by Tat 
(F(1,27)=6.7, p≤0.016). 
 Representative images are shown in Fig. 3.5C-E. Relative to controls (Fig. 3.5C), 
Tat treatment produced significant damage to the network (Fig. 3.5D). The difference 
between LQ+Tat-treated cultures and controls was not significant (Fig. 3.5E), indicating 
that the pre-treatment with LQ protects against Tat 1-86B-induced loss of F-actin rich 
structures. 
Figure 3.5 Pre-treatment with liquiritigenin (LQ) provides protection against Tat-induced 
loss of F-actin puncta. A. Chemical structure of liquiritigenin (4’,7-Dihydroxyflavanone). 
B. Quantification of F-actin puncta with a pre-treatment (24 h) of 1µM LQ and 50 nM 
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Tat 1086B (24h). LQ did not alter F-actin puncta density from control (F<1.0), 
suggesting that LQ was neither toxic nor stimulatory. Tat treatment produced a 
significant loss of F-actin puncta density from control (F<1.0), suggesting that LQ was 
neither toxic nor stimulatory. Tat treatment produced a significant loss of F-actin puncta 
(p≤0.001) and LQ provided significant protection against the puncta loss cuased by Tat 
(p≤0.016). Results are presented as mean number of F-actin labeled puncta per 10 µm of 
neuronal dendrite ± SEM. *Indicates a significant loss of F-actin puncta after Tat 1-86B 
treatment when compared with vehicle-treated controls (p≤0.01). *Indicates 1µM LQ 
pre-treatment provided significant protection from F-actin puncta loss induced by 1-86B 
(50nM; 24 h) when compared with cultures treated with Tat 1-86B alone. C-E. Neurons 
from C. Vehicle-treated control cultures, D. Tat 1-86B-treated (50nM; 24 h) cultures, and 
E. pre-treated LQ (1µM; 24 h) + incubated with Tat 1-86B (50nM; 24 h) cultures, 
displaying typical F-actin (green), MAP-2 (red) and Hoescht (blue) staining for each 
treatment group. The control image shows robust F-actin presence, complex branching 
patterns, and an extensive fine network. Tat 1-86B treatment induced a simplification of 
the dendritic network. In contrast, in the LQ pre-treated culture, Tat 1-86B failed to cause 
network simplification, indicating that LQ pre-treatment protected against Tat-induced 
synaptodendritic alterations. 
Neurorestoration of prior HIV-1 Tat-mediated synaptodendritic injury via 
Daidzein and Liquiritigenin.  
After the cytotoxic effect of Tat was fully developed (6 days), the Tat-containing medium 
was replaced with fresh medium (i.e. without Tat). Three days after medium replacement, 
a significant decrease (F(1,64)=32.2, p≤0.001) in the F-actin puncta remained in cultures 
with prior Tat exposure, relative to controls (Fig. 3.6). The cell cultures treated with DAI, 
LQ, or TMX were not significantly different from control (Fs<1.0), suggesting a lack of 
toxicity from these compounds. However, when either 1.0 µM LQ or DAI were included 
in the replaced medium, a significant increase in F-actin puncta was found (F(1,64)=10.6, 
p≤0.002). To determine if the DAI or LQ neurorestoration was dependent on ER-
signaling, a similar experiment was performed in the presence of tamoxifen (TMX). 
Inclusion of TMX with either DAI or LQ in the cultures with prior Tat exposure blocked 




Figure 3.6 Phytoestrogens enhance the recovery of F-actin puncta from HIV-1 Tat-
induced synaptodendritic injury in an estrogen receptor-dependent mechanism. The 
neurorecovery experiment was initiated by medium replacement after 6 days (i.e. after 
the initial cytotoxic effects of Tat). Three days after medium replacement (9days after 
initial Tat treatment) a significant loss of F-actin puncta remained (p≤0.001) in Tat-
treated cultures. The cull cultures treated on day 6 with either daidzein (DAI), 
liquiritigenin (LQ) or tamoxifen (TMX were not significantly different from controls. 
When either DAI or LQ were added on day 6 to the cultures initially treated with Tat, a 
significant increase in F-actin puncta was detected (p≤0.002). This enhancement by DAI 
or LQ was blocked by the estrogen receptor antagonist TMX (100nM), suggesting 
involvement of estrogen receptors in mediating the recovery of F-actin puncta. Results 
are presented as mean number of F-actin labeled puncta per 10 µm of neuronal dendrite ± 
SEM. *Indicates significant differences (p≤0.05) between indicated groups. 
 
Discussion 
The major findings of this study are (i) acute pre-treatment with either LQ or 
DAI, two plant-derived phytoestrogenic compounds, prevents the loss of F-actin puncta 
induced by HIV-1 Tat. Synaptodendritic damage was quantified by the significant loss of 
F-actin puncta after a short exposure to Tat. And Tat was found to be acutely associated 
with the dendritic arbor. Moreover, (ii) these phytoestrogens were able to promote 
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restoration of F-actin dendritic puncta and dendrites following damage from HIV-1 Tat in 
hippocampal cells. This recovery occurred via an estrogen receptor-mediated mechanism, 
as restoration of F-actin puncta was blocked by tamoxifen. These results suggest that 
DAI, LQ, and compounds of similar chemical structures, could be beneficial in HIV-1 
therapeutics because of their ability to either prevent, and/or enhance recovery, from 
synaptodendritic injury. 
 The brain serves as a reservoir for HIV-1, as cART effectively suppresses viral 
replication in the periphery, but does not eradicate the virus from the brain (Heaton et al., 
2010). Synaptodendritic injury has been found in latent HIV-1 infection, in which active 
viral replication is not present in the brain, despite the presence of proviral DNA. Latent 
HIV-1 infection in humans produces dendritic loss (decreased MAP2 staining) and 
synaptic loss (decreased synaptophysin staining) in the frontal cortex without viral 
replication (Desplats et al., 2013). HIV-1 proviral DNA may produce early proteins, such 
as Tat, without productive viral infection (Wu, 2004). In this study, the co-localization of 
Tat within the F-actin rich dendritic network and the concomitant loss of puncta suggests 
a mechanistic interaction between Tat and synaptodendritic injury, however it is currently 
unknown whether the synaptodendritic loss in human latent HIV-1 infections is caused 
by Tat expression per se. Nevertheless, our in vitro model of HIV-1 Tat exposure 
demonstrates dendritic loss (decreased MAP2 staining) and synaptic loss (decreased F-
actin puncta), similar to that observed in post-mortem tissue from human brain with latent 
HIV-1 infection. 
 F-actin puncta encompass a variety of neuronal structures, the most well-
understood being dendritic spines. Dendritic spines are F-actin rich protrusions from the 
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dendritic arbor, are the sites of post-synaptic excitatory synapses, and change shape 
rapidly in response to extracellular signaling (Kaech et al., 1997; Calabrese, Wilson, & 
Halpain, 2006; Hotulainen et al., 2009; Dent et al., 2011). Non-spiny synapses, typically 
GABA-ergic (Craig et al., 1994), have also been found to contain a significant 
concentration of F-actin and appear as patches or ‘hot spots’ on the dendritic arbor 
(Halpain et al., 1998; Lau et al., 1999). We found that intensity profiling, a semi-
automatic computer-based method, and manual counting produced similar puncta 
densities in vitro. As a result of the varying morphology spines, the ability of F-actin 
staining to detect non-spiny synapses, and the early filamentous stages of spinogenesis, 
the quantification of all F-actin rich structures, or puncta, provides a measurement of 
overall synaptic integrity, healthy of the dendritic network, and potential to recover from 
Tat-induced injury. 
 Although F-actin is known to play a role in spinogenesis and synaptic plasticity, 
the staining of F-actin is a relatively new technique used to image dendritic spines and 
monitor synaptic integrity (Matus, Ackermann, Pehling, Byers, & Fujiwara, 1982; 
Allison, Gelfand, Spector, & Craig, 1998; Sekino et al., 2007). In comparison, the Golgi 
method has been used for well over a century to identify changes in spine morphology 
and density, and is still in use. The Golgi method has been favored over the years because 
of the particular ability of Golgi to produce images with little to no background and 
complete neuronal filling. However, Golgi randomly and unpredictably stains neurons 
and has been found to significantly underestimate spine number and, moreover, fails to 
identify non-spiny synaptic structures and patch morphology (Mancuso, Chen, Li, Xue, 
& Wong, 2012). Non-spiny inhibitory synapses, which can be detected as patches by F-
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actin staining, but are not detected by the Golgi method, are important for normal 
communication between neurons (Heller et al., 2012). 
 In this sudy, we used F-actin to assess the synaptodendritic injury induced by 
HIV-1 Tat, whereas other studies have used Golgi (Sa et al., 2004; Fitting et al., 2010), 
green fluorescent protein coupled to post-synaptic density 95 (GFP-PSD95) labeling 
(Kim et al., 2008a; Shin, Kim, & Thayer, 2012b), or MAP-2 staining (Maragos et al., 
2003) to evaluate the damage to the dendritic arbor. Golgi detects changes in spine 
morphology, but not changes in non-spy synapses or thin filopodia. GFP-PSD95 staining 
can detect only post-synaptic excitatory structures, as GFP-PSD95 staining can detect 
only post-synaptic excitatory structures, as PSD-95 has not been found in non-spiny 
inhibitory synapses (Heller et al., 2012) and is not found in pre-synaptic structures. 
Although pre- and post-synaptic terminals generally correspond to one another (Craig et 
al., 1994), PSD-95 can still be located after F-actin has disappeared from the spine 
(Halpain et al., 1998), suggesting that F-actin may be a more sensitive marker. MAP-2 
staining can detect changes in overall structure of the neuronal arbor, but cannot reliably 
detect subtle changes in spine or patch morphology as microtubules have been observed 
to enter dendritic spines selectively and microtubule entry is activity dependent (Dent et 
al., 2011). Although the aforementioned techniques vary, and the studies determined the 
effects of HIV-1 Tat both in vivo (Maragos et al., 2003; Fitting et al., 2010) and in vitro 
(Shin et al., 2012b; Kim et al., 2008a), collectively these studies indicate that HIV-1 Tat 
produces dendritic damage. Therefore, identifying mechanisms or compounds that either 
prevent or reverse synaptodendritic damage inflicted by HIV-1 Tat may be useful 
approaches for providing neuroprotection during HIV-1 infection. 
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 As a potential therapeutic approach for recovery of synaptodendritic damage, 
estrogen has long been known to rapidly increase dendritic spine density in vivo (Gould, 
Woolley, Frankfurt, & McEwen, 1990; Woolley & McEwen, 1992), specifically through 
regulation of the actin cytoskeleton in spines (Sanchez et al., 2009). Phytoestrogens are 
non-steroidal, diphenolic structures found in plants that have similar chemical and 
structural properties to 17-β-estradiol (Glazier & Bowman, 2001; Lephart et al., 2005). 
We found that phytoestrogens promote recovery from the synaptodendritic injury is 
correlated with the symptoms of HAND (Ellis et al., 2007; Desplats et al., 2013), the 
extent to which synaptic restoration is possible remains unknown. Also unknown is 
whether there might be a critical therapeutic window for promoting effective recovery 
wherein neurorestoration remains possible. Unfortunately, studies of therapeutic 
pathways for enhancing dendritic recovery are few (Kim et al., 2008a; Shin et al., 2012b); 
however, estrogen has been shown to promote spine formation via modulation of F-actin 
in spines (Kramar et al., 2009; Sanchez et al., 2009). The current data suggest that 
phytoestrogens, possibly acting via F-actin, may provide a novel intervention for 
promoting neurorestoration. The activation of estrogen receptors has been shown to play 
a key role in modulation of dendritic spine dynamics (Liu et al., 2008; Kramar et al., 
2009; Sanchez et al., 2009; Srivastava, Woolfrey, Liu, Brandon, & Penzes, 2010; Phan, 
Lancaster, Armstrong, MacLusky, & Choleris, 2011), suggesting the estrogen receptor 
may be a useful target in ameliorating synaptodendritic injury, such as that seen in 
HAND. 
 Previous studies have shown that LQ is a highly specific ERβ agonist, with a 75-
fold binding preference to ERβ over ERα (Mersereau et al., 2008) and only activates ERβ 
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(Kupfer et al., 2008; Paruthiyil et al., 2009). DAI preferentially binds to ERβ (Zhao, Mao, 
& Brinton, 2009). The selectivity of LQ for ERβ suggests that LQ acts through an ERβ 
dependent mechanism to prevent synaptodendritic damage induced by HIV-1 Tat; 
however, more experimentation is needed to determine the receptor-dependent 
mechanism of LQ. 
 Our results illustrate that HIV-1 Tat causes an early reduction in F-actin positive 
puncta. Interventions aimed at promoting synaptodendritic integrity following HIV-1 
infection of the nervous system would therefore appear to be an effective approach for 
preventing HAND. Moreover, our results indicate that damage by HIV-1 Tat may be 
repaired by the phytoestrogens, liquiritigenin and daidzein, and estrogen receptor actions 
mediate this neurorestoration. Although it is presently unknown if such reversals can 
improve neurocognitive outcomes, phytoestrogenic compounds, like DAI and LQ, may 
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The use of illicit drugs, like cocaine, significantly increases the risk of HIV-1 
transmission, and continued drug use may compound neurological complications. 
Individuals that use cocaine during HIV-1 infection progress from HIV-1 to AIDS more 
quickly (Fiala et al., 1998; Baum et al., 2009), are more likely to develop neurocognitive 
disorders (Nath et al., 2001; Levine et al., 2006; Carey et al., 2006; Rippeth et al., 2004), 
and display an accelerated progression of HAND (Nath et al., 2001). Neurocognitive 
dysfunction and drug use are two of the most common factors for medication non-
compliance (Panos et al., 2014), thus these individuals have a higher risk for disease 
progression, increased mortality rates, and a lower quality of life (Baum et al., 2009; 
Cook et al., 2007; Doshi et al., 2012; Qian et al., 2014; Nath et al., 2001; Nath, 2010; 
Wisniewski et al., 2005).  
Effective combined anti-retroviral therapy (cART) results in a lack of active viral 
replication. However, infected astrocytes and microglia may continue to release 
neurotoxic proteins, like Tat and gp120, into the extracellular space (Desplats et al., 
2013). HIV-1 proteins interact with neurons to produce dysfunction and damage 
(Desplats et al., 2013; Everall et al., 1999; Masliah et al., 1997; Moore et al., 2006). 
Neuronal damage is predictive of pre-mortem cognitive status than neuronal cell death in 
HAND (Desplats et al., 2013; Everall et al., 1999; Adle-Biassette et al., 1999; Kaul et al., 
2001). In vitro, HIV-1 Tat and gp120 produce synaptodendritic damage prior to overt cell 
death (Kim et al., 2008a; Bertrand, Mactutus, Aksenova, Espensen-Sturges, & Booze, 
2014; Bertrand et al., 2013) and synaptodendritic injury may be a reversible process 
(Bertrand et al., 2014; Kim et al., 2008a).The combination of HIV-1 neurotoxic proteins, 
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like Tat, and cocaine have been shown to enhance neuronal cell death in vitro (Turchan et 
al., 2001;Kendall et al., 2005), however it is unclear how HIV-1 proteins and cocaine 
may interact at the synaptic level to produce damage early in disease. 
Pre- and post-synaptic structures are rich in actin, a dynamic cytoskeletal protein 
(Zhang & Benson, 2001; Hotulainen et al., 2009; Johnson & Ouimet, 2006; Sekino et al., 
2007). Subsequent to cellular signaling, globular actin (G-actin) is polymerized into 
filamentous actin (F-actin), resulting in a stable synaptic structure (Hotulainen et al., 
2009; Johnson & Ouimet, 2006; Sekino et al., 2007). Stabilized synaptic structures are 
rich in F-actin and appear as spots or puncta; presently, we define F-actin puncta as 
protruding dendritic spines, different stages of spine development (patch, filopodia, 
protruding spines) (Hotulainen et al., 2009; Johnson & Ouimet, 2006; Matus et al., 1982; 
Sekino et al., 2007), non-spiny or inhibitory synapses (Heller et al., 2012), and pre-
synaptic structures (Sankaranarayanan, Atluri, & Ryan, 2003; Halpain, 2003). The 
quantification of F-actin puncta allows an overall evaluation of synaptic integrity in vitro. 
Since F-actin puncta encompass a variety of post-synaptic structures and play a role in 
pre-synaptic vesicle stability (Sankaranarayanan et al., 2003; Halpain, 2003) a change in 
overall puncta number suggests altered synaptic communication.  
HIV-1 Tat produces a reduction in dendritic spines in vitro (Kim et al., 2008a) 
and in vivo (Fitting et al., 2010), and produces a reduction in F-actin rich puncta prior to 
cell death in vitro (Bertrand et al., 2014; Bertrand et al., 2013). Indeed, HIV-1 Tat 
increases actin depolymerization in endothelial cells (Wu et al., 2004), and disrupts 
microtubules to induce apoptosis (Chen, Wang, Zhou, & Zhou, 2002). HIV-1 Tat also 
alters NMDA receptor calcium currents via interactions with the actin cytoskeleton 
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(Krogh, Lyddon, & Thayer, 2015). Although it is clear that HIV-1 Tat interacts with the 
actin cytoskeleton, it is unclear if this is a concentration dependent process.  
Cocaine has been shown to cause an increase in the expression of F-actin 
(Kalivas, 2009), and increase dendritic spine density (Martin et al., 2011). Indeed, 
inhibiting the polymerization of G-actin into F-actin prevents morphological changes 
found in the nucleus accumbens of rats acutely treated with cocaine (Toda, Shen, & 
Kalivas, 2010). Although the combination of HIV-1 proteins and cocaine results in 
increased levels of neuronal cell death (Kendall et al., 2005; Turchan et al., 2001), the 
contradictory effects of HIV-1 Tat and cocaine on F-actin make the combined effects of 
HIV-1 Tat and cocaine difficult to predict.  
Estrogen prevents neuronal apoptosis and degeneration in several 
neurodegenerative diseases (Chakrabarti et al., 2014), modulates concentrations of F-
actin in dendritic spines (Sanchez et al., 2009; Kramar et al., 2009), and prevents 
apoptosis in HIV-1 Tat treated cultures (Adams et al., 2010). Furthermore, estrogen 
prevents enhanced levels of neuronal cell death mediated by HIV-1 proteins (Tat, gp120) 
and cocaine in vitro (Kendall et al., 2005; Turchan et al., 2001). However, estrogen does 
not selectively bind and interacts with various receptor subtypes including alpha (ERα), 
beta (ERβ), and G-protein coupled receptor-30 (GPR-30). ERα and ERβ are classic 
steroid receptors; they are located intracellularly where they translocate to the nucleus 
following activation (O'Lone, Frith, Karlsson, & Hansen, 2004). GPR-30 is a membrane 
receptor, responsible for some of the more immediate effects of estrogen (Raz, Khan, 
Mahesh, Vadlamudi, & Brann, 2008), although these effects are not well understood. 
There are high concentrations of ERα in reproductive tissue which has associated ERα 
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activation with the proliferative effects of estrogen. Meanwhile, ERβ is highly expressed 
in the brain (Shughrue, Lane, & Merchenthaler, 1997b), and has been found in 
extranuclear sites (Yang et al., 2004; Sheldahl, Shapiro, Bryant, Koerner, & Dorsa, 2008; 
Herrick, Waters, Drake, McEwen, & Milner, 2006) making it a more likely target for 
neuroprotection. Specific activation of ERβ, or potentially GPR-30, may bypass the 
unwanted side effects produced by ERα. 
 Phytoestrogens are a class of naturally occurring compounds that are structurally 
and functionally similar to mammalian estrogen (Glazier & Bowman, 2001; Lephart et 
al., 2005). Soy derived phytoestrogens daidzein and genestein are neuroprotective (Chen 
et al., 2008; Mao et al., 2007), have been used to treat various types of cancer, 
cardiovascular diseases, osteoporosis (Jackson et al., 2011), prevent HIV-1 Tat induced 
neuronal apoptosis (Adams et al., 2012), and prevent and reverse synaptodendritic injury 
induced by HIV-1 Tat in vitro (Bertrand et al., 2014). However, the dose of daidzein 
(1µM) required for synaptodendritic protection is 100x higher than estrogen (10nM).  
During digestion, daidzein is initially broken down into dihydrodaidzein which is 
further metabolized into either O-desmethylangolensin or cis/trans-isoflavan-4-ol 
(Jackson et al., 2011; Lampe, 2009). Finally, cis/trans-isoflavn-4-ol is processed into 
equol. Due to the chiral center at carbon 3 (figure 1A), equol can theoretically exist in 
either the S or R conformation or a racemic mixture; However, only S-Equol is excreted 
by humans and animals (Setchell et al., 2005). Equol is a more potent molecule than 
daidzein, requiring less of the compound to cross the blood-brain barrier in order to 
achieve the desired effect. Equol effects neuronal mitochondrial function (Yao et al., 
2013) and hypothalamic neuronal expression (Patisaul, Todd, Mickens, & Adewale, 
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2009) in vivo indicating that equol can cross the blood-brain barrier at effective 
concentrations, unlike daidzein. 
HIV-1+ cocaine users are also more likely to display neurocognitive deficits 
(Levine et al., 2006; Nath et al., 2001), however the mechanism producing these 
neurocognitive and behavioral effects is unclear nor are there any therapeutic agents for 
these individuals. HIV-1 proteins in combination with cocaine produced enhanced levels 
of apoptosis (Kendall et al., 2005; Turchan et al., 2001), however the synaptic effects of 
HIV-1 proteins and cocaine are unknown. The present study uses the quantification of F-
actin puncta, a marker of synaptodendritic integrity, to evaluate the effects of HIV-1 Tat 
and cocaine on the neuronal network at a time point before frank neuronal cell death. 
Additionally, we evaluate the neuroprotective effects and mechanism of both S- and R-
Equol. Our results suggest that HIV-1 Tat and cocaine together produce enhanced 
synaptodendritic injury which may contribute to the increased incidence of 
neurocognitive disorders in HIV-1+ cocaine users.  
Methods 
Ethics Statement 
Experiments that utilized animals were in accordance with NIH Guidelines. The Animal 
Care and Use Committee at the University of South Carolina (animal assurance number: 
A3049-01) reviewed and approved all animal protocols. 
Primary Neuronal Cell Culture 
Midbrain and cortical regions were dissected from gestational day 18 Sprague-Dawley rat 
fetuses (Harlan Laboratories, Indianapolis IN) as previously described (Aksenova et al., 
2006; Aksenova et al., 2009; Bertrand et al., 2011).  Following dissection tissue was 
incubated in a solution of 2mg/ml trypsin in Hank’s balanced salt solution (HBSS) 
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buffered with 10mM HEPES (GIBCO Life Technologies, Grand Island, NY) for 10 
minutes. Tissue was rinsed with fresh HBSS 3 times and then exposed to soybean trypsin 
inhibitor (1mg/ml in HBSS) for 2 minutes. Tissue was washed 3 times with HBSS 
following trypsin inhibitor treatment. For cytomorpholigical studies, cells were 
distributed to 12 well glass-bottom dishes and 35mm dishes (MatTek Corporation, 
Ashland, MA) coated with poly-L-lysine following dissociation by trituration. In order to 
observe distinct second order branching patterns, a low plating density was used (120-
140 cells/mm2).  Initial plating media contained Dulbecco’s modified Eagle’s 
medium/Ham’s nutrient mixture F-12 (DMEM/F12; GIBCO) supplemented with 100 
ml/L fetal bovine serum (Sigma Chemicals, St. Louis, MO). DMEM/F12 and fetal serum 
were removed and replaced with an equal amount of serum-free Neurobasal medium after 
24 hours. Neurobasal medium had no phenol red and was supplemented with 2% v/v B-
27, 2 mM GlutaMAX supplement and 0.5% w/v D-(1) glucose (all ingredients from 
GIBCO). Cultures were maintained at 37ºC in a 5% CO2/95% room air-humidified 
incubator at all times. Fresh Neurobasal medium was supplemented at weekly intervals. 
Midbrain cultures used for experiments were 21-30 days in vitro (DIV), cortical cultures 
used for experiments were 14-21 DIV, and both culture types were >85-90% neuronal as 
determined by MAP-2/GFAP/NucBlue fluorescent staining. 
Experimental Treatment 
 Recombinant Tat 1-86B (LAI/Bru strain of HIV-1 clade B, GenBank accession 
no. K02013) (Diatheva, Fano, Italy) was added to the serum free growth media (50 nM or 
10 nM final concentration) of both cortical and midbrain cell cultures. In experiments 
where cocaine was included, freshly prepared cocaine stock solution was added to the 
serum free grown media (1.6 µM final concentration) concurrently with HIV-1 Tat 
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treatment. Control cultures were treated with an equal amount of vehicle.  Cultures were 
incubated with either 50 nM HIV-1 Tat, 10 nM HIV-1 Tat, 1.6 µM cocaine, or HIV-1 Tat 
(10 nM) + cocaine for 24 hours prior to fixation. 
 Cortical and midbrain cell cultures were treated with S-equol (SE; final 
concentration 33 nM or 50 nM; ≥98.5% purity; Cayman Chemical, Ann Arbor, MI),R-
equol (RE; final concentration 33 nM or 50 nM; ≥98.5% purity; Cayman Chemical Ann 
Arbor, MI), tamoxifen (TMX; selective estrogen receptor modulator; final concentration 
100 nM; Tamoxifen citrate; Tocris Bioscience, Ellisville, MD), 4-[2-Phenyl-5,7-
bis(trifluoromethyl)pyrazolo[1,5-a]pyrmidin-3-yl)phenol (PHTPP; estrogen receptor beta 
antagonist; final concentration 100 nM; Tocris Bioscience, Ellisville MD), 1,3-Bis(4-
hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole 
dihydrochloride (MPP; estrogen receptor alpha antagonist; final concentration 100 nM; 
Tocris Bioscience, Ellisville, MD), and (3aS*,4R*,9bR*)-4-(6-Bromo-1,3-benzodioxol-5-
yl)-3a,4,5,9b-3H-cyclopenta[c]quinoline (G15; membrane estrogen receptor antagonist; 
final concentration 100 nM; Tocris Bioscience, Ellisville MD). TMX, PHTPP, G15, SE 
and RE were initially dissolved in DMSO and then diluted in PBS prior to treatment.  
MPP was initially dissolved in water, and diluted immediately prior to treatment. For 
protection studies cells were treated with SE or RE (33 nM or 50 nM) 24 hours prior to 
treatment with 50 nM Tat or 10 nM Tat and 1.6 µM cocaine.  In order to elucidate the 
estrogenic mechanism underlying SE and RE neuroprotection, cells were treated with 
TMX, PHTPP, MPP, or G15 for 1 hour prior to treatment with SE or RE (50 nM). 
 Studies examining the plasma levels of S-Equol following daidzein 
supplementation have found individuals with plasma concentrations of 8-20 ng/ml (See 
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review: Jackson et al., 2011). The present study chose a low dose of S-Equol (33 nM) and 
a mid-range dose of equol (50 nM), which are equivalent to plasma concentrations 
observed in humans following supplementation (8 ng/ml and 12 ng/ml, respectively).  
Fluorescent labeling and immunocytochemistry 
 Primary cortical and midbrain cell cultures were labeled using immunofluorescent 
techniques carried out in 12-well glass bottom and single 35 mm glass bottom cell culture 
dishes (MatTek Corporation, Ashland, MA). A modified protocol for filamentous actin 
(F-actin) staining was used to visualize F-actin puncta (Invitrogen Life Technologies, 
Grand Island NY). Briefly, primary neuronal cultures were fixed using 4% 
paraformaldehyde and permeabilized with 0.1% Triton X-100. Cells were incubated with 
the F-actin specific probe phalloidin (1:40; AlexaFluor 488) for 20 minutes (Invitrogen 
Life Technologies, Grand Island NY).  In order to prevent nonspecific binding, cells were 
incubated with 10% normal horse serum in PBS for 2 hours. Next, cells were co-labeled 
with chicken polyclonal anti-MAP2 (1:1000) (Abcam, Cambridge MA).  Goat anti-
chicken IgG conjugated with Alexa Red 594 (1:500; Invitrogen Life Technologies, Grand 
Island NY) NucBlue (Molecular Probes Life Technologies, Grand Island NY), a Hoescht 
dye, was used to directly identify cell nuclei. 
F-actin Puncta 
 A Nikon Eclipse TE2000-E inverted fluorescent computer controlled microscope 
(20X objective, 1600 x 1200 px image size, 0.17 µm/px image resolution at 1X zoom) in 
conjuction with an attached higher resolution CCD camera was used to obtain images of 
neurons co-labeled with F-actin (green)/MAP-2 (red)/NucBlue (blue) neurons. NIS-
Elements software package (Nikon Instruments, Melville, NY, USA) was used to select 
analyze 3-5 separate neurons with clearly identifiable dendritic arbors and normal nuclear 
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morphology per well. Saving of images resulted in an inversion of colors, resulting in 
green F-actin, blue MAP-2, and red NucBlue staining (Figure 4.3).  F-actin puncta were 
identified in several (3-4) second order dendritic fragments (15-75 µm) for the selected 
neurons. Neurites were required to have continuous MAP-2 immunofluorescence and 
normal nuclear morphology to qualify for analysis. F-actin structures included fine 
filopodia, spine protrusions, and patches, while growth cones (F-actin rich structures 
found at the most distal end of the dendritic terminus) were excluded (Bertrand et al., 
2013). 
 F-actin puncta were detected and quantified as previously described (Bertrand et 
al., 2014; Bertrand et al., 2013). Briefly, background fluorescence from the 488 (green 
phalloidin labeled F-actin) channel was subtracted, identified as low fluorescence of the 
non-synaptic dendritic shaft (20-50au).  Clearly visible F-actin rich structures (fine 
filopodia, spine protrusions, and patches) were manually counted and calculated as 
number of F-actin labeled puncta per 10 µm.  
 A trained independent observer, blinded to experimental treatment, quantified 
puncta from identically processed images, with a very high correlation (r2=0.90), 
indicating that the green F-actin puncta were readily identified. 
Statistical Analysis 
Statistical comparisons were made using ANOVA techniques, and Tukey’s multiple 
comparison tests were used to determine specific treatment effects.  Pearson’s product-
moment correlation coefficient was calculated to verify inter-rater reliability. 
Comparisons and correlations were calculated using SPSS version 22 (IBM Corporation, 
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Armonk NY). Data represents mean values ± standard error of the mean (SEM). 
Significant differences were set at p≤0.05. 
Results 
S- and R-Equol prevent HIV-1 Tat 1-86 induced synaptodendritic injury 
Primary midbrain cultures were pre-treated with either R-Equol (4.1B; 33 nM or 
50 nM) or S-Equol (4.1C; 33 nM or 50 nM) for 24 hours prior to incubation with 50 nM 
HIV-1 Tat 1-86 (24 hours) (Figure 4.1). There was a significant main effect of treatment 
F(1,22)=9.4, p≤0.001, with 50 nM HIV-1 Tat 1-86 producing a significant reduction in 
puncta (p≤0.001). Pre-treatment with 50 nM R-Equol (p≤0.01), but not 33 nM R-Equol, 
prevented significant loss of F-actin puncta following incubation with 50 nM HIV-1 Tat 
(Figure 4.1B).Pre-treatment with either 33 nM S-Equol (p≤0.05) or 50 nM S-Equol 
(p≤0.001) prevented significant HIV-1 Tat 1-86 induced loss of F-actin puncta (Figure 
4.1C). RE and SE treatment did not produce significant damage or proliferation of F-
actin puncta alone (Figure 4.1B,C). RE or SE treated Tat (50 nM) treated cultures were 
not statistically different from vehicle treated controls.  
SE and RE act through an estrogen mediated mechanism to prevent HIV-1 Tat 1-86 
induced loss of F-actin puncta  
In order to elucidate a potential mechanism underlying the neuroprotective effects of RE 
and SE, primary midbrain neuronal cultures were treated with tamoxifen (TMX), a potent 
estrogen receptor antagonist, one hour prior to treatment with 50nM SE or RE. Cultures 
were then incubated with HIV-1 Tat 1-86 (50 nM) for 24 hours. There was a significant 
effect of treatment F(3,23)=9.6, (p≤0.001). Pre-treatment with TMX prior to SE (p≤0.02) 
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and RE (p≤0.02) incubation resulted in significant damage to the neuronal network 
relative to control cultures, but were not significantly different from HIV-1 Tat (50 nM) 
treated cultures suggesting that RE and SE act through an ER dependent mechanism 
(figure 4.1D). 
 
Figure 4.1 SE and RE prevent significant synaptodendritic damage induced by a toxic 
(50 nM) dose of HIV-1 Tat 1-86 in an estrogen receptor mediated mechanism. A. 
Metabolism of daidzein to S-Equol. The circle represents a chiral center on carbon 3 
where the theoretical conformational change would occur to produce R-Equol. However, 
only S-Equol is naturally produced by mammalian gut bacteria. B. A moderate dose of R-
Equol (50 nM), but not a low dose (33 nM), prevents significant synaptodendritic injury 
induced by HIV-1 Tat 1-86 (50 nM; p≤0.01). C. Both the low (33 nM) and moderate (50 
nM) doses of S-Equol prevent HIV-1 Tat 1-86 induced synaptodendritic injury (p≤0.05 
and p≤0.001, respectively). D. One hour incubation with TMX blocked the 
neuroprotective effects of RE and SE (50 nM) against a toxic dose of HIV-1 Tat 1-86 (50 
nM) in primary midbrain cultures. Data represents mean values ± SEM, *p≤0.05 
compared to HIV-1 Tat treated cultures. 
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HIV-1 Tat and cocaine interact to produce synaptodendritic injury in primary 
midbrain and cortical cell cultures 
In order to examine the effects of HIV-1 Tat and cocaine on synaptodendritic integrity, a 
sub-toxic dose of HIV-1 Tat 1-86 (10 nM) and a physiologically relevant dose of cocaine 
(1.6 µM) were simultaneously added to primary midbrain and primary cortical cell 
cultures and incubated for 24 hours. As shown in figure 4.2 (A,D), there was a significant 
interaction between HIV-1 Tat and cocaine F(1,123)=16.4, (p≤0.001) but not a 
significant main effect of either HIV-1 Tat or cocaine individually on synaptodendritic 
integrity when compared to controls. There was not a significant main effect of region 
F(1,123)=3.4, p>0.05. 
SE and RE prevent interactive HIV-1 Tat + cocaine synaptodendritic damage 
 RE and SE neuroprotection against HIV-1 Tat (50 nM) induced damage was an ER 
dependent mechanism (figure 4.1). Thus, we hypothesized that treatment with either 
equol enantiomer would prevent HIV-1 Tat+cocaine induced puncta loss using a similar 
or identical mechanism. In order to evaluate our hypothesis, primary cortical and 
midbrain cultures were pre-treated with 50 nM RE or SE for 24 hours prior to a 24 hour 
incubation with Tat 1-86 (10 nM) and cocaine (1.6 µM). There was a significant main 
effect of treatment F(5,123)=7.6 p≤0.001 (Figure 4.2 B,E), but not a significant effect of 
region (p>0.05). Using a Tukey post hoc analysis it was determined that Tat + cocaine 
cultures pretreated with RE or SE had significantly more puncta relative to Tat + cocaine 
cultures, (p≤0.001 for both conditions) and were not significantly different than vehicle 




SE and RE act through an ERβ mediated mechanism to prevent HIV-1 Tat+cocaine 
induced synaptodendritic injury 
Next, primary cortical and midbrain cultures were treated with TMX, an estrogen 
receptor antagonist, for one hour prior to treatment with RE or SE. Following a 24 hour 
incubation with Tat + cocaine, cultures were fixed and F-actin puncta assessed. There 
was a significant main effect of treatment F(8,104)=4.3, p≤0.001, with TMX significantly 
blocking RE or SE mediated neuroprotection p≤0.01 (Figure 4.2 C,F).  
Finally, cortical cultures were treated with one of 3 selective ER subtype 
antagonists, MPP (ERα), PHTPP (ERβ), or GPR30 (G15) for 1 hour prior to treatment 
with RE or SE in order to identify the specific ER subtype required for equol mediated 
neuroprotection (Figure 4.3 A,B). There was a significant main effect of antagonist 
treatment F(3, 134)=11.2, p≤0.001. Both MPP and G15 treated cultures were not 
different from vehicle treated controls (p>0.05), however PHTPP treated cultures had a 
significant loss of F-actin puncta when compared to controls (p≤0.05) and were not 
significantly different from Tat + cocaine treated cultures (p>0.05). More specifically, 
only the ERβ antagonist PHTPP significantly prevented RE or SE mediated 




Figure 4.2 Treatment with HIV-1 Tat 1-86 (10 nM) + cocaine (1.6 µM) produces 
significant synaptodendritic injury in cortical and midbrain cultures A. Treatment with 
SE, RE, HIV-1 Tat 1-86 (10 nM), or cocaine (1.6 µM) do not significantly alter density 
of F-actin puncta compared to controls in primary midbrain neuronal cultures. Treatment 
with both HIV-1 Tat (10 nM) and cocaine (1.6 µM) induces a significant loss of F-actin 
puncta (p≤0.05). B. Treatment with SE, RE, HIV-1 Tat 1-86 (10 nM), or cocaine (1.6 
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µM) do not significantly alter synaptodendritic integrity compared to controls in primary 
cortical neuronal cultures. Treatment with HIV-1 Tat (10 nM) and cocaine (1.6 µM) 
produces significant synaptodendritic injury (p≤0.05). C. Pre-treatment with RE or SE 
(both 50 nM) prevents significant synaptodendritic damage induced by Tat + cocaine in 
primary midbrain cultures and are not significantly different from control cultures. D. 
Pre-treatment with RE or SE (both 50 nM) prevents Tat+cocaine induced loss of F-actin 
puncta (p≤0.001) in primary cortical cell cultures and are not significantly different from 
vehicle treated controls. E. Treatment with TMX (100 nM) for 1 hour prior to RE or SE 
treatment in primary midbrain cultures prevents the neuroprotective effects of RE and SE 
suggesting an estrogen receptor mediated mechanism. F. Treatment with TMX (100 nM) 
for 1 hour prior to RE or SE treatment blocks RE and SE neuroprotective effects 
indicating an estrogen receptor mediated mechanism in primary cortical cell cultures. 
Data represents mean values ± SEM, *p≤0.05 compared to HIV-1 Tat + cocaine (C,D) or 
vehicle  treated controls (A,B). 
 
Figure 4.3 RE and SE prevent Tat + cocaine induce synaptodendritic injury in an ERβ 
dependent mechanism. Primary cortical neurons were pre-treated with one of 3 selective 
estrogen receptor antagonists, A. Mean (±SEM) puncta/10 µm following treatment with 
all 3 ER antagonists and RE. PHTPP (beta selective antagonist) treatment prior to RE 
pretreatment precluded RE mediated protection resulting in significant synaptodendritic 
damage compared to controls. B. Mean (±SEM) puncta/10 µm following treatment with 
all 3 ER antagonists and SE. PHTPP treatment prior to SE pre-treatment resulted in 
significant synaptodendritic damage compared to controls. C-J. Representative images. 
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Vehicle treated (C), HIV-1 Tat (10 nM; G), and cocaine treated (H) controls and 
SE(E)/RE(F) pre-treated cultures demonstrate robust staining with F-actin(green) and 
MAP-2 (blue) neurites with complex branching patterns and a lack of aberrant features 
such as bundling or beading. PHTPP pre-treated SE(I)/RE(J) and Tat + Cocaine treated 
cultures illustrate the effects of synaptodendritic damage; there is a lack of fine network 
in the background of the image in addition to a significantly reduced F-actin stain and 
stunted dendritic branching. Data represents mean values ± SEM, *p≤0.05 compared to 
controls. 
Discussion 
Neurocognitive deficits are more prevalent among HIV-1+ positive drug users (Devlin et 
al., 2012; Nath, 2002; Weber et al., 2013; Levine et al., 2006). Cocaine is one of the most 
commonly used drugs in HIV-1+ individuals (Cook et al., 2007; Korthuis et al., 2008), 
and has been shown to augment the neurotoxicity of HIV-1 proteins in vitro (Kendall et 
al., 2005; Turchan et al., 2001; Aksenov et al., 2006). Although neuronal cell death is 
seen in HAND (Adle-Biassette et al., 1995; Adle-Biassette et al., 1999; Li, Galey, 
Mattson, & Nath, 2005; Mattson et al., 2005), synaptic dysfunction and damage are more 
predictive of neurocognitive status (Adle-Biassette et al., 1999; Ellis et al., 2007). HIV-1 
Tat + cocaine treatment resulted in a significant reduction in F-actin rich puncta, 
indicating aberrant neuronal function. Pre-treatment with RE or SE prevented HIV-1 Tat 
+ cocaine induced loss of puncta via an ERβ dependent mechanism, suggesting early 
treatment with RE or SE may prevent further neuronal damage or loss, potentially 
slowing or stopping the progression of HAND.  
 Cocaine potentiates the effects of HIV-1 Tat, as the Tat dose used in the 
combination studies was not damaging alone. The dose of HIV-1 Tat chosen was 4x 
lower than concentrations previously shown to lack neurotoxic properties in primary 
neuronal cell culture (Kendall et al., 2005; Turchan et al., 2001). The dose of cocaine 
 
80 
used was within the physiological levels observed in IV cocaine users (Evans, Cone, & 
Henningfield, 1996) and is well below the range known to produce neuronal toxicity in 
vitro (Nassogne, Evrard, & Courtoy, 1995). However, HIV-1 Tat + cocaine produce 
synaptodendritic injury prior at a time point prior to cell death, suggesting that cocaine 
potentiates the effects of HIV-1 Tat. Cocaine enhances monocyte migration across the 
blood brain barrier and disrupts intercellular junctions (Fiala et al., 2005; Fiala et al., 
1998), increasing the number of virally infected cells in the brain. Additionally, cocaine 
increases viral replication in monocytes (Peterson et al., 1991), macrophages (Roth et al., 
2002), and astrocytes (Reynolds et al., 2006) suggesting that cocaine may have powerful 
intracellular interactions with HIV-1 Tat. HIV-1 Tat and cocaine both inhibit dopamine 
transporter (DAT) function (Midde et al., 2013; Ritz & Kuhar, 1993; Ferris, Frederick-
Duus, Fadel, Mactutus, & Booze, 2009b), which may contribute to an increase in 
oxidative stress (Aksenov et al., 2006) and thus result in the depolymerization of F-actin 
and a subsequent reduction of F-actin rich puncta.   
Non-drug abusing HIV-1+ individuals have significant levels of neuronal damage 
(Moore et al., 2006; Maragos et al., 2003; Adle-Biassette et al., 1999; Masliah et al., 
1997) suggesting that extracellular HIV-1 protein levels are neurotoxic and not sub-toxic 
as used in the present study. However, by using a sub-toxic dose of HIV-1 Tat we 
demonstrate that even a low dose of a singular protein in combination with a 
physiologically relevant dose of cocaine result in significant synaptodendritic insult.  Our 
results suggest that the synaptodendritic damage observed in an HIV-1+ cocaine user 
would 1. Have more severe synaptodendritic damage than a non-cocaine user, and 2. Be 
more severe than what is demonstrated by the present in vitro study. Identification of 
 
81 
synaptodendritic injury is important because it occurs prior to cell death (Bertrand et al., 
2013) and is potentially reversible (Bertrand et al., 2014; Kim et al., 2008a).  
S-equol prevents HIV-1 Tat induced synaptodendritic injury at a lower 
concentration (33 nM) than R-Equol (50 nM), demonstrating that the neuroprotective 
properties of equol are specific to the conformation of the molecule. Equol is the active 
metabolite of the soy derived phytoestrogen daidzein (Setchell & Cassidy, 1999; Jackson 
et al., 2011), and has been proposed to be the driving force behind the cognitive health 
benefits of soy products (Jackson et al., 2011; Lampe, 2009; Setchell & Cassidy, 1999). 
Daidzein is metabolized into equol via two distinct steps by various bacteria found in the 
gut of animals and humans (Jackson et al., 2011; Setchell et al., 2005). Importantly, only 
S-Equol is naturally produced by animal and human bacterial flora in the gut (Setchell et 
al., 2005). In humans, daidzein supplementation results in plasma concentrations of 8-
20ng/ml S-equol (See review: Jackson et al., 2011). Presently, a low dose of S- and R-
equol (33 nM) and a mid-range dose of equol (50 nM), which are equivalent to plasma 
concentrations observed in humans following supplementation (8 ng/ml and 12 ng/ml, 
respectively). Both enantiomers achieve full neuroprotection at physiologically relevant 
doses and with a concentration that is at least 20x lower than that of daidzein required for 
full synaptodendritic protection (Bertrand et al., 2014). Introduction of daidzein into the 
medium of neuronal cell cultures exposed to a toxic dose of HIV-1 Tat results in a 
restoration of the F-actin rich network in an estrogen receptor dependent manner 
(Bertrand et al., 2014), combined with the present study this suggests that equol may also 
aid in the restoration of the fine network.  
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Both equol enantiomers prevent HIV-1 Tat-induced (50nM) and HIV-1 Tat 
(10nM) + cocaine induced synaptodendritic damage. TMX treatment blocked the 
neuroprotective actions of both RE and SE, indicating that equol mediated 
neuroprotection was via an estrogen receptor dependent mechanism. S-Equol is a potent 
ER agonist, with preferential binding to ERβ over ERα (Setchell et al., 2005; Jackson et 
al., 2011; Lampe, 2009). In order to determine the mechanism of action of both S- and R-
Equol for neuroprotection against HIV-1 Tat and cocaine, three estrogen receptor 
subtypes α, β, and GPR30 were examined. MPP, PHTPP, and G15 (ERα, ERβ, and 
GPR30 antagonists, respectively) were employed to determine which ER subtype 
mediated the neuroprotective effects of S- and R-equol. Only PHTPP precluded the 
neuroprotective effects of S- and R-Equol, indicating that both enantiomers provide 
neuroprotection via an ERβ dependent mechanism. Importantly, identical concentrations 
of equol (50nM) were used to achieve significant neuroprotection, suggesting that this 
treatment may be beneficial for both HAND and HAND comorbid with drug abuse. 
Treatment with 17β-estradiol mitigates interactions between HIV-1 protein and 
illicit drugs resulting in a prevention of neuronal cell death (Kendall et al., 2005; Turchan 
et al., 2001). However, ERα and ERβ activation play differential roles in protection of 
CNS cells in HIV-1. Treatment with 17β-estradiol suppresses Tat enhancement of LTR 
promoter activity in astrocytes (Wilson et al., 2006). Meanwhile over expression of ERα 
prevents suppression of Tat-LTR promoter activity in astrocytes (Heron et al., 2009), 
although the specific effects of ERβ in this process are not well understood. Action at the 
ERβ prevents HIV-1 Tat induced apoptosis (Adams et al., 2010; Adams et al., 2012). 
Additionally, activation of the ERα subtype may lead to unwanted side effects such as 
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expression of secondary sex characteristics or cancer, suggesting that an ERβ specific 
compound, like equol, would be beneficial for preventing neuronal damage and 
potentially controlling Tat-LTR interactions resulting in a decrease or prevention of viral 
replication.  
The gut-brain axis is a new area of study which recognizes the bidirectional 
communication between the gut microbiota and behavior (Cryan & Dinan, 2012; Foster 
& McVey Neufeld, 2013). Anxiety-like and depressive-like behaviors have been treated 
with probiotics in rats and mice (Neufeld, Kang, Bienenstock, & Foster, 2011a; Neufeld, 
Kang, Bienenstock, & Foster, 2011b), and have been suggested as a treatment for IBS, a 
gastrointestinal disorder linked to increased amounts of stress (Clarke, Cryan, Dinan, & 
Quigley, 2012). Equol is produced by the gut microbiota in humans and animals, but not 
all humans are equol producers. Up to 80% of individuals in China, Japan, and Korea are 
capable of producing equol (Fujimoto et al., 2008; Morton, Arisaka, Miyake, Morgan, & 
Evans, 2002), however only 25% of the population that consumes a Western diet are 
equol producers (Lampe, Karr, Hutchins, & Slavin, 1998). HIV-1 is a pandemic, however 
there are higher incidences of HAND in individuals in North America and Europe as 
opposed to Sub-Saharan Africa and Asian populations (Satishchandra et al., 2000). These 
regional differences have been contributed to differences in HIV-1 strain, however some 
variability could be due to differences in gut microbiota. It is currently unknown how 
HIV-1 may affect the gut microbiota, however it may play an important role in mediating 
disease progression as well as neurocognitive correlates of HIV-1. The ability of the gut 
metabolite equol to alter synaptodendritic injury induced by HIV-1 Tat and HIV-1 
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Tat+cocaine suggests that the gut may play an important role in modulating CNS health 
in HIV-1. 
Our results indicate that HIV-1 protein Tat in combination with cocaine results in 
significant damage to the synaptic network which may play a role in the increased 
prevalence of HAND in cocaine users (Nath et al., 2001; Purohit et al., 2011). Cognitive 
function in HAND is closely correlated with synaptodendritic injury (Ellis et al., 2007), 
and our results represent a potential culprit for the increased prevalence of HAND in 
HIV-1+ cocaine users (Nath et al., 2001; Gill & Kolson, 2014; Martin-Thormeyer & 
Paul, 2009). Importantly, synaptodendritic injury occurs prior to overt cell death 
(Bertrand et al., 2014; Kim, Martemyanov, & Thayer, 2008b; Bertrand et al., 2013) and is 
believed to be reversible (Bertrand et al., 2014; Kim et al., 2008a), emphasizing the 
importance of early detection and treatment. We also demonstrate that both equol 
enantiomers prevent Tat+cocaine induced synaptotoxicity through an ERβ dependent 
mechanism. Action specifically at ERβ may limit unwanted side-effects, yet still promote 
neuroprotection similar to the effects of 17β-estradiol (Adams et al., 2010; Kendall et al., 
2005; Turchan et al., 2001; Simpkins, Singh, Brock, & Etgen, 2012; Simpkins & Singh, 
2008). Equol is more potent than the parent compound daidzein, and works via a similar, 
if not identical, mechanism (Adams et al., 2012), suggesting that treatment with S- or R-
Equol may promote network restoration following HIV-1 Tat or Tat+cocaine insult at 
similar or enhanced rates compared to daidzein (Bertrand et al., 2014). The present study 
provides further evidence that ERβ is a novel target to prevent synaptodendritic injury 
and that gut metabolites, like equol, may play an important role in treating HIV-1 
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HIV-1 infection and drugs of abuse may exert synergistic effects on reward 
processes and motivation (Carey et al., 2006; Rippeth et al., 2004; Chang et al., 2008; 
Ferris, Mactutus, & Booze, 2008; Nath et al., 2001).  Motivation is defined as a 
fundamental state that allows an animal to regulate its internal and external environments 
through the organization of behavior (Salamone & Correa, 2012).  Goal-directed 
behavior, which encompasses Pavlovian and operant conditioning processes, is one 
example (Rescorla, 1987). Once learned, goal-directed behavior is maintained by 
motivational and cognitive processes, such as the animals’ homeostatic state, an 
expectation about the reinforcer, the current value of the reinforcer, environmental cues, 
and other learning phenomena, such as generalization and discrimination (Spear & 
Riccio, 1994; Koob, 2009). Although the construct of motivation is widely used, it has 
received little attention in HIV-1/AIDS research. 
Interestingly, neural systems that mediate the motivational features of goal-
directed behavior (Everitt and Robbins, 2013) are damaged by HIV-1 (Everitt & Robbins, 
2013; Purohit et al., 2011; Nath et al., 2000). HIV-1+ individuals exhibit high HIV-1 
viral titers in the caudate (Kumar et al., 2007; Kumar et al., 2009b) and extensive atrophy 
in the caudate-putamen and NAc are reported in HIV-1 infected patients exhibiting 
cognitive impairment (Paul et al., 2002; Hestad et al., 1993; Dal Pan et al., 1992). 
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HIV-1+ patient brains show impairments in dopaminergic cell bodies (Silvers et al., 
2006; Itoh, Mehraein, & Weis, 2000) and loss of synaptic connectivity in the 
dopaminergic projection pathways (Gelman, Spencer, Holzer, III, & Soukup, 2006). 
Interestingly, dopamine transporter (DAT) proteins are significantly reduced in 
cognitively impaired HIV-1 patients (Wang et al., 2004) and DAT function is reduced 
further in HIV-1+ cocaine abusers (Chang et al., 2008). Thus, the DA systems in the 
human brain appear particularly vulnerable to HIV-1 infection.   
The HIV-1 Tg rat incorporates HIV-1 proviral DNA into its genome, without 
active viremia (Reid et al., 2001). The aviremic state in the HIV-1 Tg rat may be similar 
to that reported for individuals latently infected with HIV-1, or treated with cART to 
reduce peripheral viral loads. In the absence of active infection or viral replication, the 
presence of HIV-1 proviral DNA may induce production of HIV-1 proteins. Brains from 
HIV-1+ patients without HIV-1 viral RNA/p24 (i.e. latent infections), show decreases in 
synaptodendritic markers (Desplats et al., 2013) and the presence of HIV-1 Tat protein in 
the cerebral spinal fluid (Johnson et al., 2013). The HIV-1 Tat protein directly inhibits 
DAT via specific Tat protein:DAT protein interactions (Zhu et al., 2009; Midde et al., 
2013). Although the DAT mediates many of the reinforcing aspects of cocaine, and HIV-
1 proteins interact with DAT (Wallace et al., 2006), it is unknown how chronic, low-
levels of HIV-1 proteins (i.e. Tat) alters the motivational and neurochemical responses to 
cocaine. 
We used the HIV-1 transgenic (Tg) rat to examine alterations in motivational 
processes and dopaminergic neurochemical correlates in the striatum and prefrontal 
cortex.  Specifically, we investigated goal-directed behavior, using self-administration of 
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IV cocaine or sucrose as reinforcement, and neurochemical alterations in the DAT.  
These findings could elucidate specific interactions between cocaine abuse and HIV-1 
and foster therapeutic strategies to treat this comorbidity in vulnerable populations. 
Methods 
Animals 
Female HIV-1 Transgenic (Tg) rats (n=14) and female F344/NHsd control rats 
(n=15) were procured at approximately 60 days of age from Harlan Laboratories, Inc. 
(Indianapolis, IN, USA). The generation of the HIV-1 Tg rats has been previously 
described (Reid et al., 2001).  In brief, the hemizygous HIV-1 Tg animals were produced 
using a construct derived from an infectious provirus (pNL4-3) after deletion of a 3.1 kb 
Sph1-Bal1 fragment.  This fragment overlaps the gag and pol genes (pNL4-3d1443).   
Thus, the HIV-1 Tg rats do not produce gag or pol proteins, which are necessary for viral 
structures (Peng et al., 2010), thus, these animals are non-infectious.  Viral proteins, such 
as Tat and gp120, are produced under the control of the native HIV-LTR in disease 
appropriate mononuclear phagocytes and astrocytes, but not in neurons, similar to that in 
human neuroAIDS (Royal et al., 2012).  HIV-1 Tg young adult female rats are generally 
healthy (Roscoe et al., 2014), can perform operant behavioral tasks (Moran et al., 2014), 
and grow at similar rates as F344 controls (Moran et al., 2013). 
All rats were ovariectomized (OVX) at Harlan Laboratories prior to arrival at the 
University of South Carolina. Ovariectomy was performed as estradiol potentiates the 
reinforcing efficacy of cocaine (Hu, Crombag, Robinson, & Becker, 2004), protects 
against HIV-1 mediated neuronal damage in vitro (Bertrand et al., 2014; Adams et al., 
2010; Heron et al., 2009), and suppresses HIV-1 transcription (Cabrera-Munoz, 
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Hernandez-Hernandez, & Camacho-Arroyo, 2012; Szotek, Narasipura, & Al-Harthi, 
2013).  In addition, rats were fed a minimal phytoestrogen diet (≤20 ppm of 
phytoestrogen; Teklad 2020X Global Rodent Diet; Harlan Laboratories, Inc., 
Indianapolis, IN). Phytoestrogens are plant-derived compounds that are structurally 
similar to estrogen, have estrogenic effects, and are found in soybean and alfalfa meal 
(Lephart et al., 2005; Setchell & Cassidy, 1999). Soy and alfalfa meal are typical 
components of rodent chow; standard rodent chow typically contains 200-500 ppm 
(Harlan Laboratories, Inc., USA). Food and water were provided ad libitum throughout 
the experiment, unless otherwise specified. The targeted conditions for maintenance of 
the animal vivarium were a temperature of 20±2◦C, 50±10% relative humidity and a 
12L:12D cycle with lights on at 0700h. The Institutional Animal Care and Use 
Committee (IACUC) at the University of South Carolina (animal assurance number: 
A3049-01) approved this research. 
Apparatus 
Sucrose preference experiment. Animals received access to water or sucrose 
solutions in 100 ml graduated cylinders equipped with a # 6.5 rubber stopper and 2.5’’ 
straight drinking tube (OT-100; Ancare, Bellmore, NY, USA) that was placed on the 
testing cage. Animals were tested in clear polycarbonate cages containing standard rodent 
bedding. Five 100 ml graduated cylinders, containing four sucrose solutions or water, 
were fitted to the cage-top of the rats’ testing cage. The testing cages were located on a 
single cage rack and the experiment was conducted in the colony room.   
Operant conditioning experiments. The individual operant chambers were within 
sound-attenuating enclosures. The front and back panels of the operant chambers (ENV-
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008; Med-Associates, St. Albans, VT, USA) were stainless steel panels, the sides and top 
of the chamber were constructed of polycarbonate. The front panel of the chamber 
housed a panel containing a receptacle that allows a recessed 0.01 cc dipper cup (ENV-
202C) to deliver a solution through a 5-cm x 5 cm opening following completion of a 
response requirement (ENV 202M-S). Two retractable metal levers (ENV-112BM) on 
either side of the receptacle were located 7.3 cm above a metal grid floor. These were 
“active” levers (responding on them could result in reinforcement). A 28-V white cue 
light, 3 cm in diameter, was located above each active response lever but never 
illuminated. An infrared sensor (ENV-254-CB) was used to detect head entries into the 
receptacle. An additional non-retractable lever was positioned on the back wall of the 
chamber and a 28-V house light was located above the lever. This was the “inactive” 
lever and there were no programmed response-reinforcer contingencies with the lever. 
During cocaine self-administration tests a syringe pump (PHM-100) was used to deliver 
intravenous drug infusions through a water-tight swivel (Instech 375/22ps 22GA; Instech 
Laboratories, Inc., Plymouth Meeting, PA), which was connected to the back mount of 
the animal using Tygon tubing (ID, 0.020 IN; OD, 0.060 IN) enclosed by a stainless steel 
tether (Camcaths, Cambridgeshire, Great Britain). The pump infusion times were 
calculated by a Med-PC computer program according to the animal’s daily bodyweight.  
Drugs 
 Cocaine hydrochloride (Sigma-Aldrich Pharmaceuticals, St. Louis, MO) was 
weighed as salt base and was dissolved in physiological saline (0.9%; Hospira, Inc. Lake 
Forest, IL). Cocaine and sucrose solutions were prepared fresh prior to the start of each 
session to prevent significant hydrolysis of cocaine and to ensure that each group 
received similar exposure to either solution prior to each operant test. Heparin was 
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purchased from APP Pharmaceuticals (Schaumburg, IL.), Butorphenol (Dolorex) from 
Merck Animal Health (Millsboro, DE), Sevofluorane, USP from Baxter (Deerfield, IL), 
and Gentamicin sulfate from VEDCO (Saint Joseph, MO). 
Synaptosomal [3H]DA Uptake Assay and [3H]WIN35,428 Binding 
 The radioligands [3H]WIN 35,428 (-)-3β-(4-flurophentl)-tropan-2β-carboxylic 
acid methyl ester tartrate - specific activity, 85 Ci/mmol, and  [3H]DA (3,4-ethyl-2[N-3H] 
dihydroxyphenylethylamine - specific activity, 31 Ci/mmol, were purchased from 
PerkinElmer Life Sciences (Boston, MA, USA). D-Glucose was purchased from Aldrich 
Chemical (Milwaukee, WI).  L-Ascorbic acid, bovine serum albumin, pyrocatechol, α-D-
glucose, HEPES, nomifensine maleate, desipramine hydrochloride, paroxetine 
hydrochlorine, pargyline hydrochloride, and sucrose were purchased from Sigma Aldrich 
(St. Louis, MO). Other chemicals were obtained from Thermo Fisher Scientific (USA).  
Overall Experimental Design  
A two-group between subjects design was employed (HIV-1 Tg vs. F344/NHsd).  All 
animals were successively assessed, trained, and tested for approximately six months, as 
illustrated in the design table (Table 1).  
Experiment 1: Sucrose Taste Preference.  
A sucrose taste preference test was conducted to assess HIV-1Tg rats’ preference 
for one of five concentrations of sucrose, i.e., 0, 1, 3, 10, and 30% (w/v), relative to F344 
controls. In order to habituate the rats to the novel bottles and stoppers, rats were placed 
in a clean testing cage with access to five graduated cylinders that contained water. This 
procedure occurred for 30 min per day for 3 consecutive days. The sucrose preference 
tests were conducted for five consecutive days following habituation. During testing 
animals were placed in a clean testing cage and had free access to the sucrose solutions 
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and water for several hr following testing. To control for a position bias, bottle order was 
randomized for each rat on the first day of testing and bottles were rotated on each 
subsequent day using a Latin square procedure so that each concentration was in each 
location at least once. Bottles were weighed and menisci read to the nearest ml before and 
after each test to determine the amount of fluid consumed from each bottle.   
Experiment 2: Sucrose-Maintained Responding  
The animals from Experiment 1 were used in the subsequent experiments, and 
thus all animals were sucrose experienced. Dipper training and auto-shaping were 
conducted according to previous research (Harrod et al., 2012; Lacy et al., 2012; Reichel 
et al., 2008). All rats learned to approach the receptacle and drink from the dipper (dipper 
training) and subsequently respond for 5% sucrose (w/v) reinforcement (autoshaping). 
Rats were water restricted for 12-15 hr prior to dipper training, autoshaping, and fixed 
ratio (FR) training.  After completion of the daily operant test, animals were given free 
access to water in their home cage for 9-12 hr. 
 Fixed-ratio (FR) schedules of reinforcement provide the reinforcer following a 
fixed set of responses. In the case of drug reinforcement responding changes if the unit-
dose of the self-administered drug is varied; a higher dose would result in fewer 
responses, although the higher dose is presumably more reinforcing (Yokel & Pickens, 
1973; Caine & Koob, 1994a). In order to assess the reinforcing efficacy of a drug, a 
progressive-ratio (PR) schedule of reinforcement is often used (Richardson & Roberts, 
1996). According to the PR schedule, the number of responses required to produce 
reinforcement is increased following completion of each ratio requirement, eventually 
resulting in a break point, wherein responding is markedly decreased. Putatively, the 
higher the break point, the more reinforcing a particular stimulus is considered, and 
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motivation to attain the reinforcer can be determined (Caine & Koob, 1994b; Harrod, 
Lacy, & Morgan, 2012a; Lacy, Morgan, & Harrod, 2014; Lacy, Hord, Morgan, & 
Harrod, 2012a).   
Two successive experiments were conducted to investigate acquisition of sucrose-
maintained responding. Experiments 2A and 2B investigated sucrose-maintained 
responding under conditions of water restriction and non-restriction (ad libitum water), 
respectively. In both experiments animals were required to respond for 5% sucrose 
according to an FR1 schedule of reinforcement. The FR1 schedule requires one response 
on an active lever to receive the consequent reinforcer; hence, the ratio requirement is 
fixed. At the beginning of the operant test the active and inactive levers were available. 
Rats responded for sucrose reinforcement (5%, w/v) on the two active levers during 42 
minute operant tests. A single response on an active lever resulted in 4s of access to 
sucrose. In order to prevent the development of a response side bias, if an animal made 
five consecutive responses on either one of the active levers, that lever was programmed 
to retract.  If a lever was retracted, the alternative lever was available for responding. 
Once the asymmetry in responding was balanced the previously retracted lever was once 
again made available. The use of two active levers was also important from the 
perspective of training the animals about response variability (Grunow and Neuringer, 
2002), especially in light of the subsequent assessment of choice behavior (Experiment 
4). Responding on the inactive lever was recorded, but no programmed consequence was 
presented. Animals were required to meet a criterion of 60 or more reinforcers per test 
over 3 consecutive days. Once this criterion was met under conditions of water restriction 
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(2A), the experiment was conducted again under conditions of ad libitum water (2B). No 
further water restriction was used for any subsequent experiment.  
Experiment 2C determined the sucrose-maintained responding curves for the 
F344 or HIV-Tg rats using the FR1 schedule of reinforcement. Testing began after three 
consecutive days of 60 or more reinforcers using the training concentration of sucrose 
(5%; FR1). For the tests, one of five sucrose concentrations (1%, 3%, 5%, 10%, and 
30%; w/v) was presented, according to a Latin-square procedure. There were six total 
concentration-response test days and those occurred every other day. Maintenance trials 
occurred on the non-test days. The training concentration of sucrose (5%) was the 
reinforcer on the maintenance days. Water was the reinforcer on the sixth and final test 
day. Water was used primarily as a control condition to assess responding in the absence 
of sucrose. It was presented as the sixth and last reinforcer for all rats in order to prevent 
potential extinction learning if water was not reinforcing to the animals (e.g., the absence 
of reinforcement). No water restriction was used for this experiment.  
Experiment 2D determined the sucrose-maintained responding curves for the 
F344 or HIV-Tg rats using the progressive-ratio (PR) schedule of reinforcement. Animals 
were experienced with FR schedules and did not require new training in order to progress 
to the PR phase of the experiment. After three maintenance days (5%; FR1) the schedule 
of reinforcement was changed to PR. During PR tests meeting the ratio requirement 
yielded 4-s access to reinforcement. Ratios progressively increased according to an 
exponential function (Response ratio (rounded to nearest integer) = [5e(injection numberX0.2)] – 
5) (Richardson & Roberts, 1996).  
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Fig. 5.2 shows the values for a number of rats mixed responses across the two 
active levers, then reinforcement was delivered after the ratio requirement was 
completed. One of five sucrose concentrations (1%, 3%, 5%, 10%, and 30%; w/v; Latin 
square procedure) was presented as the reinforcer on the concentration-response test 
days, which occurred every other day. Maintenance trials, which made 5% sucrose 
available (FR1), occurred on the non-PR test days. Water was presented as the sixth and 
last reinforcer for all rats in order to prevent potential extinction learning if water was not 
reinforcing to the animals. The PR tests were a maximum of 120 min in length. No water 
restriction was used for this experiment. 
Experiment 3: Cocaine-Maintained Responding 
Surgery 
 Following completion of experiment 2D, all animals were implanted with IV 
catheters.  IV catheterization was performed according to established methods (Smith, 
Lacy, & Strickland, 2014). Anesthesia was induced using 5-7% inhalant sevofluorane and 
animals were maintained at 3-4% sevofluorane throughout the surgical procedure. 
Following anesthesia, a sterile IV catheter was implanted into the right jugular vein and 
secured with 4-0 Perma-Hand Silk sterile sutures (EthiconEndo-Surgery, Inc). The dorsal 
portion of the catheter was affixed to an acrylic pedestal embedded with mesh. The dorsal 
portion/backmount was subcutaneously implanted above the right and left scapulae, and 
then sterile 4-0 Monoweb sutures were used to stitch the backmount into place. All rats 
were administered butorphenol (1.0 mg/kg, s.c.) and gentamicin (0.2 ml 1%, i.v.) 
immediately following the surgery to provide post-operative analgesia and to prevent 
infection, respectively. Immediately after surgery, animals were monitored in a heat-
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regulated warm chamber and returned to the colony room following recovery from 
anesthesia. All animals survived surgery. The catheters were “flushed” daily with a post-
flush solution containing the anti-coagulant heparin (2.5%) and 0.2 ml gentamicin (1%) 
for an additional 7 days to prevent blood clotting and infections following the surgery. 
Prior to testing each day, catheters were flushed with a 0.9% saline solution, and 
following the operant test catheters were treated with the post-flush solution. Cocaine 
testing began at least 7 days post-surgery.  
Cocaine-maintained responding 
In brief, the cocaine self-administration procedure was a modified version of 
Morgan et al., (2006). In our experiments, rats responded for cocaine according to a FR1 
schedule of reinforcement, and were switched to daily PR tests with a significantly higher 
concentration of IV cocaine. The reinforcing efficacy increased over the 14 PR test days, 
as rats demonstrated a progressive increase in cocaine-maintained responding. We used 
this procedure to assess potential differences in cocaine-maintained responding between 
the F344 and HIV-Tg animals.  
There were three phases to experiment 3. In phase one, F344 and HIV-Tg rats 
could respond for cocaine (0.33 mg/kg/inj) according to a FR1 schedule of reinforcement. 
A 20s time-out, i.e. active levers retracted and the house light was turned off, occurred 
upon the completion of the ratio requirement. Phase one lasted for five days and each 
operant test was one hour in duration. In phase 2, animals could respond for cocaine (1.0 
mg/kg/inj) according to a PR schedule of reinforcement (Response ratio (rounded to 
nearest integer) = [5e(injection numberX0.2)] - 5) (Richardson & Roberts, 1996), and this phase 
lasted for 14 days. The dose of cocaine was 1.0 mg/kg/inj and the operant test was a 
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maximum of 120 min in duration. The program timed out if 60 min elapsed without the 
completion of the next response requirement. A 20-s time-out occurred upon completion 
of the ratio requirement. In the final phase, a PR cocaine dose-response experiment was 
conducted. The cocaine concentrations were 0.01, 0.03, 0.10, 0.33, and 1.0 mg/kg/inj and 
they were presented in an ascending manner. A 20s time-out occurred upon the 
completion of the ratio requirement. Maintenance trials, which made the 0.33 
mg/kg/infusion cocaine concentration available on an FR1 schedule, occurred every other 
day.  
Experiment 4: Choice Behavior 
Following completion of the cocaine studies, both groups of animals were subject 
to a choice self-administration protocol. The EC50 for sucrose and cocaine were used as 
the concentrations for choice behavior. The EC50 for the F344 controls was the training 
dose (0.33mg/kg/infusion) and due to a lack of differential responding in the HIV-1 Tg 
animal the training dose was also used as the test dose. Each session began with 4 forced 
choice (2 nondrug and 2 drug rewards) followed by the choice component. During forced 
choice, only one active lever was present. The position of the sucrose paired lever (right 
or left) was balanced between groups. During the choice component, both levers were 
available simultaneously allowing the animals to freely choose between sucrose and 
cocaine. During all studies there was an inactive lever located in the center back panel of 
the chamber. 
Experiment 5: Neurochemical measures of the dopamine system [3H] DA uptake 
in striatum and PFC 
Animals were sacrificed within 24 hr following completion of the self-
administration choice procedure. The kinetic parameters (Vmax and Km) of synaptosomal 
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[3H]DA uptake were determined using a previously described method (Zhu et al., 2009; 
Zhu, Green, Bardo, & Dwoskin, 2004). Briefly, brain regions from each rat were 
homogenized following sacrifice in 20ml of ice-cold sucrose solution (0.32M sucrose and 
5mM sodium bicarbonate, pH 7.4) with 16 up-and-down strokes using a Teflon pestle 
homogenizer (clearance approximately 0.003 inch). The resulting crude synaptosomal 
preparation was centrifuged at 2,000g for 10 min at 4ºC, and the resulting supernatants 
were centrifuged at 20,000g for 15 min at 4ºC. The resulting pellets were resuspended in 
4.0ml for PFC and 3.0ml for striatum of ice-cold Krebs-Ringer-HEPES assay buffer 
(125mM NaCl, 5mM KCl, 1.5mM MgSO4, 1.25 CaCl2, 1.5 KH2PO4, 10mM D-glucose, 
25mM HEPES, 0.1mM EDTA, 0.1mM pargyline, and 0.1mM L-ascorbic acid, saturated 
with 95%O2/5%CO2, pH 7.4). Half of the striatal synaptosomes from individual rats were 
used in the [3H]DA uptake assay, and the other half  were used for [3H]WIN 35,428 
binding assays as described below.  The Bradford protein assay (Bradford, 1976) using 
bovine serum albumin as the protein standard, was used to determine protein 
concentrations (Bio Rad, USA). 
Dopamine is transported by the DAT, the norepinephrine transporter, and the 
serotonin transporter in the PFC (Moron, Brockington, Wise, Rocha, & Hope, 2002; 
Williams & Steketee, 2004). In order to isolate the uptake of DA to only DAT within the 
PFC,  kinetic analysis of [3H]DA uptake by the DAT was assessed in the presence of 
desipramine (1µM) and paroxetine (5nM) to prevent [3H]DA uptake into norepinephrine 




Synaptosomes containing ~100µg protein/100µl and ~50µg protein/30µl, 
respectively, were incubated in a metabolic shaker for 10 min at 34ºC and then incubated 
for 8 min at 34ºC after adding one of 8 [3H]DA concentrations (1nM-1µM, final 
concentration). Assays were performed in duplicate with a total volume of 500µl. 
Incubation was terminated by the addition of 3ml ice-cold assay buffer. Samples were 
immediately filtered through Whatman GF/B glass fiber filters using a Brandel cell 
harvester (Model M-48’ Biochemical Research and Development Laboratories Inc., 
Gaithersburg, MD). Filters were presoaked with 1mM pyrocatechol in assay buffer and 
washed 3 times with 3ml ice-cold assay buffer containing 1mM pyrocatechol.  
Pyrocatechol is a catechol-O-methyltransferase (COMT) inhibitor. In the current study, 
pyrocatechol (1 mM) was included in the assay buffer to prevent the degradation of 
[3H]DA during the processes of washing and harvesting by COMT (Napolitano, Zurcher, 
& Da, 1995). Non-specific uptake was determined in duplicate at each [3H]DA 
concentration by including 10µM nomifensine in the assay buffer. Radioactivity was 
determined by liquid scintillation spectrometry (Model TRI-CARB 2900TR, Perkin 
Elmer Instruments, Shelton, CT, USA). GraphPad Prism 5.0 (GraphPad Software, Inc., 
San Diego, CA, USA) was used to determine kinetic parameters (Vmax and Km) 
Striatal [3H]WIN 35,428 Binding Assay 
In order to determine whether [3H]DA uptake into striatal synaptosomes was the 
result of a direct interaction with the DAT, the maximal number of binding sites (Bmax) or 
affinity (Kd) for [
3H]WIN 35,428 binding in striatal synaptosomes were examined using a 
previously described method (Zhu et al., 2009; Zhu, Bardo, Bruntz, Stairs, & Dwoskin, 
2007). As described above, half of the striatal synaptosomes from each rat were 
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centrifuged at 20,000 g for 15 min at 4oC and resuspended in 3.0ml ice-cold sodium-
phosphate buffer (2.1mM NaH2PO4, 7.3mM Na2HPO4 7H2O, pH 7.4). 
 To generate saturation isotherms, striatal synaptosomes containing ~50µg/30µl 
were added to assay tubes containing one of the eight concentrations of [3H]WIN 35,428 
(0.5 to 30 nM, final concentration). Assay tubes were incubated for 2 hr on ice. 
Nonspecific binding at each concentration of [3H]WIN 35,428 in the presence of cocaine 
(30µM, final concentration) was subtracted from the total binding in order to calculate 
specific binding. Rapid filtration (Brandel cell harvester) onto Whatman GF/B glass fiber 
filters, which were presoaked for 2 hr with assay buffer containing 0.5% 
polyethylenimine, was used to terminate the assay.  Filters were then rinsed 3 times with 
3 ml of ice-cold assay buffer. Radioactivity on the filters was determined using liquid 
scintillation spectrometry (Model TRI-CARB 2900TR, PerkinElmer Instruments, 
Shelton, CT, USA). 
Data Analysis 
Data analyses were performed using SPSS version 21 (IBM Corp., Somers, NY), 
BMDP version 2009 (Statistical Solutions, Saugus, MA), and GraphPad Prism version 
5.02 (GraphPad Software, Inc. La Jolla, CA). For experiment 1, a mixed-design analysis 
of variance (ANOVA) was used to analyze sucrose consumption, with genotype (HIV-1 
Tg vs. F344 control) as the between-subjects factor, and sucrose concentration (0-30%, 
w/v, or day 1-5) as the within-subjects factor. Experiments 2A and 2B were analyzed 
using an independent samples t-test, using time to meet criterion (60+ reinforcers over 3 
days) as the measure of performance. Experiments 2C and 2D were analyzed using a 
mixed-design ANOVA with genotype (HIV-1 Tg vs. F344 control) as the between-
subjects factor and sucrose concentration as the within-subjects factor. Similarly, for 
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experiments 3A-C, a mixed-design ANOVA was used and genotype was the between-
subjects factor and day or concentration was the within-subjects factor. For experiment 4, 
a 2 (genotype) × 2 (reinforcer type) mixed-design ANOVA was used to analyze the slope 
of the linear regression lines representing the change in sucrose and cocaine preference 
over the first 5 days of the choice period (slope values were obtained for each animal for 
each reinforcer from linear regression analyses on the number of reinforcers obtained 
over the first 5 days of the choice period). A 2 (genotype) × 2 (reinforcer type) × 5 (day) 
mixed-design ANOVA was used to analyze number of reinforcers earned and number of 
active lever press responses. Greenhouse-Geisser corrections were used in cases where 
Maulchey’s tests detected a violation of sphericity. 
For experiments 5 and 6, which are the DA uptake and binding experiments, the 
data are presented as mean values ±S.E.M.; n represents the number of independent 
experiments for each treatment group. Kinetic parameters of [3H]DA uptake (Vmax and 
Km) and [
3H]WIN 35,428 binding (Bmax and Kd) were determined from saturation curves 
by nonlinear regression analysis using a one-site model with variable slope. To determine 
the differences in the kinetic parameters, separate two-way ANOVAs were used to 
evaluate any differences between genotype (HIV-1 Tg vs. F344 control) and treatment 
(cocaine or sucrose) between-subject factors. Simple pairwise comparisons were used to 
evaluate planned-comparisons. Log transformed values of Km or Kd were utilized for 
statistical comparisons.  Differences were considered significant at p≤0.05. 
Stepwise regression was used to detect any significant behavioral predictors of 
neurochemical changes observed in the DA uptake and binding experiments. Significant 
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models were further explored using multiple linear regression analyses. Models were 
considered significant if p≤0.05. 
 An exploratory discriminant function analysis was employed to determine which 
neurochemical measures best differentiated group performance, and the extent to which 
the observed differences in measures correctly identified animals in regard to their group 
membership (HIV-1 Tg vs. F344 control). 
Results 
Motivational alterations in HIV-1+ individuals are associated with decreased 
performance on tasks known to involve the frontal-subcortical circuitry (Cole et al., 
2007), and associated with decreased volume of the nucleus accumbens (Paul et al., 
2005b). Apathy is not generally addressed in animal models; however, the concept of 
motivation, or how willing an animal is to “work” for reinforcement, is frequently tested 
in animals using operant conditioning. In the current experiments, operant schedules of 
reinforcement were used to assess potential differences in sensitivity to the reinforcer 
(i.e., FR;Yokel & Pickens, 1973; Arnold & Roberts, 1997) and changes in reinforcement 
efficacy (i.e., PR;Morgan, Liu, & Roberts, 2006) between control and transgenic rats that 
constitutively express multiple proteins associated with the HIV-1 virus.   
The HIV-1 Tg rat does not exhibit altered sucrose taste preference 
We first examined the ability of HIV-1 Tg rats to detect sucrose and whether any 
taste preference might bias subsequent testing of the HIV-1 Tg rats using sucrose as a 
reinforcer (Figure 5.1A).  A 2 × 5 × 5 mixed-design ANOVA revealed a significant main 
effect of concentration [F(4, 108)=55.03, pGG≤0.001], and a significant day × 
concentration interaction [F(16, 432)=3.05, pGG≤0.05]. There was no significant main 
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effect of genotype [F(1,27)<1.0]. As illustrated (Figure 5.1C), the orthogonal components 
of the significant two-way interaction indicated fluid consumption was a robust linear 
function of sucrose concentration from 0 - 30% w/v [F(1,27)=81.81, p≤0.001].  Sucrose 
preference was not altered in the HIV-1 Tg rats, relative to F344 controls. 
Critically, bottle position was also evaluated in order to assess any potential 
confound with animal side bias or preference, as illustrated in the Latin-Square design 
(Figure 5.1B). A 2 × 5 × 5 mixed-design ANOVA of bottle position revealed no 
significant main effect of bottle position, day, or day × position interaction (Figure 5.1D) 
indicating that the sucrose taste preference results were not altered by any positional or 
side bias of the animals.   
Figure 5.1 The HIV-1 Tg rat does not exhibit altered sucrose preference.  Prior to the 
evaluation assessing the effects of long-term HIV-1 protein exposure on motivated 
behavior using sucrose, an assessment of sucrose preference was conducted.   A. Animals 
had free access for 1 hour to five bottles filled with 0, 1, 3, 10, or 30% (w/v) sucrose 
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solutions; bottles were weighed and menisci read to the nearest ml before and after each 
test.  B. To control for a position bias, bottle order was randomized for each rat on the 
first day of testing and bottles were rotated on each subsequent day using a Latin square 
procedure so that each concentration was in each location once.  C. Mean (±SEM) 
consumption (ml) of each solution over the 5 testing days illustrated that regardless of 
genotype, fluid consumption was a robust linear function of sucrose concentration 
[F(1,27)=81.81, p≤0.001; ±95%CI].  D. Mean (±SEM) fluid consumption from each 
bottle position across days revealed there was no confound with any positional or side 
bias of the animals, i.e., there was no significant effect of bottle position, day, or a day x 
position interaction.  
HIV-1 Tg rats successfully acquire sucrose-maintained responding under either 
restricted or non-restricted conditions 
Given that there were no alterations in sucrose preference, operant procedures 
were used to determine sensitivity to sucrose reinforcement (Figure 5.2A).  The 
proportion of animals (HIV-1 Tg or F344 controls) meeting criterion across days under 
conditions of water restriction, as illustrated (Figure 5.2B) showed there was no overall 
effect of the HIV-1 transgene on the number of animals that were able to acquire the task; 
at the end of 68 days, 100% of the F344 controls and 93% of the HIV-1 Tg rats met 
criterion (15/15 vs. 13/14, z=1.05, p≤0.29).  However, also illustrated is the observation 
that the HIV-1 Tg animals took longer (a mean of 20 additional days) to reach criterion 
(60+ reinforcers for 3 consecutive days) relative to F344 controls.  A linear regression on 
the proportion data revealed that the results for both genotypes were a significantly linear 
fit (r2= 0.9219 and r2= 0.9427 for F344 and HIV-1 Tg animals, respectively) and further 
confirmed that the slopes of the lines were significantly different from one another 
[F(1,99)=177.08 p≤0.001].   
Once animals met criterion for 3 consecutive days under water restriction, they 
were allowed ad libitum access to water in their home cages and were tested on an FR1 
schedule of reinforcement. The proportion of animals (HIV-1 Tg or F344 controls) 
meeting criterion across days without extrinsic motivation (no water restriction), as 
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illustrated (Figure 5.2C), showed there was no overall effect of the HIV-1 transgene on 
the number of animals that were able to acquire the task; at the end of 68 days, 80% of 
the F344 controls and 54% of the HIV-1 Tg rats met criterion [12/15 vs. 7/13, z=1.48, 
p≤0.14].  Again, also illustrated is the observation that the HIV-1 Tg animals took longer 
(a mean of 20 additional days) to reach criterion (60+ reinforcers for 3 consecutive days), 
relative to F344 controls.  Specifically, regression on the proportion of animals meeting 
criterion across days revealed robust linear functions (r2=0.95 and r2=0.89 for F344 and 
HIV-1 Tg animals, respectively) and confirmed that the slopes of the lines were 
significantly different from one another [F(1,74)=193.30, p≤0.001].  
Thus, HIV-1 Tg rats successfully acquired the self-administration task, under 
either restricted or even non-restricted conditions, albeit the rate at which the groups 
acquired the task was significantly slower as a function of expression of the HIV-1 
transgene.  
Response vigor for, but not sensitivity to, or reinforcing efficacy of, sucrose 
reinforcement was diminished in the HIV-1 Tg rat across multiple sucrose concentrations 
Next, a FR schedule of reinforcement was used to determine if there were any 
detectable differences in sensitivity to sucrose as a reinforcer across multiple 
concentrations of sucrose (i.e., FR;Yokel & Pickens, 1973; Arnold & Roberts, 1997). A 2 
x 6 repeated-measures ANOVA on total earned reinforcers revealed a main effect of 
genotype [F(1,27)=10.7 (p≤.003)], a main effect of concentration [F(5, 135)=65.9, 
pGG≤0.001], and more importantly, a genotype x concentration interaction [F(5,135)=5.2, 
pGG≤0.006].  More specifically, as illustrated (Figure 5.2D), a sigmoidal curve fit 
provided a robust characterization of the dose-response function for both HIV-1 Tg and 
control animals (r2=0.99 for both the HIV-1 Tg and F344 control groups). The curve was 
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shifted significantly downward [F(4,2)=1194.0, p≤0.001], however, there was no 
significant shift in the EC50; i.e., although there was clear evidence of a decrease in 
overall response vigor as suggested by the overall decrease in responding, there was no 
compelling evidence for any change in sensitivity to sucrose as a reinforcer in the HIV-1 
Tg animals. 
Figure 5.2 Response vigor for, but not sensitivity to, or reinforcing efficacy of, sucrose 
reinforcement was diminished in the HIV-1 Tg rat across multiple sucrose 
concentrations.  A. Given that there were no alterations in sucrose preference, operant 
procedures were used to determine sensitivity to sucrose reinforcement. B. HIV-1 Tg rats 
successfully acquired (criterion of 60+ reinforcers for 3 consecutive days) sucrose-
































































































































































maintained responding under conditions of 12-15 hr of water restriction.  No overall 
effect of the HIV-1 transgene on the number of animals that were able to acquire the task 
was detected after 68 days (15/15 vs. 13/14, F344 controls and the HIV-1 Tg rats, 
respectively), however, the HIV-1 Tg animals took longer to reach criterion relative to 
F344 controls (slopes of the lines were significantly different from one another 
[F(1,99)=177.08 p≤0.001]).  C. HIV-1 Tg rats successfully acquired (criterion as above) 
sucrose-maintained responding without extrinsic motivation (no water restriction). No 
overall effect of the HIV-1 transgene on the number of animals that were able to acquire 
the task was found at the end of 68 days (12/15 vs. 7/13, F344 controls and the HIV-1 Tg 
rats, respectively].  Again, however, the HIV-1 Tg animals took longer to reach criterion, 
relative to F344 controls (slopes of the lines were significantly different from one another 
[F(1,74)=193.30, p≤0.001]). D. A robust characterization of the dose-response function 
(1-30% w/v sucrose) under the FR schedule of reinforcement was provided for both HIV-
1 Tg and control animals by a sigmoidal curve fit (r2=0.99 for both the HIV-1 Tg and 
F344 control groups). The curve was shifted significantly downward [F(4,2)=1194.0, 
p≤0.001], however, there was no significant shift in the EC50, providing no compelling 
evidence for any change in sensitivity to sucrose as a reinforcer in the HIV-1 Tg animals.  
E. Similarly, a robust characterization of the dose-response function (1-30% w/v sucrose) 
under the PR schedule of reinforcement was provided for both HIV-1 Tg and control 
animals by a sigmoidal curve fit (r2=0.99 and r2=0.95 for HIV-1 Tg and F344 controls, 
respectively). (r2=0.99 and r2=0.95 for HIV-1 Tg and F344 controls, respectively). The 
curve was significantly shifted downward [F(3,4)=57.42, p≤0.001], however, again, there 
was no significant shift in the EC50, providing no compelling evidence for any change in 
efficacy of sucrose as a reinforcer in the HIV-1 Tg animals. 
A PR schedule of reinforcement was then used to assess potential differences in 
reinforcement efficacy of sucrose across a range of concentrations (i.e., PR;Morgan et al., 
2006). A 2x6 repeated-measures ANOVA on total earned reinforcers revealed a main 
effect of genotype [F(1,27)=18.52, p≤0.001], and a main effect of concentration 
[F(5,135)=9.071, pGG≤0.001] but no significant concentration x genotype interaction.  A 
sigmoidal dose-response analysis, as illustrated (Figure 5.2E), again confirmed a robust 
characterization of the dose-response function for both HIV-1 Tg and control animals 
(r2=0.99 and r2=0.95 for HIV-1 Tg and F344 controls, respectively). The curve was 
significantly shifted downward [F(3,4)=57.42, p≤0.001], however, again, there was no 
significant shift in the EC50; i.e., the clear evidence of a decrease in response vigor as 
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indexed by the decreased overall responding was not accompanied by any evidence for 
an alteration in efficacy of sucrose as a reinforcer in the HIV-1 Tg animals. 
Sensitivity to, and reinforcing efficacy of, cocaine is diminished in the HIV-1 Tg 
rats relative to F344 control rats   
An FR1 schedule of reinforcement was used to train the animals to self-administer 
cocaine as well as to assess any potential differences in sensitivity to cocaine as a 
reinforcer with daily access to a moderate dose of cocaine (0.33mg/kg/infusion). As 
illustrated (Figure 5.3B), a 2 × 5 repeated-measures ANOVA revealed a significant effect 
of genotype with HIV-1 Tg animals receiving fewer infusions that F344 controls 
[F(1,19)=4.8, p≤0.05]. There was no significant effect of day nor was there any 
significant orthogonal component to characterize a trend across days, indicating that the 
animals neither escalated nor regressed in their drug intake. However, the data were 
significantly greater than zero, suggesting that this dose of cocaine was not aversive to 
these animals.  
Following FR1 training, animals underwent 14 consecutive days of PR 
responding for a dose of cocaine three times that of the training dose (1.0mg/kg/infusion). 
As illustrated (Figure 5.3C), a 2 × 14 mixed-design ANOVA on number of cocaine 
infusions earned indicated a significant effect of genotype [F(1,13)=45.3, p≤0.001], and a 
significant main effect of day [F(13, 169)=2.9, pGG≤0.05].  Orthogonal decomposition of 
the day effect confirmed a prominent linear increase consistent with an escalation of 
cocaine intake across days [F(1,13)=10.0, p≤0.01].  Regression analyses substantiated a 
prominent linear fit for both genotypes (r2= 0.67 and r2= 0.66 for F344 and HIV-1 Tg 
animals, respectively) and further confirmed that the slopes of the lines were significantly 
different from one another [F(1,24)=6.3 p≤0.02].  Thus, differential escalation to cocaine 
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was observed with the HIV-1 Tg animals showing a significantly slower rate relative to 
F344 controls. 
A PR schedule with 5 different concentrations of cocaine was subsequently 
employed to assess how willing the animals were to work for cocaine with the 
establishment of their respective dose-response functions. As illustrated (Figure 5.3D), a 
2 × 5 mixed-design ANOVA on infusions earned found an overall significant effect of 
genotype with HIV-1 Tg animals earning significantly fewer infusions of cocaine relative 
to F344 controls [F(1,13)=6.4, p≤0.025].  Regression analyses demonstrated a linear log-
log fit for both genotypes (r2= 0.52 and r2= 0.33 for F344 and HIV-1 Tg animals, 
respectively) and further confirmed that the slopes of the lines were significantly different 
from one another [F(2,6)=67.5, p≤0.001]. Similarly, as illustrated (Figure 5.3E), a 2 x 5 
mixed-design ANOVA on response break point found an overall effect of genotype with 
HIV-1 Tg animals achieving a significantly lower break point [F(1,12)=8.8, p≤0.012].  
Regression analyses confirmed a linear log-log fit for both genotypes (r2= 0.81 and r2= 
0.25 for F344 and HIV-1 Tg animals, respectively) and demonstrated that the slopes of 
the lines were significantly different from one another [F(2,6)=30.0, p≤0.001]. Thus, 
sensitivity to, and reinforcing efficacy of, cocaine was diminished in the HIV-1 Tg rats 
relative to F344 control rats. 
Choice between sucrose and cocaine indicated change in preference 
Since the animals had a history of responding for sucrose as well as cocaine, and the 
animals were also trained to preclude the development of a response side bias, the choice 
behavior for sucrose vs. cocaine was subsequently assessed (Figure 5.4A). Regression 
analyses on the number of reinforcers earned across days, collapsed across genotype 
(Figure 5.4B), substantiated a prominent decrease in sucrose reinforcers earned (linear, 
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r2= 0.85) vs. a prominent increase in cocaine infusions earned (single phase association, 
r2= 0.88). The initial choice for sucrose over cocaine by a greater than 2:1 ratio shifted 
across the 7-day period to a greater than 2:1 ratio for cocaine over sucrose.  The rate of 
change was -3.4±0.63 for sucrose vs. 1.1±0.35 for cocaine, significantly different from 
each other [F(1,10)=38.7, p≤0.001] and from zero ([F(1,5)=28.5, p≤0.005 and 
F(1,5)=10.3, p≤0.025], respectively). With the replacement of cocaine with saline on day 
8, the drug extinction day, the choice shifted to a return for sucrose over cocaine by an 
approximate 2:1 ratio.  
Figure 5.3 Sensitivity to, and reinforcing efficacy of, cocaine was diminished in the HIV-
1 Tg rats relative to F344 control rats.   A. Cocaine self-administration (acquisition, 






























































































































escalation, and PR dose-response) was employed to assess potential differences in 
cocaine-maintained responding between the F344 and HIV-Tg animals. B. The mean 
number of infusions (±95% CI) earned during the 5 day cocaine acquisition period 
demonstrated that both HIV-1 Tg and F344 animals maintained a stable response during 
the acquisition period, however, the HIV-1 Tg animals received significantly fewer 
infusions than F344 controls [F(1,19)=4.8, p≤0.05]. C. The mean number of infusions 
(±95% CI) earned across the 14-day PR sessions revealed robust effects of genotype 
[F(1,13)=45.3, p≤0.001] and day [F(13,169)=2.9, pGG≤0.05], which was functionally 
linear [F(1,13)=10, p≤0.01], indicative of an escalation of cocaine intake across sessions. 
Regression analyses substantiated a prominent linear fit for both genotypes (r2= 0.67 and 
r2= 0.66 for F344 and HIV-1 Tg animals, respectively) and further confirmed that the 
slopes of the lines were significantly different from one another [F(1,24)=6.3 p≤0.02].  
Escalation to cocaine was significantly slower for the HIV-1 Tg animals rate relative to 
F344 controls. D. Number of infusions (±95% CI) earned and E. last ratio completed 
(break point) during cocaine dose-response sessions under the PR schedule of 
reinforcement demonstrated that the F344 animals received more cocaine infusions as 
dose increased [F(1,13)=18.77, p≤0.02], whereas the responding of the HIV-1 Tg animals 
did not vary as a function of increased cocaine dose.  The slopes of the linear log-log fits 
for number of infusions earned (r2= 0.52 and r2= 0.33 for F344 and HIV-1 Tg animals, 
respectively) were significantly different from one another [F(2,6)=67.5, p≤0.001].  
Similarly, the slopes of the linear log-log fits for break point (r2= 0.81 and r2= 0.25 for 
F344 and HIV-1 Tg animals, respectively) were significantly different from one another 
[F(2,6)=30.0, p≤0.001]. Thus, sensitivity to, and reinforcing efficacy of, cocaine was 
diminished in the HIV-1 Tg rats relative to F344 control rats. 
 
The choice behavior of the F344 control group (Figure 5.4C) and HIV-1 Tg 
animals (Figure 5.4D) was subsequently examined. The rate of change in choice 
behavior, captured by a 2 × 2 × 5 repeated measures ANOVA on the number of 
reinforcers received, revealed a significant genotype × reinforcer type × day interaction 
[F(4,36) = 2.95, p≤0.05].  For the F344 control group, regression analyses confirmed a 
prominent decrease in sucrose reinforcers earned (single phase decay, r2= 0.96) vs. a 
prominent increase in cocaine infusions earned (single phase association, r2= 0.78). The 
initial choice for sucrose over cocaine by a greater than 2:1 ratio shifted within 5 days to 
a greater than 2:1 ratio for cocaine over sucrose. The rate of change across the 5-day 
period before reaching their response plateau was -8.8 ±0.99 for sucrose vs. 3.5±1.08 for 
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cocaine, significantly different from each other [F(2,6)=39.8, p≤0.001] and from zero 
([F(1,3)=79.5, p≤0.005 and F(1,3)=10.8, p≤0.05], respectively). With the replacement of 
cocaine with saline on day 8, the drug extinction day, the choice shifted to a return for 
sucrose over cocaine by an approximate 2:1 ratio.  The F344 control group displayed a 
significantly greater number of active lever presses for sucrose on day 8 than they did on 
day 7, the last day of choice, (t(5)= -2.8, p≤0.05), and had returned to a level that was not 
significantly different from the number of active lever presses for sucrose on the first day 
of the choice period. 
 For the HIV-1 Tg group, regression analyses confirmed a prominent decrease in 
sucrose reinforcers earned (linear, r2= 0.72) vs. a nominal decrease in cocaine infusions 
earned (linear, r2= 0.008). The initial choice for sucrose over cocaine by a greater than 
2:1 ratio shifted across the 7-day period to no choice preference for cocaine vs. sucrose. 
The rate of change across the 7-day period was -2.3 ±0.65 for sucrose vs. -0.07±0.34 for 
cocaine, significantly different from each other [F(2,10)=6.9, p≤0.015]. The rate decrease 
in sucrose reinforcers earned was significantly different from zero ([F(1,5)=12.7, 
p≤0.025], not unlike that noted in the choice behavior of the F344 control animals.  
However, no rate change was discernible for cocaine infusions earned across the 7-day 
period (not significantly different from zero, F(1,5)<1.0]), despite the fact that the HIV-1 
Tg animals nevertheless chose cocaine infusions at a mean level greater than zero 
[F(1,6)=74.2, p≤0.001]. With the replacement of cocaine with saline on day 8, the drug 
extinction day, no differential choice was observed for the sucrose vs. cocaine response 
levers. Collectively, choice behavior was significantly disrupted by the HIV-1 transgene; 
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i.e., although responding of the HIV-1 Tg animals was sensitive to the reinforcing 
properties of cocaine, it was not driven by any increase in choice behavior for cocaine. 
 
 
Figure 5.4 HIV-1 transgene disrupts choice behavior. A. With a history of responding for 
sucrose as well as cocaine as well as explicit training to preclude the development of a 
response side bias, B. the choice behavior of the animals across days, collapsed across 
genotype, displayed a prominent decrease in sucrose reinforcers earned (linear, r2= 0.85) 
vs. a prominent increase in cocaine infusions earned (single phase association, r2= 0.88). 
The initial choice for sucrose over cocaine by a greater than 2:1 ratio shifted across the 7-
day period to a greater than 2:1 ratio for cocaine over sucrose; with the replacement of 
cocaine with saline on day 8, the drug extinction day, the choice shifted to a return for 
sucrose over cocaine by an approximate 2:1 ratio.   Given the significant genotype × 
reinforcer type × day interaction [F(4,36) = 2.95, p≤0.05], the choice behavior of the 
F344 control group (C) and HIV-1 Tg animals (D) is displayed. C. For the F344 control 
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group, their choice behavior displayed a prominent decrease in sucrose reinforcers earned 
(single phase decay, r2= 0.96) vs. a prominent increase in cocaine infusions earned 
(single phase association, r2= 0.78). The initial choice for sucrose over cocaine by a 
greater than 2:1 ratio shifted within 5 days to a greater than 2:1 ratio for cocaine over 
sucrose. With the replacement of cocaine with saline on day 8, the drug extinction day, 
the F344 control group displayed a significantly greater number of active lever presses 
for sucrose on day 8 than they did on day 7, the last day of choice, (t(5)= -2.8, p≤0.05), 
and had returned to a level that was not significantly different from the number of active 
lever presses for sucrose on the first day of the choice period.  D. For the HIV-1 Tg 
group, their choice behavior also displayed a a prominent decrease in sucrose reinforcers 
earned (linear, r2= 0.72) vs. only a nominal decrease in cocaine infusions earned (linear, 
r2= 0.008). The initial choice for sucrose over cocaine by a greater than 2:1 ratio shifted 
across the 7-day period to no choice preference for cocaine vs. sucrose. No rate change 
was discernible for cocaine infusions earned across the 7-day period (not significantly 
different from zero, F(1,5)<1.0]), despite the fact that the HIV-1 Tg animals nevertheless 
chose cocaine infusions at a mean level greater than zero [F(1,6)=74.2, p≤0.001]. With 
the replacement of cocaine with saline on day 8, the drug extinction day, no differential 
choice was observed for the sucrose vs. cocaine response levers. Thus, choice behavior 
was significantly disrupted by the HIV-1 transgene; i.e., although responding of the HIV-
1 Tg animals was sensitive to the reinforcing properties of cocaine, it was not driven by 
any increase in choice behavior for cocaine. 
 
Dopamine Transporter in the HIV-1 Tg rat  
To determine the relationship between brain neurochemistry changes in the DAT 
and behavior, animals were sacrificed within 24 hr of the last cocaine self-administration 
session.  The brains were rapidly dissected and used immediately for neurochemical 
analyses. These and other relevant neurochemical findings regarding dopamine terminal 
regulation are summarized in Figures 5.5 D-G. 
Vmax increases in F344 controls, but not in HIV-1 Tg animals, following cocaine 
self-administration 
A 2 × 2 ANOVA was used to analyze the effects of cocaine self-administration 
and genotype on Vmax and Km in the striatum. There was a significant genotype by 
treatment interaction [F(1,20)=7.8, p≤0.01] with Vmax as the dependent variable. As 
illustrated (Figure 5.5A), F344 control rats with a history of cocaine self-administration 
displayed a significantly increased Vmax, compared to F344 sucrose rats (p≤0.05). 
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Conversely, cocaine self-administration did not significantly affect Vmax in HIV-1 
transgenic rats compared to HIV-1 Tg sucrose animals. F344 control animals with a 
history of cocaine self-administration had significantly higher Vmax rates than HIV-1 Tg 
animals with a history of cocaine self-administration (p≤0.05).  There were no significant 
effects of cocaine self-administration or genotype on Km in the striatum. 
In the prefrontal cortex, a similar pattern emerged. There was a significant 
genotype by treatment interaction [F(1,20)=6.1, p≤0.02] with Vmax as the dependent 
variable.  HIV-1 Tg animals displayed a significantly reduced Vmax following cocaine 
self-administration when compared with cocaine naïve HIV-1 Tg rats (p≤0.05), while the 
F344 control animals did not have an altered Vmax following cocaine self-administration. 
HIV-1 Tg rats with a history of cocaine self-administration displayed a significantly 
decreased Vmax compared to F344 control rats with a history of cocaine self-
administration, p≤0.05. There were no significant effects of cocaine self-administration 
or genotype on Km in the PFC. 
Bmax is significantly decreased in HIV-1 Tg animals and increases following 
cocaine self-administration 
Analysis of maximum binding (Bmax) using a two-way ANOVA revealed a 
significant main effect of genotype [F(1,18)=4.58, p≤0.05]. HIV-1 Tg sucrose rats had a 
significantly lower maximum [3H]WIN 35,428 binding, relative to F344 sucrose animals. 
Additionally, a significant genotype × treatment (cocaine vs. sucrose) interaction was 
also detected [F(1,18)=4.15, p≤0.05]. As illustrated (Figure 5.5B), F344 sucrose control 
rats had a significantly higher Bmax compared to HIV-1 Tg cocaine naïve rats (p≤0.05). 
Bmax in HIV-1 Tg animals with a history of cocaine self-administration, was not 
significantly different from F344 animals which had also self-administered cocaine. 
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Decreased DA turnover rate in the striatum of the HIV-1 Tg rat following cocaine 
self-administration 
DA turnover rate was determined by dividing striatal Vmax by striatal Bmax. Using 
the resulting turnover values, a two-way ANOVA was used to determine effects of 
cocaine self-administration on DA turnover in these animals. A significant genotype × 
treatment interaction was noted [F(1,18)=6.74, p≤0.02], albeit no main effects of 
genotype or treatment were found.  As illustrated (Figure 5.5C), F344 animals had a 
significantly increased DA turnover rate following cocaine self-administration (p≤0.05); 
in contrast, HIV-1 Tg animals showed a significant decrease in DA turnover following 
cocaine self-administration (p≤0.05).  
Figure 5.5 Dopamine transporter dysregulation in HIV-1 Tg animals and interactions 
with cocaine self-administration.  A.  [3H]DA uptake in striatal synaptosomes from 
sucrose and cocaine self-administering animals (Mean ± SEM). A significant genotype 
by treatment interaction was detected F(1,20)=7.79, p≤0.01. Cocaine self-administration 
in F344 animals produced a significant increase in Vmax, p≤0.05, compared to sucrose 
F344 controls. There was no significant effect of cocaine self-administration on Vmax in 
 
117 
the HIV-1 Tg rat, relative to sucrose; however, cocaine self-administration in HIV-1 Tg 
animals produced a significantly lower Vmax , in comparison to cocaine self-
administration in F344 animals, p≤0.05. There were no significant effects of genotype, 
treatment, or a significant interaction, on Km in the striatum. All experiments were 
performed in duplicate, tissue from each animal was considered an individual 
experiment. B. [3H]WIN 35,428 binding to DAT in striatal synaptosomes (Mean ± SEM).  
HIV-1 Tg sucrose rats had a significantly lower Bmax in comparison to F344 sucrose 
animals, F(1,18)=4.58, p≤0.05. Cocaine self-administration had a significant interaction 
with genotype F(1,18)=4.15, p≤0.05; cocaine self-administering HIV-1 Tg rats increased 
Bmax  to those of cocaine self-administering F344 animals. There was no significant effect 
of genotype or drug treatment on Kd in striatal synaptosomes. C. Dopamine turnover rate 
was determined via Vmax/Bmax. A significant genotype by treatment interaction was found 
F(1,18)=6.74, p≤0.02. Cocaine self-administration produced a significantly increased 
turnover rate in F344 animals p≤0.05 and, conversely, a significantly decreased turnover 
rate in HIV-1 Tg animals p≤0.05.D,E.  Illustration of a dopamine terminal following 
sucrose (D) and cocaine (E) self-administration in F344 animals. Cocaine self-
administration leads to increased rates of dopamine uptake (Ramamoorthy, Samuvel, 
Balasubramaniam, See, & Jayanthi, 2010); increased dopamine turnover (Goeders & 
Smith, 1993); increased phasic concentrations of DA (Pettit & Justice, Jr., 1991); and 
decreased post-synaptic D1 receptors (Graziella de Montis et al., 1998), relative to 
sucrose animals. F. Illustration of dopamine terminal in HIV-1 Tg animals. HIV-1 
proteins (tat, gp120) modulate DAT function (Zhu et al., 2009; Midde et al., 2013; 
Wallace et al., 2006) and VMAT2 (Midde et al., 2012); more efficient DAT 
function/higher turnover rate and no increase in DA dopamine concentration (Ferris et al., 
2010).  Increased postsynaptic D1 receptors in HIV-1 (Silvers et al. 2007; Aksenov et al., 
2006).G. Illustration of dopamine terminal following cocaine self-administration in HIV-
1 Tg animals. Cocaine and HIV-1 proteins both bind to the DAT protein (Zhu et al., 
2011); HIV-1 proteins bind to VMAT2 (Midde et al., 2012); DAT funding is less 
efficient, resulting in lower turnover rate of dopamine. Dopamine concentrations increase 
in the presence of both HIV-1 proteins and cocaine, producing chronic 
hyperdopaminergic tone (Ferris et al., 2010). Status of D1 postsynaptic receptors is 
unknown. 
Behavior predicting neurochemical outcomes: Cocaine and sucrose 
Cocaine. The cocaine FR acquisition period was determined to significantly 
predict Vmax in the PFC (data from each day were considered to be independent 
predictors, [F(5,8)=12.374, p≤.005]). The adjusted r2 indicated that 81.4% of the variance 
in PFC Vmax was associated with number of infusions received on days 1-5 of cocaine 
acquisition. Cocaine self-administration produced a significant decrease in [3H]DA Vmax 
in the HIV-1 Tg rat PFC in comparison to both HIV-1 Tg drug-naïve animals and F344 
cocaine self-administration animals. In contrast, cocaine self-administration did not 
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significantly affect [3H]DA Vmax in the PFC of F344 animals, which is similar to previous 
findings (Grimm, Shaham, & Hope, 2002; Miguens et al., 2008; Ben-Shahar, Moscarello, 
& Ettenberg, 2006; Williams & Steketee, 2004). Interestingly, the number of cocaine 
infusions received during cocaine acquisition significantly predicted the neurochemical 
changes in the prefrontal cortex, suggesting that dopamine in the prefrontal cortex plays a 
significant role in establishing cocaine reinforcement in the HIV-1 Tg rat.   
The cocaine PR escalation period was also determined to significantly predict 
Vmax in the PFC using multiple linear regression (data from each day – day 1 to day 14 -- 
were considered to be independent predictors, [F(7,4)=20.57, p≤.01]). The adjusted r2 
indicated that 92.6% of the variance in PFC Vmax was associated with the number of lever 
presses across the 14-day period of cocaine escalation.  The number of active lever 
presses during the cocaine PR dose-response experiment (data from each dose were 
considered independent predictors) was determined to significantly predict both Vmax in 
the striatum [F(5,6)=15.77, p≤0.005] and DA turnover [F(5,6)=17.07, p≤0.005]. The 
adjusted r2 values indicated that 87% of the variance in STR Vmax and 88% of the 
variance in DA turnover were associated with the number of active lever presses during 
the cocaine PR dose-response experiment. The number of infusions during the cocaine 
PR dose-response experiment (data from each dose were considered independent 
predictors) was determined to significantly predict Bmax in the striatum [F(5,6)=6.4, 
p≤0.05]. The adjusted r2 indicated that 71.3% of the variance in STR Bmax was associated 
with the number of infusions received during the cocaine PR dose-response experiment. 
Thus, those neurochemical measures that were significantly predicted by behavioral 
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measures were PFC Vmax, STR Vmax, STR Bmax, and DA turnover in multiple regression 
analyses. 
Sucrose. FR responding for sucrose did not predict neurochemical outcomes. The 
number of active lever presses during the sucrose PR dose-response experiment (data 
from each concentration were considered independent predictors) was determined to 
significantly predict both Vmax in the striatum [F(6,15)=2.95, p≤0.05] and DA turnover in 
the striatum [F(6,15)=3.134, p≤0.05] using multiple linear regression. The adjusted r2 
values indicated that 35.7% of the variance in STR Vmax and 37.9% of the variance in DA 
turnover were associated with the number of active lever presses during the sucrose PR 
experiment. The slope of the linear regression lines representing the change in sucrose 
preference over the first 5 days of the choice period significantly predicted Bmax in the 
striatum in the control group [F(1,4)=8.3, p≤0.05], but not in the HIV-1 Tg group. The 
adjusted r2 indicated that 59.6% of the variance in STR Bmax was associated with the 
change in sucrose preference over the 5-day period.  Relative to the number of significant 
behavioral:neurochemical correlations found for cocaine reinforcement, far fewer 
behavioral alterations for sucrose reinforcement predicted alterations in the dopamine 
neurochemistry. 
Discriminant Function Analysis 
A discriminant function analysis was conducted to further explore the effects of 
expression of the HIV-1 transgene (Figure 5.6), by assessing the ability of various 
neurochemical measures to correctly identify group membership of individual animals 
(HIV-1 Tg vs. control). The predictor variables that were selected for the analysis (PFC 
Vmax, STR Vmax, STR Bmax, and DA turnover) were those neurochemical measures that 
were significantly predicted by behavioral measures in multiple regression analyses (as 
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noted above). The discriminant function revealed a significant association between 
groups and all predictors, accounting for 67.2% of between group variability (canonical 
correlation of 0.82) and correctly classified the animals’ group membership with 92.9% 
accuracy (100% of HIV-1 Tg animals, and 85.7% of controls) (Wilks’ λ = 0.328, 
p≤0.05). 
Figure 5.6 Discriminant function analysis. An exploratory discriminant function analysis 
was conducted to determine which neurochemical measures best differentiated group 
performance, and more critically, the extent to which the observed differences in 
measures correctly identified animals in regard to their group membership (HIV-1 Tg vs. 
F344 control).   The predictor variables that were selected for the analysis were those 
neurochemical measures that were significantly predicted by behavioral measures in 
multiple regression analyses (PFC Vmax, STR Vmax, STR Bmax, and DA turnover). Animal 
classification is illustrated as a function of the canonical variable representing the 
simplest linear function that best separated the HIV-1 Tg and control groups (canonical 
correlation of 0.82) and correctly classified the animals’ group membership with 92.9% 
accuracy (100% of HIV-1 Tg animals, and 85.7% of controls; Wilks’ λ = 0.328, p≤0.05). 





















Psychostimulant abuse is highly comorbid with HIV-1 infection (Purohit et al., 
2011; Ferris, Frederick-Duus, Fadel, Mactutus, & Booze, 2010)08), but it remains 
unclear how HIV-1 may impact the motivational processes which underlie drug abuse 
(Ferris et al, 2010).  We found that the reinforcing efficacy of cocaine was diminished in 
the HIV-1 Tg rat.  Specifically, although both HIV-1 Tg and control animals increased 
their cocaine intake over 14-days of PR responding, the HIV-1 Tg rats responded 
significantly less and maintained consistent low-level responding to cocaine (unit dose 
1.0 mg/kg/infusion).  There was no significant shift in EC50 for sucrose, although HIV-1 
Tg rats responded significantly less for sucrose using both FR-1 and PR schedules of 
reinforcement.  These findings suggest a profound effect on cocaine-maintained 
responding in the HIV-1 Tg rats, relative to sucrose responding.  When animals were 
allowed a choice between cocaine and sucrose, animals initially preferred sucrose, but 
over time switched to a preference for cocaine. Thus, HIV-1 Tg rats exhibit disrupted 
choice behavior. DAT function was altered in the striatum of HIV-1 Tg rats; however 
prior cocaine self-administration produced a unique effect on dopamine homeostasis in 
the HIV-1 Tg rat, relative to the effects of either cocaine or HIV-1 alone. The alterations 
in reinforcing efficacy in the HIV-1 Tg rat resembles altered motivational states 
following HIV-1 infection (Paul et al., 2005a; Kamat et al., 2012; Castellon et al., 1998a). 
Our data suggest these alterations may reflect selective dysregulation within the 




The dopamine transporter (DAT) may play a fundamental role in determining 
responding of HIV-1 Tg rats even in the absence of co-morbid drug exposure. There was 
a significant reduction in [3H] WIN35,428 binding in the striatal synaptosomes derived 
from HIV-1 Tg animals when compared to F344 controls.  This reduction in Bmax HIV-1 
Tg animals is consistent with our prior in vitro  studies, which demonstrated that  acute 
treatment with HIV-1 Tat protein reduced  the membrane expression of the DAT (Midde 
et al., 2012), decreased [3H]WIN 35,428 binding in rat striatal synaptosomes (Zhu et al., 
2009) and decreased  [3H]WIN 35,428 binding in midbrain neurons in vitro (Aksenova et 
al., 2006).  We found an increase in striatal Vmax for dopamine transport in the HIV-1 
Tg rats. In sum, for the HIV-1 Tg rats, there was an increase in dopamine turnover in the 
striatum, reflecting that, although there were fewer DAT proteins on the membrane 
surface, these transporters were more efficient in dopamine clearance.  This may 
represent a homeostatic process in which the HIV-1 Tg rat maintains consistent synaptic 
basal dopaminergic tone. 
In contrast, dopamine homeostasis was differentially affected by cocaine self-
administration in the HIV-1 Tg rats.  In control animals, cocaine self-administration 
increased Vmax, which is an oft reported finding following repeated cocaine 
administration  (Ramamoorthy et al., 2010; Oleson et al., 2009); however HIV-1 Tg 
animals which self-administered cocaine did not significantly increase Vmax, yet had 
similar [3H]WIN35,428 binding  as controls following cocaine. This resulted in decreased 
DA turnover in the striatum of the HIV-1 Tg rat following cocaine self-administration. 
We previously reported that direct infusion of the HIV-1 protein Tat into the NAc in 
animals with prior chronic cocaine experience produced a hyperdopaminergic basal tone 
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(Ferris et al., 2010) and altered behavior (Harrod et al., 2008).  Specifically, the NAc of 
animals with prior cocaine experience had elevated basal DA levels when infused with 
Tat protein, but not following either cocaine or Tat alone; animals with Tat + cocaine 
treatments had approximately 400% greater extracellular DA levels (Ferris et al., 2010). 
Indeed, higher DA levels might be anticipated if the DAT function is compromised. 
Interestingly, acute treatment with Tat alone did not significantly alter DA levels, prior 
cocaine exposure was required.  Collectively, these actions by HIV-1 following repeated 
cocaine administration may contribute to decreased DA turnover, subsequently increasing 
extracellular DA, but only with prior cocaine experience.     
The HIV-1 Tg rat not only expresses Tat protein (Peng et al., 2010), but also 
gp120, Nef, and Rev viral proteins (without gag-pol genes, thereby rendering the rat non-
infectious). HIV-1 protein expression in the HIV-1 Tg rat is under the control of the 
natural HIV-1 promoter, LTR, with protein expression in mononuclear 
phagocytes/astrocytes, but not in neurons (Royal, III et al., 2012) – a pattern similar to 
that observed in human HIV-1+ brains.  Protein expression in the HIV-1 Tg rat is 
regulated by the viral LTR and uses rat cyclin-T as a cofactor to regulate Tat production 
(Reid et al., 2001). HIV-1 proviral DNA thereby produces viral proteins without active 
viremia.  HIV-1 patients with latent HIV-1 infection (HIV-1+ without HIV-1 viral RNA 
or p24) may display mild to moderate cognitive impairment (Desplats et al., 2013). Tat 
protein is found in the CSF of aviremic patients (Johnson et al., 2013). Thus, without 
active infection, HIV-1 proviruses in the brain may produce viral proteins, and the 
production of these HIV-1 proteins is, for the most part, unaffected by antiretroviral 
drugs.  Similar to Tat, gp120 protein has been found in HIV-1+ humans (Toneatto, Finco, 
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van der Putten, Abrignani, & Annunziata, 1999; Oh et al., 1992; Jones, Bell, & Nath, 
2000) and gp120 exposure results in dopamine neuropathology in vitro (Hu, Sheng, 
Lokensgard, Peterson, & Rock, 2009; Wallace, Dodson, Nath, & Booze, 2006) and in 
vivo (Toggas et al., 1994). The HIV-1 Tg rat also produces gp120 (Peng et al., 2010). 
Thus, the HIV-1 Tg rat gives rise to a chronic exposure of the brain to HIV-1 viral 
proteins under the control of the natural promoter in disease appropriate cells. Thus, these 
proteins may be generated from proviral DNA without active infection; an aviremic state 
which may reflect protein expression in HIV-1 + patients on combined antiretroviral 
therapy (cART).   
We found that sucrose had a lower reinforcing efficacy in the HIV-1 Tg rat. First, 
we used the sucrose preference task to assess changes in gustatory perception, and similar 
to a prior report (Peng et al., 2010), we found no difference in sucrose preference 
between HIV-1 Tg rats and controls.  Second, HIV-1 Tg rats consistently responded for 
fewer sucrose reinforcers when compared to control rats, although there was no shift in 
the EC50 between groups.  It is important to note that the animals were neither food nor 
water restricted during PR testing, so responses for sucrose were not affected by 
variations in satiety.  Relative to mechanisms of cocaine reinforcement mechanisms, such 
as DAT function, alterations in sucrose reinforcement may reflect an impairment in either 
more widespread neural pathways (Berridge, Robinson, & Aldridge, 2009; Pennartz, 
Groenewegen, & Lopes da Silva, 1994) or dysfunction of a separate, discrete, neuronal 
system located within the NAc which is sensitive to sucrose and insensitive to cocaine 
(Carelli, 2002; Carelli & Wondolowski, 2006). As we found no shift in the EC50 for 
sucrose relative to controls, the neuronal systems underlying sucrose reinforcement 
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maybe less impaired in the HIV-1 Tg rats, relative to those for drug cocaine 
reinforcement.  
It is interesting to compare the findings from the PR test with the choice task, as 
the two procedures may not assess the same motivational processes (Ahmed, Lenoir, & 
Guillem, 2013).  All animals had extensive experience with both cocaine and sucrose 
reinforcement and were explicitly trained such that each lever had an equal likelihood of 
presenting either reinforcer (i.e., no bias).  Importantly, cocaine preference was not 
attributed to a lack of interest in sucrose. Prior to the choice procedure, both cocaine and 
sucrose were consumed on several trials in which each reinforcer was presented alone.  
We found in the choice procedure, animals initially had a strong preference for choosing 
sucrose over cocaine.  This is consistent with prior publications in which cocaine was 
found to have low value relative to natural rewards, such as sucrose, in rats (Cantin et al., 
2010).  Interestingly, over a period of days, most of the control animals shifted to a 
cocaine preference, suggesting an addictive process in that animals ultimately preferred 
to take cocaine at the expense of other available choices (i.e., sucrose); however, choice 
behavior was disrupted for the HIV-1 Tg rats.  Additional research using choice 
procedures may determine if HIV-1+ drug abusers may be at particular risk for continued 
drug abuse or find psychostimulant drugs particularly rewarding.  
The nucleus accumbens/ventral striatum has high levels of HIV-1 following 
infection (Wiley et al., 1998), decreases in volume following infection (Aylward et al., 
1993; Paul et al., 2005b) and is a key area for the reinforcing actions of cocaine (Kalivas 
& Volkow, 2005). In particular, the medium spiny neurons (MSNs) of the NAc play a 
key role in many motivational (Enoksson, Bertran-Gonzalez, & Christie, 2012) and goal-
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directed behaviors (Shen et al., 2009; Lesscher & Vanderschuren, 2012). We recently 
reported that the MSNs of the NAc are morphologically altered in HIV-1 Tg female rats 
(Roscoe, Jr., Mactutus, & Booze, 2014).  MSNs in the NAc of HIV-1 Tg female rats had 
decreased dendritic branching and a population shift to shorter, less projected dendritic 
spines, relative to controls (Roscoe, Jr. et al., 2014) in response to chronic HIV-1 protein 
exposure.  Chronic cocaine treatment is also known to significantly alter MSNs, primarily 
by increasing spine density and spine head diameter (Shen et al., 2009), as well as by 
bringing about increased synaptic strength (Robinson & Kolb, 1999; Shen, Moussawi, 
Zhou, Toda, & Kalivas, 2011).  MSNs receive regulatory input from both the prefrontal 
cortex and the ventral tegmental area (Di Chiara & Imperato, 1988; Nestler, 2005); both 
of these afferents are modulated by cocaine.  Given the apparent central role of MSNs in 
HIV-1 infection and cocaine abuse, it is possible that the MSNs represent structural loci 
(or part of key circuitry) for the interaction of HIV-1 proteins and cocaine on goal 
directed behaviors.   
In sum, prior cocaine-exposure alters HIV-1 protein interactions with DA nerve 
terminals, producing unique motivational and neurochemical outcomes.  We found, 
contingent upon prior cocaine self-administration, HIV-1 produces neurochemical 
alterations in the DAT with divergent outcomes relative to cocaine-free animals.  The 
current study of synaptosomal DAT function/DA turnover in HIV-1 Tg animals which 
were self-administering cocaine, and our prior microdialysis study of HIV-1 Tat protein + 
cocaine (Ferris et al., 2010), suggests unique interactions between HIV-1 and repeated 
cocaine exposure.  We reported that the HIV-1 Tat protein directly impairs DAT function 
(Zhu et al., 2009; Midde et al., 2013), produces oxidative damage in neurons (Aksenov et 
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al., 2006) and rat striatal tissue (Bansal et al., 2000; Aksenov et al., 2001). Similarly, the 
HIV-1 gp120 protein also impairs the function of the DAT in dopaminergic neurons (Hu 
et al., 2009) and produces oxidative damage (Agrawal et al., 2010; Yao, Allen, Zhu, 
Callen, & Buch, 2009; Wallace et al., 2006). The increased levels of synaptic dopamine, 
as a consequence of HIV-1 proteins and repeated cocaine co-exposure, may generate 
localized, low-level, oxidative stress, resulting in dysfunction of dopaminergic neurons 
following HIV-1 infection.  Over a prolonged period of exposure to HIV-1 proteins and 
cocaine, loss of dopaminergic nerve terminals, and ultimately, dopaminergic cell loss 
may occur, as has been reported in HIV-1+ human drug abusers (Kumar et al., 2011).  
Our results suggest that DAT functions in the face of HIV-1+cocaine challenge may be 
fundamental in determining the expression of goal-directed behaviors for cocaine in the 
HIV-1 Tg rat.  The goal of maintaining DAT functionality in the presence of cocaine and 
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The use of illicit drugs, like cocaine, compound peripheral and neurological 
complications of HIV-1 (Baum et al., 2009; Chang et al., 2008; Nath et al., 2001; Nath, 
2010). HIV-1+ cocaine users progress from HIV-1 to AIDS  more quickly (Fiala et al., 
1998; Baum et al., 2009), and are more likely to display neurocognitive disorders than 
their non-abusing cohorts (Devlin et al., 2012; Weber et al., 2013; Levine et al., 2006; 
Gongvatana et al., 2014; Nath et al., 2001). Cocaine use in conjunction with HIV-1 is 
also associated with decreased medication adherence (Panos et al., 2014), increased viral 
load both as a result of poor medication adherence (Qian et al., 2014) and independent of 
antiretroviral therapy (ART) compliance (Rasbach et al., 2013). Presently there are no 
therapeutics for HIV+ drug users, or HIV-1 associated neurocognitive disorders (HAND) 
in general. Addressing HIV-1+ drug use may result in a reduction in disease 
transmission, an increase in medication adherence and decreased viral load (Roux et al., 
2008), resulting in a higher quality of life and decreased mortality. 
HIV-1+ individuals have an increased incidence of apathy, or a lack of motivation 
(Kamat et al., 2012; Rabkin et al., 2000; Tate et al., 2003). Clinically apathetic HIV-1+ 
individuals are more likely to exhibit neurocognitive deficits (Paul et al., 2005a; Rabkin 
et al., 2000; Shapiro et al., 2013), decreased NAc volume (Paul et al., 2005b), and a 
poorquality of life (Tate et al., 2003). HIV-1 targets the dopamine system (Agrawal et al., 
2010; Gelman et al., 2006; Kumar et al., 2009a), which plays a major role in maintaining 
and initiating motivated behavior (Baik, 2013); and the dopaminergic system is believed 
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to be ‘hijacked’ by drugs of abuse through long term morphological changes (Shen et al., 
2009; Toda, Shen, Peters, Cagle, & Kalivas, 2006; Nestler, 2005). Individuals with 
HAND who use cocaine have decreased dopamine transporter (DAT) levels in the 
striatum (Chang et al., 2008), decreased TH staining at autopsy (Silvers et al., 2006) and 
increased neuronal damage (Gill & Kolson, 2014; Martin-Thormeyer & Paul, 2009). 
HIV-1 and stimulant drugs act in concert to produce a greater risk for neurocognitive 
disorders and apathy, indicating a need for therapeutic intervention.  
The HIV-1 transgenic (HIV-1 Tg) rat has been used to study the neurological 
effects of HIV-1 proteins without active viral replication (Moran, Booze, Webb, & 
Mactutus, 2013; Moran et al., 2014; Moran et al., 2013), similar to an individual on 
antiretroviral therapy (ART) (Peng et al., 2010). The HIV-1 Tg rat expresses 7 of the 9 
HIV-1 genes. The virus lacks the genes gag and pol, and thus is not replicative (Reid et 
al., 2001). Neurotoxic proteins gp120 and Tat proteins, which both interact with stimulant 
drugs to produce enhanced neurological insult (Bansal et al., 2000; Aksenov et al., 2006), 
are present in the brain of the HIV-1 Tg rat (Rao et al., 2011). There is significant 
dopaminergic dysfunction (Moran et al., 2013; Moran et al., 2012; Webb, Aksenov, 
Mactutus, & Booze, 2010), and altered response vigor for sucrose and cocaine in the 
HIV-1 Tg rat (See chapter 5). Although the HIV-1 Tg rat does not fully mimic the 
pathological hallmarks of HIV-1, it does provide a solid model of neurological 
complications that occur due to chronic exposure to HIV-1 proteins and provides the 
opportunity to test potential therapeutics for neurocognitive dysfunction. 
The soy derived phytoestrogen daidzein prevents synaptodendritic damage and 
restores the F-actin rich network after exposure to HIV-1 Tat (Bertrand et al., 2014). 
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During digestion, daidzein is metabolized by the gut bacteria to produce S-equol 
(Setchell et al., 2005). Equol is 50-70 fold more potent than its parent compound (Jiang et 
al., 2013b), and S-equol has a 24-fold binding specificity for estrogen receptor subtype 
beta (ERβ) over estrogen receptor subtype alpha (ERα) (Jiang et al., 2013b). ERβ 
activation has been shown to attenuate HIV-1 Tat induced cell death (Adams et al., 2010) 
and synaptodendritic injury (See chapter 4). Importantly, both enantiomers of equol 
successfully prevent interactive damage produced by HIV-1 Tat and cocaine through an 
ERβ dependent mechanism (see chapter 4). However the effects of equol on motivation 
and/or drug abuse or HIV-1 have not been studied. 
HIV-1 is associated with dendritic alterations in vivo (Masliah et al., 1997; Moore 
et al., 2006; Sa et al., 2004), and these alterations are predictive of cognitive performance 
(Moore et al., 2006; Adle-Biassette et al., 1999). The HIV-1 Tg rat has alterations in 
temporal processing and deficits in executive function tasks (Moran et al., 2014; Moran 
et al., 2013), in addition to altered dendritic spine morphology (Roscoe, Jr. et al., 2014), 
suggesting that altered neuronal structure may play a role in behavioral changes of the 
HIV-1 Tg rat. Exposure to cocaine and other stimulant drugs often results in an increase 
in spine density of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) 
(Robinson & Kolb, 2004; Grueter, Robison, Neve, Nestler, & Malenka, 2013; Russo et 
al., 2010). On the other hand, HIV-1 proteins produce a decrease in overall spine density 
in vitro (Atluri, Kanthikeel, Reddy, Yndart, & Nair, 2013; Atluri et al., 2014; Tovar et al., 
2013; Kim et al., 2008a) and in vivo (Fitting et al., 2010b; Fitting et al., 2013). The 
effects of HIV-1 and cocaine in combination on dendritic spine parameters are difficult to 
predict. Since dendritic injury occurs prior to cell death in HIV-1 and is potentially 
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reversible, it is an important marker for therapeutic potential of compounds in HIV-1 
associated neurocognitive disorders and stimulant abuse. 
Estrogen is a well-known proliferator of dendritic spine density (Phan et al., 2011; 
Gould et al., 1990; Woolley & McEwen, 1992), and a potent neuroprotective agent 
(Simpkins et al., 2012; Simpkins & Singh, 2008). Although both traditional ER subtypes 
(α,β) participate in the modulatory actions of estrogen, selective activation of ERβ 
increases spine density and PSD95 accumulation (Srivastava et al., 2010). ERβ activation 
prevents HIV-1 Tat induced neuronal apoptosis (Adams et al., 2010), and 
synaptodendritic damage produced by HIV-1 Tat and cocaine in vitro (See chapter 4). 
Together, these results suggest that ERβ activation, through the use of a subtype selective 
compound (e.g., equol), would be a beneficial therapeutic for HIV-1+ drug users. 
We used the HIV-1 Tg rat to evaluate the therapeutic potential of oral 
administration of equol in ameliorating the alterations in response vigor displayed by the 
HIV-1 Tg rat. Sucrose and IV cocaine self-administration paradigms were used to 
evaluate the effectiveness of equol treatment in modifying motivated behavior. Following 
behavioral testing, the impact of equol treatment and HIV-1 on medium spiny neurons 
(MSNs) in the NAc was evaluated using DiOlistic labeling and confocal microscopy. The 
results suggest that equol treatment results in long-term behavioral and morphological 
changes, particularly in control F344 rats.  
Methods 
Animals 
A total of 42 adult female ovariectomized (OVX) (21 HIV-1 Transgenic and 21 
F344 control) rats were purchased from Harlan Laboratories, Inc. (Indianapolis, IN, 
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USA). All animals were ovariectomized due to the potentially confounding effects of 
estradiol. Estradiol potentiates the reinforcing efficacy of cocaine (Hu et al., 2004) and 
prevents HIV-1 mediated neuronal damage (Bertrand et al., 2014; Adams et al., 2010; 
Heron et al., 2009), and suppresses HIV-1 transcription (Cabrera-Munoz et al., 2012). 
Additionally, estradiol effects may have confounded equol treatment effects. 
Ovariectomies were performed at Harlan Laboratories prior to arrival at the University of 
South Carolina. Rats were fed a minimal phytoestrogen diet (≤20 ppm of phytoestrogen; 
Teklad 2020X Global Rodent Diet; Harlan Laboratories, Inc., Indianapolis, IN). Standard 
rodent chow contains 200-500ppm soy and alfalfa (Harlan Laboratories, Inc., USA). Soy 
and alfalfa contain phytoestrogens, compounds which have estrogenic effects due to their 
natural structural similarity to estrogen (Lephart et al., 2005; Setchell & Cassidy, 1999). 
Additionally, soy contains the compound daidzein which is converted into s-equol, the 
experimental compound, by the gut microbiota (Setchell & Cassidy, 1999; Setchell et al., 
2005). Throughout the experiment animals had ad libitum access to food and water, 
unless otherwise specified. The animal colony was maintained at 21±2◦C, 50±10% 
relative humidity and a 12L:12D cycle with lights on at 0700h. The Institutional Animal 
Care and Use Committee (IACUC) at the University of South Carolina (animal assurance 
number: A3049-01) approved all experimental procedures involving animals.  
Apparatus  
Sound-attenuating enclosures housed operant chambers (ENV-008; Med-
Associates, St. Albans, VT, USA) which were controlled by Med-PC computer interface 
software. Front and back panels were composed of stainless steel, the sides and top of the 
chamber consisted of polycarbonate. The front stainless steel panel contained a magazine 
that allowed a recessed 0.01cc dipper cup (ENV-202C) to deliver a solution through a 
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5cm x 5cm opening following completion of a response requirement (ENV 202M-S). 
Two retractable active (i.e., response resulted in reinforcement) metal levers (ENV-
112BM) on either side of the receptacle were located 7.3 cm above a metal grid floor. A 
28-V white cue light, 3 cm in diameter, was located above each active response lever but 
never illuminated. Head entries into the magazine were detected using an infrared sensor 
(ENV 254-CB). There was a non-retractable lever (“inactive”; responses made on this 
lever were recorded but not reinforced) located on the center back panel and a 28V house 
light was located above the lever. A syringe pump (PHM-100) was used to deliver 
intravenous cocaine infusions through a water-tight swivel (Instech 375/22ps 22GA; 
Instech Laboratories, Inc., Plymouth Meeting, PA), which was connected to the 
backmount of the animal using Tygon tubing (ID, 0.020 IN; OD, 0.060 IN) enclosed by a 
stainless steel tether (Camcaths, Cambridgeshire, Great Britain). The pump infusion 
times were calculated by a Med-PC computer program according to the animal’s 
bodyweight, which was updated daily. 
Drugs 
 In order to prevent significant hydrolysis, cocaine solutions were prepared prior to 
the start of each operant test. Cocaine hydrochloride (Sigma-Aldrich Pharmaceuticals, St. 
Louis, MO) was weighed as a salt and was dissolved in physiological saline (0.9%; made 
fresh daily). Sucrose solutions were prepared fresh at the beginning of each testing day. 
Heparin was purchased from APP Pharmaceuticals (Schamburg, IL), butorphenol 
(Dolorex) from Merck Animal Health (Millsboro, DE), Sevofluorane, USP from Baxter 
(Deerfield, IL), and Gentamicin sulfate from VEDCO (Saint Joseph, MO). Equol and 
sucrose pellets (100 mg; banana flavor) were purchased from Bio-Serv (Flemington, NJ, 
USA). Equol was purchased from Cayman Chemical (Ann Arbor, MI, USA) and 
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formulated into 100 mg sucrose pellets (0.05 mg equol/pellet) by Bio-Serv prior to arrival 
at the University of South Carolina. Pellets were color coded (equol: orange; sucrose: 
yellow) to avoid experimenter confusion. 
Treatment 
 Each genotype was randomly assigned to one of two treatment groups: Sucrose 
(n=10 F344-S and n=10 HIV-1-S) and equol (n=11 F344-E and n=11 HIV-1-E). 
Treatment consisted of 0.2 mg equol (4 pellets) or 4 sucrose control pellets per animal. 
Oral dosing of equol (0.2mg) used is within the dose range used in human studies (~10-
30mg for ~60kg human) (Jackson et al., 2011; Setchell, Zhao, Shoaf, & Ragland, 2009). 
Animals were treated once daily for one week prior to the start of testing, and every day 
thereafter until catheterization. Animals did not receive treatment for one week following 
surgery. When treatment resumed, it was given every other day until the end of the 14-
day cocaine self-administration progressive ratio task. No treatment occurred during the 
cocaine dose-response or choice tasks. During sucrose tasks animals were pair-housed in 
their home cages. To ensure individual treatment consumption, animals were placed into 
separate, empty cages until designated pellets were consumed. Following catheterization, 
animals were single housed, and thus were given treatment in their home cage. 
Experiment 1: Sucrose-Maintained Responding 
 Previously established research protocols were used to determine dipper training 
and auto-shaping (Harrod, Lacy, & Morgan, 2012b; Lacy, Hord, Morgan, & Harrod, 
2012b; Reichel, Linkugel, & Bevins, 2008). Briefly, during dipper training all animals 
learned to approach the magazine and drink from the dipper. Next, animals learned to 
respond for 5% sucrose (w/v) during autoshaping.  Animals were water restricted for 12-
15 hours prior to dipper training, and auto-shaping. During the auto-shaping task two 
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retractable active levers (responding was recorded and reinforced) were present at the 
front of the chamber. During all phases of the experiment active levers were programed 
to retract if there was a difference of 5 or more responses on either lever in order to 
control for side bias. In the rear center panel of the chamber there was an inactive lever 
on which responses were recorded but not reinforced. After completion of the daily 
operant task, animals were given free access to water in their home cage for 9-12 hours. 
Once animals met the criterion of 60 or more reinforcers for 3 consecutive days, animals 
had ad libitum access to water and continued onto experiment 1.1. 
 Experiment 1.1 
 Due to auto-shaping, animals were experienced with the fixed ratio (FR) schedule 
of reinforcement and did not require new training in order to participate in the 
progressive ratio (PR) or FR phases of the experiment. After 1 maintenance day (5%; 
FR1) the schedule of reinforcement was changed to PR (max. 120 minute sessions). 
During PR tests responding on either active lever contributed to meeting the ratio 
requirement; once the ratio requirement was met, animals had 4s access to sucrose 
reinforcement. Ratios progressively increased, according to the following function: 
[5e(reinforcer number X 0.2)]-5 (rounded to the nearest integer) (Richardson & Roberts, 1996). 
One of five sucrose concentrations (1%,3%,5%,10%, and 30% w/v; Latin square 
procedure) was presented as the reinforcer on the test days, which occurred every other 
day. Maintenance trials occurred on non-test days, which made 5% sucrose available on 
an FR1 schedule of reinforcement. Water was presented as the sixth and last reinforcer 
for all rats in order to prevent potential extinction learning if water was not reinforcing to 
the animals.  
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 Experiment 1.2 
 Following completion of the PR sucrose paradigm, animals were given the 
opportunity to respond for identical sucrose concentrations (1-30%) on an FR1 schedule 
of reinforcement. Testing days were every other day, with a 5% maintenance day on the 
intervening days. Water was presented as the sixth and last reinforcer for all rats. 
Experiment 2: Cocaine maintained responding 
Surgery 
 Following the completion of experiment 1, IV catheters were implanted into all 
animals. Catheterization was performed according to Smith et al, (2014). Anesthesia was 
induced using 5% inhalant sevofluorane and animals were maintained at 3.5-4% 
sevofluorane throughout the surgical procedure. After anesthesia induction, a sterile IV 
catheter was implanted into the right jugular vein and secured with 4-0 Perma-Hand silk 
sterile sutures (EthiconEnd-Surgery, Inc.). The catheter extended dorsally, where it was 
connected to an acrylic pedestal embedded with mesh. The catheter pedestal was 
implanted subcutaneously above the right and left scapulae. The back-moiunt was 
stitched into place using Sterile 4-0 Monoweb sutures. In order to provide post-operative 
analgesia and prevent infection, all animals were administered butorphenol (0.8 mg/kg, 
s.c.) and gentamicin (0.2 ml 1%, I.V.) immediately following surgery. All rats were 
monitored in a heat-regulated warm chamber following surgery and returned to the 
colony room after recovery from anesthesia. For one week following surgery catheters 
were flushed daily with a solution containing the anti-coagulant heparin (2.5%) and the 
antibiotic gentamicin (1%) to prevent clotting and infections. Catheters were flushed with 
0.9% saline solution prior to testing each day and flushed again with post-flush solution 
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after operant testing. Cocaine testing began and equol treatment resumed 7 days post-
surgery. Two HIV-1 Tg animals died immediately following surgery; one of unknown 
causes and one suffered from a seizure after returning to the home cage but prior to 
returning to the colony room. 
Cocaine-maintained responding 
 There were three phases to this experiment. The first two phases (experiments 2.1 
and 2.2) of this experiment utilized a modified version of the Morgan et al., (2006) 
cocaine self-administration procedure that was employed previously (see chapter 5). 
During experiment 2.1, rats responded for cocaine according to a daily FR1 schedule of 
reinforcement (0.2 mg/kg/inj) for 5 consecutive days (1 hour sessions); once the response 
requirement was complete a 20s time-out occurred, i.e. active levers retracted and the 
house light was extinguished. Next, during experiment 2.2 they were switched a higher 
concentration (0.75 mg/kg/inj) of IV cocaine using a PR schedule of reinforcement 
([5e(reinforcer number X 0.2)]-5; rounded to the nearest integer) (Richardson & Roberts, 1996) 
for a maximum of 120 minutes for 14 consecutive days. Upon ratio completion there was 
a 20s time-out. Finally, experiment 2.3 consisted of a PR paradigm with ascending doses 
of cocaine (0.01, 0.05, 0.1, 0.2, 0.75, and 1.0 mg/kg/inj) across sessions to evaluate 
potential changes in sensitivity and reinforcing efficacy of cocaine induced by genotype 
and/or equol treatment. Following completion of the ratio requirement a 20s time-out 
occurred. Maintenance trials using the training dose (0.2 mg/kg/inj) on a FR1 schedule 
occurred every other day during the dose-response paradigm. 
Experiment 3: Choice Behavior 
 All four groups of animals were subjected to a choice self-administration protocol 
following completion of the cocaine experiments. The training dose for sucrose (5%) and 
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cocaine (0.2mg/kg/inj) were used as the concentrations for choice behavior. The training 
doses were used due to a lack of clear EC50 in the cocaine or sucrose data for any group. 
Four forced choice trials, with only one lever available during these trials, began each 
session (2 nondrug and 2 drug reinforcers) followed by the choice component. Sucrose 
paired lever presentation (right or left) was balanced between groups. Following the 
forced choice trials, both levers were concurrently available to allow the animals to freely 
choose between sucrose and cocaine. Once a response was made, a 20s time out occurred 
between responses. During all studies there was an inactive back lever located in the 
center back panel of the chamber. Responses on the back lever were recorded but not 
reinforced. 
Experiment 4: Dendritic Spine Analysis 
Preparation of Tissue 
Animals were sacrificed within 24 hours of their last self-administration session. First, 
animals were deeply anesthetized using sevofluorane (Abbot Laboratories, Chicago IL, 
USA) and then transcardially perfused with 100 ml of 100 mM PBS wash followed by 
100-150 ml 4% paraformaldehyde buffered in PBS (Sigma-Aldrich, St. Louis, MO, 
USA). After dissection, brains were post-fixed in 4% paraformaldehyde for 10 minutes 
and then cut into 200 µm thick coronal slices using a rat brain matrix (ASI Instruments, 
Warren, MI, USA). Serial slices were then washed 3x in PBS, notched for orientation, 






Preparation of DiOlistic Cartridges 
DiOlistic labeling was performed according to published techniques (Roscoe, Jr. et al., 
2014; Seabold, Daunais, Rau, Grant, & Alvarez, 2010). Tungsten beads (~300mg; Bio-
Rad, Hercules, CA, USA) were dissolved in 99.5% pure methylene chloride (Sigma-
Aldrich, St. Louis, MO, USA) and sonicated in a water bath for 30 minutes (37°C). 
Methylene chloride was also used to dissolve crystalized DiI (14.5 mg; Invitrogen Life 
Sciences, Carlsbad, CA, USA). After sonication, the bead solution (100 µl) was placed 
on a glass slide and the DiI solution (150 µl) was titrated on top and mixed using a 
pipette tip. The mixture was then allowed to air dry. A razor blade was used to collect 
and transfer the dried dye/bead mixture onto wax-coated weigh paper. Finally, the 
dye/bead mixture was transferred to a 15 ml conical tube (BD Falcon, San Jose, CA, 
USA) with 3 ml ddH2O and was then sonicated for 45-60 minutes. 
Preparation of Tefzel Tubing 
Polyvinylpyrrolidone (PVP, 100mg; Sigma-Aldrich, St. Louis, MO) was dissolved in 10 
ml ddH2O, vortexed, and then passed through three 1.7 m lengths of Tefzel tubing (IDEX 
Health Sciences, Oak Harbor, WA, USA). Subsequently, 3 ml bead/dye solution was 
slowly drawn into the tubing and placed into the tubing prep station (Bio-Rad, Hercules, 
CA) for 5 min. Water was drained from the tube and the dry tubing was spun for 
approximately 10 min with a nitrogen gas flow of 1.0LPM in the tubing prep station. 
Then the nitrogen gas flow through the tubing was adjusted to 0.4-0.5 LPM and the 
tubing was spun for an additional 50-60 min. Finally, dry tubing was cut into 13 mm 
segments and stored under anhydrous conditions until use. 
DiOlistic Labeling using the Helios Gene Gun and Immunohistochemistry 
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The Helios gene gun (Helium gas 80 PSI; Bio-Rad, Hercules, CA, USA) was loaded with 
previously prepared cartridges, and particles were delivered through 3 µm pore filter 
paper directly onto the slice with the barrel placed approximately 2.5 cm away from the 
sample. Sections were washed 3x in PBS and stored overnight at 4°C to allow dye 
diffusion. Tissue sections were mounted using Pro-Long Gold Antifade (Invitrogen Life 
Sciences, Carlsbad, CA, USA), coverslipped (#1 cover slip; Thermo Fisher Scientific, 
Waltham MA, USA) and stored in the dark at 4°C. 
Medium Spiny Neuron Dendritic Analysis and Spine Quantification 
 MSNs were analyzed from the NAc, located approximately 2.28 mm to 0.60 mm 
anterior to Bregma (Paxinos & Watson, 2007). For dendritic branch order analysis 1-4 
MSNs per animal were randomly selected. Branch order was only determined for animals 
with clear dendritic arbor as assessed by the maximum intensity projection image (F344-
S: n=14; F344-E: n=15; HIV-1-S: n=11; HIV-1-E: n=15). MSNs in the NAc were used 
for spine analysis provided the following criteria were satisfied: 1. Continuous staining 
beginning in the cell body extending throughout the dendrite, 2. Minimal DiI diffusion, 
and 3. Low background fluorescence. Each animal had 3-8 MSNs that were randomly 
selected for spine analysis. Numbers of individual neurons per group were  F344-S: 36, 
F344-E: 39, HIV-1-S: 30, and HIV-1-E: 44. 
 Z-stack images were obtained using a Nikon-TE 2300T confocal microscope with 
Nikon’s EZ-C1 software (version 3.81b). Dendritic spine analysis and branch order 
analysis was performed at 60x (n.a.=1.4) with Z-plane intervals between 0.15-0.25 µm 
(pinhole size 30 µm; back-projected pinhole radius 167 nm). For DiI fluorophore 
excitation, a green helium-neon (HeNe) laser with an emission of 533 nm was used. 
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Neurolucida version 10.52, equipped with AutoNeuron and AutoSpine extension 
modules (MicroBrightField, Williston, VT, USA) was used to analyze dendritic spine 
parameters.  
Dendritic Spine Parameters 
Dendritic spine parameters of length, volume, and head diameter were analyzed. 
Spine length was defined to be between 0.01 to 4 µm; lengths greater than 4 µm were 
considered to be filopodia and excluded from the study (Blanpied & Ehlers, 2004; 
Ruszczycki et al., 2012). Spine volume parameters were defined as those measures 
between 0.02 and 0.2 µm3 (Merino-Serrais et al., 2013). Spine head diameters were 
defined as those measures between 0.3 and 1.2 µm (Bae, Sung, Cho, Kim, & Song, 
2012). 
Statistical Analysis 
Data analyses were performed using SPSS version 22 (IBM Corporation, Armonk 
NY) and Graphpad version 5.02 (Graphpad Software, Inc., La Jolla, CA). For experiment 
1, a mixed-design analysis of variance (ANOVA) was used to analyze to performance on 
an FR and PR schedule of reinforcement with genotype (HIV-1 Tg vs. F344 control) and 
treatment (Equol vs. Sucrose) as the between-subjects factors and sucrose concentration 
(1-30%, w/v) as the within-subjects factors and obtained sucrose reinforcers as the 
dependent variable. Experiment 2 was also analyzed using a mixed-design ANOVA, with 
genotype and treatment as the between-subjects factors and day or concentration as the 
within-subjects factors and obtained reinforcers as the dependent variable. For analysis of 
the choice paradigm, a mixed-design ANOVA was used to analyze choice results with 
genotype, treatment, reinforcer type (Sucrose vs. Cocaine) as the between-subjects 
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factors and day as the within-subjects factor with active presses as the dependent 
variable. Curve fit and regression analyses were used to detect individual group 
differences revealed by the overall ANOVA. For analysis of dendritic spine parameters, a 
two-way ANOVA was utilized with each spine parameter (length, diameter, volume, or 
density) as the dependent variable, and treatment and genotype as the between-subjects 
variables. Statistical comparisons were made using ANOVA techniques with a priori 
contrasts to determine specific treatment effects. For analysis of cocaine data, animals 
with obvious patency issues (e.g. leak at base of back mount or inability to flush) were 
excluded from the analysis. Significant differences were set at p≤0.05. 
 Stepwise regression was used to detect any significant behavioral predictors of 
morphological changes in the NAc. Models were considered significant if p≤0.05. 
Results 
Experiment 1.1: Sucrose PR responding 
 Animals were treated with 0.2 mg equol formulated into sucrose pellets or 
identical sucrose pellets without equol daily for one week prior to the start of the 
experiment, and daily for the duration of experiment 1. Following successful completion 
of an auto-shaping task (60+ reinforcers/3 consecutive days), HIV-1 Tg and F344 rats 
were given the opportunity to respond on a progressive ratio schedule of reinforcement 
for 1, 3, 5, 10, and 30% (w/v) sucrose solutions. A 2 x 2 x 5 mixed ANOVA using 
number of active lever presses as the dependent variable was used to examine these data. 
Planned contrasts revealed significant linear effect of concentration F(1,34)=8.3, p≤0.01, 
with all animals having an increased response for higher concentrations of sucrose (figure 
6.1A). There was a significant main effect of genotype F(1,34)=4.0, p≤0.05, with HIV-1 
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Tg rats responding less overall compared to F344 control rats across all concentrations, 
regardless of treatment (figure 6.1A). 
Experiment 1.2: Sucrose FR responding 
 During the second phase of experiment 1, animals were given the opportunity to 
respond on a FR1 schedule of reinforcement for the same sucrose concentrations used in 
phase 1. A 2 x 2 x 5 mixed ANOVA with reinforcers received as the dependent variable 
was used to examine these data. Similar to experiment 1.1, there was a prominent linear 
effect of concentration F(1,24)=103.2, p≤0.001, with animals across genotypes 
responding with increased vigor as concentration increased. There was a significant main 
effect of genotype F(1,24)=9.0, p≤0.02, with HIV-1 Tg rats receiving fewer sucrose 
reinforcers than F344 rats (figure 6.1B). There was a significant main effect of treatment 
F(1,25)=7.9, p≤0.01, with equol treated animals responding significantly more than 
sucrose treated animals on concentrations 1-10%. There were significant concentration x 
genotype F(4,96)=4.2, p≤0.02 and concentration x treatment F(4,96)=3.4, p≤0.05 
interactions. Planned contrasts revealed a significant quadratic interaction between 
concentration and treatment F(1,24)=6.3, p≤0.05, and a significant cubic effect of 
concentration by genotype F(1,24)=9.4 p≤0.01.  
A curve fit analysis was used further explore the significant concentration x 
treatment interaction. A one phase association curve was a significant fit for equol treated 
animals (r2=0.98), while sucrose treated animals had a significantly linear fit (r2=0.99) 
(figure 6.1C). These fits were significantly different from one another F(1,90)=6.7, 
p≤0.01, and indicate that equol treatment results in a response plateau between the 
highest sucrose concentrations (10% and 30%).  
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A curve fit analysis was also used to evaluate the genotype x concentration 
interaction. F344-E animals had a significantly different fit than F344-S animals in 
experiment 1.2, F(1,37)=7.8, p≤0.01. A one phase association curve was found to 
significantly fit F344-E (r2=0.99), alternatively, there was a significant linear fit to the 
F344-S animals (r2=0.95) (Figure 6.1E). HIV-1-S (r2=0.98) and HIV-1-E (r2=0.89) 
followed a significantly linear pattern, however HIV-1-E rats received significantly more 
sucrose reinforcers than HIV-1-S rats, as demonstrated by a significantly higher intercept 
F(1,92)=3.8, p≤0.05 (figure 6.1D).  
Figure 6.1 The HIV-1 Tg rat demonstrates diminished response vigor for sucrose and S-
equol functionally alters sucrose response. A. F344 and HIV-1 animals had a 
significantly linear response, p≤0.01, to increasing concentrations of sucrose (1-30%; 
w/v) using a progressive ratio schedule of reinforcement. There was a main effect of 
genotype, with HIV-1 Tg rats responding less overall (p≤0.05) regardless of 
concentration. B. F344 animals respond more overall for sucrose on an FR1 schedule of 
reinforcement p≤0.02, however both groups display a linear response to increasing 
concentrations of sucrose (1-30%; w/v), p≤0.001. C. Equol treatment results in a 
functionally different response to increasing concentrations of sucrose. Equol treatment 
resulted in a quadratic response to sucrose; there was a significant plateau of responding 
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between 10% and 30% (w/v) sucrose (one phase association curve; r2=0.98). Meanwhile 
sucrose treatment resulted in a functionally linear response for increasing concentrations 
of sucrose (linear fit; r2=0.99). D. Equol treatment did not significantly alter the linear 
response for sucrose in the HIV-1 Tg rat; although it did result in a significantly higher 
intercept, p≤0.05, suggesting HIV-1-E animals respond more for sucrose than HIV-1-S 
animals. E. F344-E animals have a significant fit of a one phase association curve 
(r2=0.99) while F344-S rats have a significant linear fit (r2=0.95). Data represents mean 
values ± 95% CI. 
Experiment 2.1: Cocaine acquisition 
 Animals were catheterized and allowed to heal for one week prior to testing. A 
mixed 2 x 2 x 5 ANOVA was used to analyze the data obtained during the 5 day 
acquisition period. There was a significant linear effect of day F(1,36)=9.0, p≤0.01, and a 
significant day x treatment interaction F(4,144)=3.1, p≤0.05. Regression analyses 
confirmed that equol treated animals, regardless of genotype, had a negative slope 
significantly different from zero F(1,196) =4.1, p≤0.05 across the 5 days of acquisition 
when compared to sucrose treated animals; on the other hand, sucrose treated animals had 
a slope that was not significantly different from zero (figure 6.2A).  
Experiment 2.2: 14 Day Cocaine PR 
 Following experiment 2.1, a 14 day progressive ratio task was used to evaluate 
the ability of the animals to escalate their cocaine intake. A 2 x 2 x 14 mixed ANOVA 
was initially used to evaluate these results. There was a significant main effect of day 
F(13,364) =2.0, p≤0.02, suggesting that all animals increased their drug intake over the 
14 day testing period. Linear regression analyses confirmed that the slope of the lines for 
both HIV-1 Tg and F344 animals were positive and significantly different than zero 
F(1,12)=28.8, p≤0.001 and F(1,12)=35.3, p≤0.001, respectively.  
Linear regression analyses also revealed that there was not a significant genotype 
difference between slopes. However HIV-1 Tg rats (r2=0.70) had a significantly different 
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intercept than F344 (r2=0.75) rats F(1,557)=5.2, p≤0.02, indicating that HIV-1 Tg rats 
received more infusions overall but escalated at the same rate as F344 rats (figure 6.2B). 
Furthermore, F344-E treated rats (r2=0.68) had a significantly different intercept 
compared to F344-S (r2=0.50) rats F(1,291)=16.6, p≤0.001 but not a significantly 
different slope suggesting that F344-E rats responded more than F344-S treated rats but 
both groups escalated at the same rate (figure 6.2C). Conversely, HIV-1-E rats (r2=0.50) 
had a significantly different intercept than HIV-1-S (r2=0.69) rats F(1,263)=7.1, p≤0.01, 
but a similar slope, indicating HIV-1-S and HIV-1-E rats increased intake at the same 
rate but HIV-1-E rats received fewer cocaine reinforcers than HIV-1-S rats (figure 6.2D). 
Experiment 2.3: Cocaine Dose-Response 
 Following experiment 2.2, animals were tested on 6 doses of cocaine (0.01-
1mg/kg/infusion) on a PR schedule in an ascending manner. Testing occurred every other 
day, with a maintenance day (FR) on the intervening days. Animals were no longer given 
equol or sucrose pellets. A 2 x 2 x 6 ANOVA with number of earned infusions as the 
dependent variable was employed initially to examine these data. There was a significant 
main effect of dose F(5,95)=6.4, p≤0.003, which was found to be a linear effect using 
planned contrasts F(1,19)=9.4, p≤0.006. There was a significant main effect of genotype 
F(1,19)=5.2, p≤0.05, which HIV-1 Tg animals receiving fewer cocaine infusions overall. 
There was also a significant dose x genotype interaction F(5,95)=2.9, p≤0.05.  
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 A linear regression was used to examine the effects of genotype on the slope of 
the line, F344 animals had a robust linear fit (r2=0.96) while HIV-1 Tg animals only had 
a moderate fit (r2=0.44) and the slopes were significantly different from one another 
F(1,134)=4.6, p≤0.03. Only F344 animals had a slope significantly different from zero 
F(1,58)=11.7, p≤0.001, indicating that HIV-1 Tg animals did not vary in responding to 
increasing doses of cocaine (figure 6.2E). Prior experience with equol did not produce a 
significant effect in either HIV-1 Tg or F344 animals. 
Figure 6.2 Equol treatment differentially modulates response for cocaine according to 
genotype. A. During the acquisition phase, equol treated animals, regardless of genotype, 
have a significantly negative slope p≤0.05, while sucrose treated animals have a slope 
that is not significantly different from zero. Equol treated animals initially took more 
cocaine than sucrose treated animals, but eventually fell to similar levels of responding. 
B. During the 14 day PR task, HIV-1 Tg animals and F344 animals both have non-zero, 
but similar, slopes (p≤0.001), indicating that both groups of animals escalated cocaine 
intake at the same rate. However, HIV-1 Tg animals have a significantly higher intercept 
p≤ 0.02 demonstrating that HIV-1 Tg animals took more cocaine overall. C. F344-E and 
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F344-S animals had similar slopes, but different intercepts (p≤0.001) establishing that 
F344-E animals obtain more cocaine reinforcers than F344-S animals but they respond at 
the same rate. D. HIV-1-S and HIV-1-E animals have parallel slopes, but have different 
intercepts p≤0.01 indicating that although equol treatment did not change the rate of 
responding, it did change consumption with HIV-1-S rats consuming more cocaine. E. 
Animals were given the opportunity to respond on a PR paradigm that introduced 
increasing concentrations of cocaine across testing days. All animals have a robust linear 
response p≤0.006; however, HIV-1 Tg animals do not have a non-zero slope, indicating 
that increasing concentrations of cocaine do not alter responding and F344 animals 
obtained significantly more infusions of cocaine at all concentrations (p≤0.05). Equol 
experience did not alter responding in either genotype. Data represents mean values ± 
95% CI. 
Experiment 3: Choice 
 All animals had a significant amount of experience with both cocaine and sucrose 
in an operant paradigm. The next experiment examined the ability of these animals to 
choose between reinforcers simultaneously. A 2 x 2 x 2 x 7 mixed ANOVA using 
number of lever presses was used to examine these results. There was a significant day x 
genotype interaction F(6,84)=3.0, p≤0.05 and a significant day x genotype x treatment 
interaction (6,84)=2.7, p≤0.02. Finally, there was a significant reinforcer type x treatment 
interaction F(1,14)=11.1, p≤0.01.  
Regression analyses were used to further explore significant interactions. A 
history of equol treatment differentially modulated choice across days in both genotypes. 
F344-E animals had significantly different slopes F(1,94)=4.5, p≤0.05, indicating a 
differential response rate between reinforcers. F344-E animals had a functionally linear 
response to both reinforcers; animals preferred cocaine over sucrose, at a roughly 3:1 
ratio. There was a negative slope for cocaine responding significantly different from zero 
F(1,47)=6.3, p≤0.02 (r2=0.89), resulting in a decrease in preference by day 7 (figure 
6.3C), but F344-E animals still preferred cocaine over sucrose at a 2:1 ratio. Meanwhile, 
F344-E animals did not change their response rate for sucrose over the course of choice 
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testing, with a slope that was not significantly different from zero (p>0.1; figure 6.3C). 
Replacement of cocaine with saline on day 8 resulted in an increase in responding for 
sucrose, roughly a 2:1 response for sucrose over drug. On day 9 when sucrose was 
replaced with water, there was not a significant preference for sucrose or drug. 
 Conversely, F344-S rats had significantly different intercepts F(1,53)=12.5, 
p≤0.001 between reinforcer type but not a significant difference in slope, indicating that 
F344-S preferred sucrose over drug however they did not differ in their response rate 
(figure 6.3E). During extinction trials on days 8 and 9 there was not a significant shift in 
reinforcer preference. 
HIV-1-E animals had significantly different slopes F(1,76)=4.4, p≤0.05 with 
responding for sucrose having a significantly non-zero, positive slope F(1,38)=4.5, 
p≤0.05 and the slope of drug response not being significantly different from zero, 
indicating that sucrose responding increased across testing days while drug response 
remained the same (figure 6.3D). HIV-1-S animals did not have slopes significantly 
different from zero for either reinforcer, however they had significantly different 
intercepts F(1,55)=6.1, p≤0.02 indicating that HIV-1-S animals had a stable preference 
for sucrose over drug (figure 6.3F). Extinction trials on days 8 and 9 resulted in a 
decrease in responding for both sucrose and cocaine resulting in a lack of preference for 
both HIV-1-S and HIV-1-E groups. 
Experiment 4: Dendritic Spine Analysis 
Within 24 hours of the last cocaine self-administration session, animals were 
sacrificed and their tissue processed for identification of dendritic spines. Medium spiny 
neurons were identified and imaged (n=4-8 per animal). A Kruskal-Wallis test was 
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utilized to confirm that all cells analyzed were from similar populations. The null 
hypothesis failed to be rejected (p>0.4), indicating that all cells used for analysis were 
from the same population. Spine length, head diameter, and volume were analyzed using 
a 2x2 ANOVA with each parameter as the dependent variable.  
Figure 6.3 History of equol treatment modulates choice.  A. When collapsed across 
treatment, F344 animals do not have a significant preference for drug or sucrose. 
Extinction trials (sessions 8[saline] and 9[water]) did not result in a preference shift. B. 
When collapsed across treatment HIV-1 Tg animals prefer sucrose over cocaine (p≤0.02). 
Extinction trials (sessions 8 [saline] and 9 [water]) did not result in a preference shift C. 
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F344-E animals have significantly different slopes for each reinforcer, p≤ 0.05. Cocaine 
was preferred over sucrose, however this is a significantly negative slope p≤ 0.02 
resulting in a shift from a 3:1 preference to a 2:1 preference for cocaine, while sucrose 
responding was stable across testing days.  Replacement of cocaine with saline resulted in 
an increase in responding for sucrose, resulting in roughly a 2:1 preference for sucrose 
over cocaine. D. HIV-1-E animals have significantly different slopes between reinforcer 
type p≤0.05, indicating a differential response for one reinforcer over the other. More 
specifically, HIV-1-E animals have a significantly positive slope for sucrose 
reinforcement while drug reinforcement remains stable, these slopes are significantly 
different from one another, p≤0.05, indicating HIV-1-E animals respond at different rates 
for sucrose and cocaine. Extinction trials (8 and 9) resulted in a decrease in sucrose 
responding resulting in a shift to non-preference between reinforcers. E. F344-S animals 
prefer sucrose over cocaine over the course of choice testing as evidenced by the 
significantly different intercept p≤0.001. Neither line was significantly different from 
zero, indicating a stable preferences for sucrose over cocaine. Replacement of cocaine 
with saline or sucrose with water did not alter choice preference. F. HIV-1-S animals do 
not have slopes significantly different from zero for either reinforcer, however their 
intercepts are significantly different p≤0.02 indicating a stable preference for sucrose 
over drug. Extinction trials (8 and 9) did not produce a preference shift. Data represents 
mean values ±95% CI. 
Analyses revealed that F344 animals, regardless of treatment, had longer dendritic 
spines F(1,56975)=142.1, p≤0.001 (figure 6.4), with larger spine head diameter 
F(1,48905)=33.9, p≤0.001 (figure 6.5), than HIV-1 Tg rats. History of equol treatment 
produced a significant reduction in spine head diameter F(1,38616)=25.9, p≤0.001 
(figure 6.5) and a corresponding loss of spine volume F(1,13832)=12.2, p≤0.001 (figure 
6.6). There were significant genotype x treatment interactions for spine head diameter 
F(1,38616)=35.3, p≤0.001 (figure 6.5) and spine length F(1,48905)=4.0, p≤0.05. Equol 
treatment resulted in a decreased spine head diameter, and longer spines in F344 animals. 
However equol treatment resulted in increased spine head diameter, and marginally 
shorter spines in HIV-1 Tg animals. 
 
153 
There was a significant main effect of genotype on the complexity of branching in 
the MSNs of the NAc F(1,51)=33.3, p≤0.001, with F344 animals having a significantly 
more complex network than HIV-1 Tg animals (figure 6.7).  
Figure 6.4 Spine length histograms illustrating A. relative and B. cumulative frequencies. 
C. Represents mean (±SEM) differences between genotypes. Regardless of treatment, 
there was an overall reduction in spine length in HIV-1 Tg animals reflecting a shift in 
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the population of spines observed. HIV-1 Tg animals have a shorter population of 
dendritic spines compared to F344 controls [F(1,56975)=142.1, p≤0.001]. 
 
Figure 6.5 HIV-1 Tg animals have smaller spine head diameter relative to F344 animals 
and equol differentially modulates diameter. A. Mean (±SEM) plot illustrating the 
significant effect of genotype, treatment, and genotype x treatment interaction. B. 
Relative and C. cumulative frequencies of spine head diameter in HIV-1 Tg and F344 
animals. HIV-1 Tg animals have a smaller spine head than F344 animals 
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F(1,48905)=33.9, p≤0.001. D. Relative and E. cumulative frequencies of spine head 
diameter as a function of treatment. Equol produces a shift in the population of spines; 
according to treatment. More specifically, equol treatment resulted in a significantly 
smaller spine head F(1,38616)=25.9, p≤0.001. F. Relative and G. cumulative frequency 
distributions of spine head diameter of F344-S and F344-E spines; Equol treatment 
results in a shift in the population of spines to smaller head diameter F(1,38616)=35.3 
p≤0.001 in the F344 rat. H. Relative and I. cumulative frequency distributions of spine 
head diameter in HIV-1-S and HIV-1-E spines. Unlike F344 animals, there was not a 
significant shift in spine head diameter. 
 
Figure 6.6 Equol modulates spine volume. A. Relative and B. cumulative frequency 
histograms illustrating the population shift of spine volume according with equol treated 







































































































































illustrating the effect of equol treatment on spine volume. Regardless of genotype, spine 
volume was reduced in equol treated animals resulting in a shift in the population of 
spines observed. 
 
Figure 6.7 DiOlistic labeling of medium spiny neurons in the NAc. A. Representative 
F344 control image showing complex branching patterns resulting in an increased 
number of dendrites due to higher branch order (60x). B. HIV-1 Tg MSNs exhibit less 
complex branch order patterns, resulting in a stunted neuronal tree and potentially 
dysfunctional neural communication (60x). C. F344 animals displayed spines that were 
longer and with larger spine head diameter. D. HIV-1 Tg animals had shorter spines with 
less prominent spine heads. F. There was a significant main effect of genotype on 




Behavior predicting structural outcomes 
  An exploratory stepwise regression was used to determine the ability of 
performance on the behavioral tasks to predict individual spine parameters.  
 Spine head diameter. Performance on FR and PR sucrose tasks were determined 
to significantly predict spine head diameter in medium spiny neurons of the nucleus 
accumbens (data from each day were considered to be independent predictors, 
[F(4,8)=15.6, p≤0.001]). The adjusted r2 indicated that 85.6% of the variance in spine 
head diameter was associated with number of sucrose reinforcers received during FR-5%, 
FR-30%, and PR-1%. 
 Length. Dendritic spine length was significantly predicted by performance on day 
7 of choice, specifically by responding for the sucrose reinforcer F(1,10)=8.8, p≤0.05. 
The adjusted r2 indicated that 46.7% of the variance in spine length was associated with 
performance on sucrose responding on day 7 of choice. 
 Volume. Dendritic spine volume was also significantly predicted by performance 
on both sucrose, cocaine self-administration, and choice behavior F(4,7)=36.9, p≤0.001. 
The adjusted r2 indicated that 92.9% of the variance in spine volume was associated with 
the number of sucrose reinforcers received on PR30 and Day1 of choice; the number of 
cocaine reinforcers received in the 0.75mg/kg/inj dose in the cocaine dose response study 
and the first day of acquisition. 
Discussion 
Drug use, especially cocaine use (Cook et al., 2007; Korthuis et al., 2008), is a 
common comorbid condition with HIV-1+ serostatus (Ferris et al., 2008; Qian et al., 
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2014; Purohit et al., 2011). HIV-1+ status alone is known to increase apathy and 
depression (Paul et al., 2005a; Paul et al., 2005b; Rabkin et al., 2000; Shapiro et al., 
2013), decreasing the likelihood of medication adherence and disrupting quality of life 
(Shapiro et al., 2013; Tate et al., 2003). Current drug use plays a role in worsening 
neurocognitive deficits (Nath, 2010; Purohit et al., 2011), and there are no treatment 
options for these individuals. Presently, the HIV-1 Tg rat was used to evaluate the 
effectiveness of the gut metabolite equol on ameliorating alterations in response vigor for 
sucrose and cocaine. HIV-1 Tg rats display a decreased response rate for sucrose 
compared to F344 control rats, regardless of treatment status using a PR paradigm. 
Conversely, when an FR paradigm is used for testing there is a significant effect of equol 
treatment with equol treated animals responding more regardless of genotype. However, 
equol treatment differentially modulates cocaine acquisition and performance on the 14 
day PR task in HIV-1 Tg rats versus F344 rats. Although treatment history does not alter 
responding for increasing concentrations of cocaine, it significantly alters choice 
behavior. Dendritic spine analysis revealed that HIV-1 Tg rats had significantly shorter 
spines with smaller head diameter, suggesting altered synaptic function. Additionally, 
history of equol treatment produced dendritic spines with smaller head diameter and less 
volume than in sucrose treated animals. Finally, performance on behavioral tasks was 
used to attempt to predict structural changes in dendritic spines. This revealed a complex 
set of predictors indicating that performance on both sucrose, cocaine, and choice tasks 
produce profound structural effects. 
The HIV-1 Tg has an altered response for sucrose reinforcement on PR and FR 
schedules of reinforcement; specifically, response vigor is diminished. Equol treatment 
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did not enhance response vigor for sucrose during the PR task, however there was a 
significant effect of equol treatment resulting in an increase in sucrose rewards received 
in the FR task. Both HIV-1 Tg and F344 equol treated animals had increased responding 
for lower concentrations of sucrose but less for the highest concentration of sucrose, 
30%. Although HIV-1-E rats respond more for sucrose than HIV-1-S rats, they still 
respond with significantly less vigor that either F344 group. The HIV-1 Tg rat also 
displays dopaminergic dysfunction (Moran et al., 2013; Moran et al., 2012), and HIV-1 
proteins disrupt dopaminergic tone in vivo (Ferris et al., 2009a), and alter dopaminergic 
function in vitro (Ferris, Calipari, Yorgason, & Jones, 2013) and in vivo (Bertrand et al, 
2015). The dopaminergic system plays an important role in motivated behavior (Baik, 
2013; Robbins & Everitt, 1996) and the present results suggest that equol treatment may 
blunt responsiveness for highly appetitive reinforcement, like 30% sucrose, in control 
animals and modulate response vigor in HIV-1 Tg rats. Although equol treatment appears 
to modulate dopaminergic involvement in motivated behavior for sucrose, equol does not 
completely ameliorate deficits in motivational drive. 
During the cocaine acquisition period equol treated animals initially respond more 
vigorously for cocaine, unlike sucrose treated animals which respond in a stable manner 
across five days; however, cocaine intake decreases over the 5 day acquisition period for 
equol treated animals. Animals had not received equol treatment for one week prior to the 
start of the acquisition period and did not receive treatment until after the first testing 
session. The initial up-regulation of responsiveness suggests that previous history with 
equol, a potent ERβ agonist, may increase response to novelty and/or increase initial 
sensitivity to the drug. However, as animals receive treatment over the 5 day acquisition 
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period there is a significant decrease in response suggesting that direct ERβ activation 
may play a significant role in acquisition. Estradiol is known to significantly increase 
acquisition of cocaine self-administration in OVX female rats (Hu et al., 2004; Hu & 
Becker, 2008), and estrogen modulates dopamine receptor expression in the VTA and 
midbrain (Zhou, Cunningham, & Thomas, 2002b). ERβ activation is involved in cocaine 
primed reinstatement (Larson & Carroll, 2007b), and here we demonstrate that ERβ may 
play an important role in the acquisition of cocaine self-administration. 
Similar to the actions of cocaine, the neuroactive protein HIV-1 Tat inhibits DAT 
function (Midde et al., 2012; Midde et al., 2013) increasing the extracellular 
concentrations of dopamine. HIV-1 Tg rats self-administering cocaine have a slower 
dopamine turnover rate and Vmax in the striatum (Bertrand, 2015). Together these results 
suggest that cocaine self-administration results in hyperdopaminergic tone, which is 
similar to what is found in rats treated with exogenous HIV-1 Tat and cocaine (Ferris et 
al., 2010), which may result in fewer responses for higher doses of cocaine. Presently, 
both HIV-1 Tg and F344 rats display a significant increase in cocaine intake on the 14 
day PR schedule. However, HIV-1 Tg rats received more cocaine reinforcers than F344 
rats overall, which is contrary to our previous report (Bertrand et al., 2015). In our 
previous study we showed that HIV-1 Tg rats had a modified response to cocaine, 
however, presently we illustrate that this may be due to an increased sensitivity to the 
drug itself. Indeed, a recent report describes the HIV-1 Tg rat as being more sensitive to 
the effects of cocaine at low doses (McIntosh et al., 2015). A lower dose of cocaine was 
used during the acquisition phase in order to more clearly differentiate the sensitivity of 
the HIV-1 Tg rat from the reinforcing efficacy of cocaine. Although HIV-1 Tg rats 
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respond more for a lower dose of cocaine, suggesting they may be more sensitive to 
lower cocaine doses, the reinforcing efficacy of the drug is also altered as demonstrated 
by the lack of a response to increasing doses of cocaine.  
During the 14 day PR task, treatment with the potent ERβ agonist equol resulted 
in a differential modulation of behavior according to genotype. HIV-1-E rats take 
significantly fewer hits of cocaine compared to HIV-1-S animals over the two week time 
period; meanwhile F344-E rats take significantly more hits of cocaine compared to F344-
S rats. Together, these results suggest that equol may have action in the dopaminergic 
system resulting in an alteration in dopaminergic tone. Once cocaine use is initiated, 
females are more likely than males to develop addiction and that estrogen plays a major 
role in this sex difference (Anker & Carroll, 2011). The role of estrogen in enhancing 
addiction indicates that estrogen has powerful effects on the dopamine system (Zhang, 
Yang, Yang, Jin, & Zhen, 2008). ERβ expression has been shown to alter DAT dynamics 
in the striatum (Al-Sweidi et al., 2012), and plays a role in the reinstatement process 
(Larson & Carroll, 2007b).  
Activation of ERβ in HIV-1 Tg rats may result in a normalization of 
dopaminergic tone via DAT regulation, thus decreasing cocaine sensitivity. On the other 
hand, ERβ activation in F344 rats may result in dysfunctional dopamine regulation 
leading to an increased responsiveness to cocaine.  Estradiol facilitates acquisition (Anker 
& Carroll, 2011; Jackson, Robinson, & Becker, 2006; Zhao & Becker, 2010), escalation 
(Larson, Anker, Gliddon, Fons, & Carroll, 2007), and reinstatement (Anker & Carroll, 
2011). Estrogenic effects during reinstatement are ERβ dependent (Larson & Carroll, 
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2007a), and the present results suggest that ERβ activation may play an important role in 
regulating the escalation of cocaine intake in OVX F344 rats. 
Drug addiction is commonly defined as a compulsive disorder, in which obtaining 
the drug occurs at the expense of obtaining natural reinforcers, such as food (Hyman, 
Malenka, & Nestler, 2006; Robinson & Berridge, 2003). Previously, we have shown that 
the HIV-1 genome disrupts the choice profile of the rat (see chapter 5). The equol effects 
in the choice paradigm occurred well after active treatment with equol had ended, thus, 
highlighting the long lasting behavioral effects of equol and the potential effectiveness of 
this gut metabolite to treat HIV-1+ cocaine users, but not seronegative cocaine users. 
History of S-equol treatment differentially modulates choice across days according to 
genotype. F344-E rats choose drug over sucrose suggesting an increase in compulsivity 
to obtain the drug; however, HIV-1-E rats choose sucrose over drug, similar to HIV-1-S 
and F344-S rats. Interestingly, F344-E rats almost triple their response for sucrose when 
cocaine is replaced with saline, and this increased responding does not change when 
sucrose is replaced with water.  
Dendritic spines are dynamic structures that are thought to play major role in 
learning and memory (Sala & Segal, 2014; Segal, 2005). Alterations in dendritic spine 
morphology are correlated with neurotransmitter release (Murthy, Sejnowski, & Stevens, 
1997), and spines with a large head diameter (i.e. mushroom spines) are more stable than 
thin or stubby spines (Segal, 2005). Although behavioral correlates spine morphology are 
not completely understood (Sala, Cambianica, & Rossi, 2008), there are specific spine 
phenotypes associated with neurochemical mechanisms. We demonstrate that HIV-1 Tg 
rats have shorter spines, with smaller head diameter, and less volume compared to F344 
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rats, suggesting that HIV-1 Tg rats have less mature spines and/or transient, dysfunctional 
synapses present consistent with our previous findings (Roscoe, Jr. et al., 2014). There 
was no significant treatment effect in HIV-1 Tg rats; however, history of equol resulted 
in dendritic spines with a smaller head diameter and overall volume in F344 animals 
indicating that equol produced a long lasting structural effect. The equol induced 
alterations in spine head diameter and volume suggest a less stable spine phenotype than 
non-equol treated controls.  
History of equol treatment did not significantly alter dendritic spine parameters in 
the HIV-1 Tg rat, potentially due to the cessation of equol treatment 4-5 weeks prior to 
sacrifice. Although equol treatment ended, it is important to note that cocaine self-
administration continued. HIV-1 proteins and cocaine result in enhanced synaptodendritic 
injury (see chapter 4) and neuronal cell death in vitro (Kendall et al., 2005; Turchan et al., 
2001). The present results suggest that cocaine and HIV-1 proteins interact and may 
produce morphological changes consistent with a less stable phenotype (Segal, 2005).  
Previously we reported that HIV-1 Tg rats have significantly shorter dendritic 
spines with a decreased volume, indicating a shorter stubbier spine phenotype (Roscoe, 
Jr. et al., 2014). Presently we demonstrate a similar dendritic spine phenotype, with HIV-
1 Tg rats having shorter spine length and a reduced spine head however there was not a 
significant change in overall spine volume between genotypes. Estrogen is known to 
effect spine head diameter and spine volume (Velazquez-Zamora et al., 2012; Brocca, 
Pietranera, Beauquis, & De Nicola, 2013), which may explain differential findings of 
dendritic spine parameters in our present study and our previous study. The present 
experiment used OVX females self-administering cocaine under operant conditions, 
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while our previous report utilized intact females allowing estrogen mediated spinogenic 
effects to occur. Additionally, the rats in the present experiment also performed tasks to 
receive palatable reinforcement which is known to alter dendritic spine morphology 
(Guegan et al., 2013; Pitchers et al., 2010; Pitchers et al., 2013). Moreover, cocaine self-
administration is also known to effect dendritic spines (Pitchers et al., 2013; Dobi, 
Seabold, Christensen, Bock, & Alvarez, 2011; Robinson & Kolb, 2004; Robinson & 
Kolb, 1999). Cocaine self-administration in the HIV-1 Tg rat results in significant 
alterations in dendritic morphology and that the interactions between neurotoxic HIV-1 
proteins and cocaine may overcome the effects of equol treatment. The morphological 
results presented here suggest that HIV-1+ drug abusers may need more intensive 
treatment to alter structural changes induced by cocaine self-administration in the 
presence of HIV-1. 
 Morphological data were employed to predict performance on behavioral tasks, 
revealing a complex relationship between behavior and dendritic spines. Performance on 
a specific behavioral task did not uniformly predict morphological alterations, however, 
performance exclusively on sucrose associated tasks predicted spine head diameter and 
length. Conversely, spine volume was predicted by performance on both sucrose and 
cocaine tasks. Together these indicate that experience with natural rewards in an operant 
paradigm produces a long term morphological change that may contribute to cocaine 
taking behavior. Moreover, the morphological changes in the NAc predicting the 
response vigor for sucrose are consistent with the literature (Salamone & Correa, 
2012).The complex associations between behavior and dendritic morphology are 
consistent with the current literature (Sala & Segal, 2014), and may require more direct 
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quantifications of behavior to better understand the predictive nature of morphological 
changes in operant tasks with both natural and drug reinforcement. 
Our results illustrate the potential of the gut metabolite equol to treat motivational 
alterations in HIV-1. These results may translate into humans, suggesting that the gut 
microbiome plays an important role in treating HIV-1 associated neurocognitive 
disorders. Although equol appears to be a potential therapeutic candidate for HIV-1+ 
drug users, this does not appear to be a treatment appropriate for seronegative cocaine 
users. Equol treatment increased sensitivity and responsivity to lower doses of cocaine in 
F344 animals, suggesting equol alters dopamine signaling in normal rats as well as HIV-1 
Tg rats.  Interestingly, equol treatment also blunted the response for the highest dose of 
sucrose, 30%, compared to sucrose treated rats across genotypes. This suggests that 
equol, or gut metabolites in general, may alter the reinforcing properties of foods high in 
sugar as well as responsiveness to cocaine. The gut metabolite equol has long lasting 






 High HIV-1 viral load are found in brain regions that regulate motivation, and 
alterations in motivated behavior are predictive of neurocognitive status in HIV-1 (Wiley 
et al., 1998; Berger & Nath, 1997; Chang et al., 2008). Neuronal damage and dysfunction 
in dopamine-rich areas are also predictive of neurocognitive status pre-mortem (Chang et 
al., 2008; Wang et al., 2004; Silvers et al., 2006). Phytoestrogens both prevent and restore 
synaptodendritic damage induced by HIV-1 Tat in vitro (see chapters 3 and 4). The 
combination of a sub-toxic dose of HIV-1 Tat and cocaine resulted in a significant loss of 
synaptodendritic integrity, and both enantiomers of equol prevented synaptodendritic 
injury induced by Tat+cocaine (see chapter 4). Similar to an HIV-1+ individual, the HIV-
1 Tg rat has dopaminergic alterations; The HIV-1 Tg rat displays deficits in goal-directed 
motivated behavior (see chapters 5 and 6) and alterations in both dopamine transporter 
(DAT) function (see chapter 5) and dendritic spine morphology (see chapter 6)(Roscoe, 
Jr. et al., 2014). Treatment with the gut metabolite equol altered motivated goal-directed 
behavior in HIV-1 Tg rats for sucrose and cocaine (see chapter 6).   
Motivation is fundamental to behavior, however it is not formally considered  
within the domain of cognition (Keeler & Robbins, 2011). Undeniably, the neural 
processes that mediate motivation are critical for multiple aspects of cognitive function. 
The construct of motivation is widely used in behavioral neuroscience research, although 
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it has been given very little attention with respect to HIV-1. Motivation is defined as a 
state that allows an animal to regulate its internal and external environments through the 
organization of its behavior (Koob, 2009; Salamone & Correa, 2012). Goal-directed 
behavior, which encompasses Pavlovian and operant conditioning processes, is one 
example (Rescorla, 1987). The function of goal-directed behavior is to bring 
environmental contingencies under control, and it requires, at minimum, motivation, 
associative learning processes, and memory, e.g., stimulus-outcome associations 
(incentive wanting;Robinson & Berridge, 2003), stimulus-response associations (habit; 
Everitt & Robbins, 2013) and response-outcome associations (Adams & Dickinson, 
1981; Rescorla, 1987). Once learned, goal-directed behavior is maintained by 
motivational and cognitive processes, such as the animals’ homeostatic state, an 
expectation about the reinforcer, the current value of the reinforcer, environmental cues, 
and other learning phenomena, such as generalization and discrimination (Spear & 
Riccio, 1994; Koob, 2009).  
Apathy operationalized as a reduction in self-initiated and goal-directed behavior, 
or a lack of motivation (Marin, 1991). HIV-1+ individuals consistently report higher 
incidence of apathy than seronegative controls (Kamat et al., 2012; Castellon et al., 
1998a; Paul et al., 2005a). Elevated apathy scores are predictive of decreased medication 
adherence (Panos et al., 2014), more cognitive complaints, decreased neurocognitive 
performance (Shapiro et al., 2013; Kamat et al., 2012), and diminished everyday 
functioning (Kamat et al., 2012; Kamat et al., 2013).  In HIV-1 positive individuals, 
elevated levels of apathy are related to alterations in learning efficiency and cognitive 
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flexibility (Paul et al., 2005a), in addition to decreased working memory performance 
(Castellon et al., 1998a) and executive dysfunction (Castellon et al., 2000). 
The construct of apathy is not frequently discussed in animal models; however the 
concept of motivation, or how willing an animal is to work for reinforcement, is 
frequently tested in animals using operant techniques (Caine & Koob, 1994b; Harrod et 
al., 2012a; Lacy et al., 2014; Lacy et al., 2012a). However, this only evaluates one facet 
of motivation – specifically, vigor, or effortful work in order to obtain a reinforcer. 
Consummatory behavior, or direct interaction with the reinforcer, also encompasses 
motivated behavior; and this aspect of motivation is not disrupted by dopamine. Fixed 
ratio (FR) schedules of reinforcement, where animals perform a fixed set of responses for 
reinforcement, generally only assesses how much of a particular reinforcer is consumed 
in a particular session. In the case of drug reinforcement these results may be skewed if 
there are varying doses because a higher dose would result in fewer responses, however, 
the higher dose is presumably more reinforcing. In order to more easily interpret operant 
results, frequently a progressive ratio (PR) schedule of reinforcement is used. The amount 
responses required to obtain a reinforcer are increased following each successful ratio 
completion, eventually resulting in a break point where the animal stops responding. 
Generally, the higher the break point, the more valuable a particular reinforcer.   
Apathy is defined as a substantial lack of motivation, operationalized by 
diminished goal-directed behavior, diminished goal-directed cognition, diminished 
concomitants of goal directed behavior (Starkstein & Leentjens, 2008), a reduction in 
emotional engagement, reduced interest in normal purposeful behavior, and problems in 
beginning of purposeful movement (Moretti, Cavressi, & Tomietto, 2014). Apathy is an 
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important facet of HIV-1 associated neurocognitive disorders as it greatly impacts the 
quality of life in HIV-1+ individuals (Kamat et al., 2012; Kamat et al., 2013; Shapiro et 
al., 2013), and is a major predictor in medication adherence (Panos et al., 2014). A 
reduction in seeking or approach behavior, e.g. operant performance for sucrose, has been 
used to measure apathy in animal models of neurodegenerative disorders like Parkinson’s 
disease (Favier et al., 2014; Martinowich et al., 2012). However, this is only one aspect 
of motivation and thus only measures a small portion of apathy symptomology. Further 
studies examining primary reinforcer intake (e.g. food) independent of operant tasks, 
social engagement, locomotor activity, and response to novelty may increase the 
understanding of apathy in an animal model. 
Dysfunction of, and damage to, the frontal-subcortical system is believed to play a 
role in manifestation of apathy (Masterman & Cummings, 1997; Tekin & Cummings, 
2002). The basal ganglia play an important role in the initiation of motivated behavior, 
voluntary movement, and learning stimulus-response associations. Damage to the 
striatum and the basal ganglia impair the ability of animals (McDonald & White, 1994) 
and humans (O'Doherty et al., 2004; Knowlton, Mangels, & Squire, 1996) to learn 
stimulus-response associations. Reports of apathy in HIV-1 positive individuals are 
associated with decreased performance on tasks known to involve the frontal-subcortical 
circuitry (Cole et al., 2007), and lower overall volume of the nucleus accumbens (Paul et 
al., 2005b). Areas in the mesocorticolimbic system are dopamine rich and are known to 
be more susceptible to HIV-1 infection (Berger & Nath, 1997; Nath et al., 2000; Wiley et 
al., 1998). HIV-1+ patients have decreased DAT labeling in the striatum (Chang et al., 
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2008), fewer TH stained neurons at autopsy (Silvers et al., 2006), and parkinsonian-like 
symptoms (Tse et al., 2004).  
The DAT in the striatum of the HIV-1 Tg rat are dysfunctional, which may result 
in an altered dopaminergic tone. In drug naïve animals, HIV-1 Tg rats have a lower 
binding coefficient compared to F344 control animals, indicating fewer DAT on the 
membrane. However, these DAT act more efficiently, as the Vmax is higher in HIV-1 Tg 
rats than F344 control rats, resulting in a higher dopamine turnover rate at baseline. In 
HIV-1 Tg animals that have a history of cocaine self-administration, these results are 
reversed – the binding coefficient increases, but Vmax decreases resulting in a significantly 
lower dopamine turnover rate, potentially translating to a hyperdopaminergic tone within 
the synapse compared to F344 rats. Indeed, previous work has demonstrated that HIV-1 
Tat and cocaine (i.p. injection) result in hyperdopaminergic tone (Ferris et al., 2010) and 
impaired DAT function (Ferris et al., 2009b).  
Dysfunctional modulation of dopamine release and uptake may result in an up-
regulation of free radical production. HIV-1 Tat decreases surface expression of the DAT 
and diminishes the function of vesicular monoamine transporter (VMAT-2) (Midde et al., 
2012) and produces a reversible conformational change of the DAT  in striatal 
synaptosomes (Midde et al., 2013). The interactions of HIV-1 Tat with the DAT, in 
addition to the acute inhibition of the DAT by cocaine, may result in a prolonged period 
of synaptic DA exposure. Additionally, inhibition of VMAT-2 suggests that DA that has 
been successfully removed from the synapse is not packaged into vesicles.  Overall, 




The prolonged exposure of DA in the intra- and extra-cellular space may result in 
an increase in oxidative damage. Indeed, HIV-1 proteins lead to an increase in oxidative 
stress in primary hippocampal cell cultures (Aksenov et al., 2006) and there is an increase 
in protein oxidation in animals acutely treated with HIV-1 Tat (Aksenov et al., 2003; 
Aksenov et al., 2001). Thus, it is plausible that in the current studies that the HIV-1 Tg 
rats self-administering cocaine, and primary neuronal cultures treated with Tat + cocaine, 
have elevated MAO-A levels resulting in an increase in protein oxidation and cellular 
damage above and beyond Tat induced changes on the DAT. The final result may be that 
HIV-1 rats have an altered choice profile and altered reinforcing efficacy of cocaine. 
Morphologically, the increase in oxidative damage may result in depolymerization of F-
actin, causing the reduction of F-actin rich structures observed in the in vitro studies, and 
alterations in dendritic spine morphology in vivo. 
Dendritic spine morphology is correlated with spine function (Segal, 2005), with 
enlargement of spine head diameter associated with long-term potentiation (Sala & Segal, 
2014; Segal, 2005). In the NAc and striatum medium spiny neurons play a major role in 
mediating reward and reinforcement (Yagishita et al., 2014). MSNs receive input from 
excitatory neurons and modulatory (e.g. dopamine) neurons. Not only is dopamine 
required for MSN spine head enlargement, but the precise timing of dopamine release is 
also a major player in the degree of spine head enlargement (Yagishita et al., 2014). 
Timing of reward presentation has been long known to be important in instrumental 
conditioning (Benjamin & Perloff, 1983), and this appears to be a molecular correlate of 
reinforcement driven behavior. HIV-1 and cocaine significantly alter DAT functionality 
which results in altered release and re-uptake of dopamine, potentially disrupting ideal 
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timing of dopamine interaction with the dendritic spine head. Indeed, we see that the 
HIV-1 Tg rat (control) has significantly smaller spine head diameter, which may indicate 
that HIV-1 Tg rats have less robust formations of LTP in the NAc resulting in altered 
processing of reinforcement.  
The persistent change seen in addiction requires a strong association and an  
increase in synaptic strength, accompanied by a structural change in the axon or dendrite 
(Chklovskii, Mel, & Svoboda, 2004). LTP and LTD play an important role in experience-
dependent learning and memory (Papper, Kempter, & Leibold, 2011), and are mediated 
by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and N-
methyl-D-aspartate (NMDA) receptor, as well as metabotropic glutamate receptors 
(mGluR).  HIV-1 Tat is known to interact with NMDA receptors (Aksenov et al., 2012; 
Li et al., 2008), potentially disrupting the formation of LTP in the NAc resulting in a 
smaller spine head diameter. 
In the in vitro studies presented in this dissertation, there was a loss of F-actin 
puncta density following either a 24 hour incubation with HIV-1 Tat (1-86B, 1-72B, 1-
101B; 50 nM) or HIV-1 Tat (1-86, 10 nM) + cocaine (1.6 µM). This is consistent with in 
vivo studies which report a loss of dendritic spine density in humans (Atluri et al., 2013) 
and animal models (Fitting et al., 2010b). F-actin is a major cytoskeletal protein that is 
found in both pre- and post-synaptic structures (Johnson & Ouimet, 2006). F-actin is 
found in both the spine head and shaft (Sekino et al., 2007; Dent et al., 2011), filopodia 
(long, headless, “pre-spines”) (Jacinto & Wolpert, 2001; Hotulainen et al., 2009; Kaech 
et al., 2001; Sekino et al., 2007), and in patches along the dendrite (Halpain et al., 1998). 
Patch morphology appears both at the initiation of spinogenesis (Johnson & Ouimet, 
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2006), and as non-spiny synapses (Craig et al., 1994; van Spronsen & Hoogenraad, 
2010). Thus, in vitro changes in F-actin puncta density may reflect an inability of the 
neuronal network to maintain plastic potential.  
In chapter 4, equol pre-treatment prevented loss of F-actin rich puncta induced by 
both toxic HIV-1 Tat doses (50 nM) and sub-toxic HIV-1 Tat doses (10 nM) + cocaine 
(1.6 µM) via an estrogen receptor dependent mechanism. A subsequent experiment 
determined that the neuroprotective properties of both equol enantiomers were mediated 
through the ERβ subtype. ERβ expression has been found in dopaminergic rich regions 
like the substantia nigra, basal ganglia (Shughrue et al., 1997b; Laflamme, Nappi, Drolet, 
Labrie, & Rivest, 1998), NAc (Shughrue et al., 1997b), and rostral portions of the VTA 
where it is co-localized with TH (Creutz & Kritzer, 2002b). ERβ immunopositve cells in 
the VTA and substantia nigra project to the striatum and NAc (Creutz & Kritzer, 2004). 
Estradiol upregulates D2 receptor and DAT density in the NAc via an ERβ dependent 
mechanism (Le Saux, Morissette, & Di, 2006; Le Saux & Di, 2006). The behavioral 
experiments described in chapter 6 demonstrated that equol resulted in complex 
behavioral and morphological changes in both HIV-1 Tg and control F344 rats, which 
may be mediated by the activation of ERβ in the VTA.  
Equol may be potentiating communication between the VTA and the NAc 
following cocaine self-administration, contributing to the increase in response that is 
observed in F344 control animals for cocaine. Under normal conditions, like those 
present in the F344 control rats, activation of ERα or ERβ results in an increased 
response of the VTA to amphetamine (Sarvari et al., 2014). In HIV-1 Tg rats, this may 
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effectively ‘normalize’ the dopaminergic tone or may induce transcription of functional 
DATs.  
Drug addiction is frequently classified as a compulsive need for the drug, where 
drug associated activities (e.g. acquiring and administering the drug) take center stage 
and nondrug activities (e.g. work, family obligations) are secondary (Hyman et al., 2006; 
Robinson & Berridge, 2003). Although self-administration models demonstrate increased 
drug intake (escalation; Ahmed & Koob, 1999; Morgan et al., 2006), animals are only 
given the option of responding on levers within the operant chamber. Seminal research in 
rhesus macaques demonstrated that when given the opportunity to respond for cocaine or 
food, cocaine was the preferred choice (Negus, 2003; Nader & Woolverton, 1991; 
Woolverton & Balster, 1979; Aigner & Balster, 1978). Conversely, more recent studies in 
rodent models have illustrated that rats and mice prefer sucrose or saccharin 
reinforcement over cocaine reinforcement (Cantin et al., 2010; Lenoir, Serre, Cantin, & 
Ahmed, 2007; Lenoir, Augier, Vouillac, & Ahmed, 2013).  
The results in the choice paradigm discussed in chapters 5 and 6 present two 
different responses to choice between sucrose and cocaine. In chapter 5, we find contrary 
results in F344 control rats compared to the current literature (Cantin et al., 2010; Lenoir 
et al., 2007; Lenoir et al., 2013). Although F344 control rats initially prefer sucrose, over 
a period of days they shift to preference for cocaine, nearly 2:1 over sucrose. Similar to 
the prior literature (Cantin et al., 2010; Lenoir et al., 2007), our rats had extensive 
histories with both reinforcers prior to exposure to the choice procedure. However, the 
dose of cocaine used in our studies was determined by deriving the EC50 of cocaine and 
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sucrose from dose-response tasks prior to the choice task. Using the optimal 
concentration for both reinforcers may have produced an alteration in choice profile. 
On the other hand, F344 control animals in chapter 6 display a relatively stable 
(e.g. slopes do not differ from zero) 2:1 preference for sucrose over cocaine. Both sets of 
animals had extensive experience with both sucrose and cocaine reinforcement and were 
explicitly trained to anticipate reinforcement from either active lever (e.g. no side bias). 
However, unlike in chapter 5, it was not possible to determine the drug EC50 for either 
genotype, so the training dose was used. The sucrose training dose (5% w/v) was also 
used for sucrose, in order to compare the choice effectiveness of training doses. The 
training dose in chapter 6 (0.2 mg/kg/inj) was lower than both the training dose and EC50 
dose (0.33 mg/kg/inj) used in the choice paradigm in chapter 5. The differential results 
presented between these two studies may exhibit that although cocaine is preferred by 
OVX F344 rats, it is a dose-dependent preference. Additionally, the use of optimal 
concentrations for both drug and non-drug reinforcers may drive choice preference 
results. 
HIV-1 Tg control rats also display differential results between the two studies 
presented in chapters 5 and 6. However, this is more prominent in chapter 5, where HIV-
1 Tg animals initially prefer sucrose over cocaine, however over the choice period they 
decrease their sucrose responding and no longer have a preference between either 
reinforcer at the end of testing. On the other hand, HIV-1 Tg sucrose treated animals in 
chapter 6 prefer sucrose over cocaine, albeit not as pronounced as F344 sucrose-treated 
rats. The difference in response between studies may be contributed to the different doses 
of cocaine used throughout the study. In addition to the altered response of HIV-1 Tg 
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sucrose-treated rats in the acquisition, 14-day PR, and dose-response tasks in chapter 6 
compared to chapter 5 suggest that the HIV-1 Tg rat may be more sensitive to lower 
concentrations of cocaine, similar to what was found in a recent study (McIntosh et al., 
2015). Together the results of equol on choice indicate that equol has a long lasting 
behavioral effect, and may have detrimental properties in the non-HIV-1+ population. 
The effects of equol in the HIV-1 Tg rat require more evidence to reach a concrete 
conclusion. 
In order to reach more firm conclusions in regards to the effects of equol on HIV-
1, and evaluating the construct of motivation in HIV-1, in addition to the present studies 
ongoing in the lab (e.g. locomotor activity, wheel running), more experiments must be 
done. In order to more fully examine the behavioral effects of equol, a more consistent 
treatment schedule during cocaine self-administration should be performed. Due to 
supply limitations, following surgery equol was only given every other day until the end 
of the 14-day PR period. Due to the interactive effects of HIV-1 proteins and cocaine (see 
chapter 4; Kendall et al., 2005; Turchan et al., 2001) and low dose of equol used the 
morphological changes may not have been captured. The evidence of long-term 
morphological changes in the F344 rat provides evidence that long lasting structural 
changes occur in equol treated animals.  
Second, it would be useful to evaluate the effects of equol treatment on sucrose 
preference using a five bottle test, similar to what was used in chapter 5. Preference 
testing may allow us a better understanding of the effects of equol on consummatory 
behavior, giving a more complete picture of the alterations of equol treatment on 
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motivation for sucrose solutions. Finally, using a higher dose of equol may alter response 
vigor of the HIV-1 Tg rat for sucrose, ameliorating the deficits noted in chapters 5 and 6. 
It was not until recently that the gut microbiome was examined in any kind of 
depth. Nearly 15 years ago, the word gut microbiome was coined (Lederberg, 2001). 
Since then technology has increased exponentially allowing scientists to delve more 
deeply into the bacteria that inhabit the humans. Recently, the bidirectional 
communication between the resident gut microbiota and their effects on behavior were 
described as the ‘gut-brain axis’ (Cryan & Dinan, 2012; Foster & McVey Neufeld, 2013). 
Modulation of the gut microbiota with probiotic treatment have been successful 
treatments for anxiety-like and depressive-like behaviors in rats and mice (Neufeld et al., 
2011a; Neufeld et al., 2011b). Probiotic treatment has also been suggested as a treatment 
for inflammatory bowel syndrome (IBS), a gastrointestinal disorder linked to increased 
stress levels (Clarke et al., 2012). However, the effects of the gut microbiota on diseases 
like HIV-1 have not been explored.  
HIV-1 is currently a pandemic, however, there are higher incidences of HAND in 
individuals in North America and Europe as opposed to Sub-Saharan Africa and Asian 
populations (Satishchandra et al., 2000). Although these regional differences are 
generally believed to be due to viral strain differences, some variability may be due to 
differences in gut microbiota and diet. The gut microbiota may play an important role in 
mediating disease progression as well as the neurocognitive correlates of HIV-1. The 
ability of the gut metabolite equol to alter neuronal morphology and behavior in the 
studies in this dissertation suggests that the gut and diet may play an important role in 
modulating CNS health in HIV-1 and potentially other disease states. 
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Cocaine use during HIV-1 infection results in an increased incidence and severity 
of HAND (Baum et al., 2009; Chang, Connaghan, Wei, & Li, 2014; Nath et al., 2001; 
Nath, 2010). HIV-1 Tat and cocaine produce interactive damage on neurons in vitro 
(chapter 4), and attenuates the escalation of drug intake (chapter 6) suggests that 
treatment with equol may promote sobriety and protect from further neurological insult. 
The neuroprotective properties of equol, and the restorative properties of the parent 
compound daidzein (chapter 3), indicate that equol may be a potential therapeutic for 
HAND. Equol treatment in the HIV-1 Tg rat did not provide concrete answers on the 
effects of equol treatment on motivation. However, equol does not appear to be an 
optimal treatment for the HIV-1 negative cocaine using population, as equol appears to 
increase response to lower doses of cocaine, and may potentiate aberrant choice behavior. 
Importantly, because equol is a naturally occurring compound translation in to clinical 
testing would be faster than most therapeutic developments. Treatment with equol at 
HIV-1 diagnosis may reduce drug intake and prevent neuronal injury, however treatment 
may need to be constant or higher for positive effects. The effectiveness of equol may 
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